Filed 28 Jun 18

Document and Entity Information

Document and Entity Information12 Months Ended
Mar. 31, 2018shares
Document And Entity Information [Abstract]
Document Type40-F
Amendment Flagfalse
Document Period End DateMar. 31,
2018
Document Fiscal Year Focus2018
Document Fiscal Period FocusFY
Trading SymbolCGC
Entity Registrant NameCANOPY GROWTH CORPORATION
Entity Central Index Key1737927
Current Fiscal Year End Date--03-31
Entity Well Known Seasoned IssuerYes
Entity Current Reporting StatusYes
Entity Voluntary FilersNo
Entity Filer CategoryLarge Accelerated Filer
Entity Common Stock Shares Outstanding200,989,264

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Current assets
Cash and cash equivalents $ 322,560 $ 101,800
Amounts receivable21,425 5,815
Biological assets16,348 14,725
Inventory101,607 45,981
Prepaid expenses and other assets19,837 4,285
Current assets other than non-current assets classified as held for sale481,777 172,606
Assets classified as held for sale6,180
Current assets481,777 178,786
Property, plant and equipment303,682 96,270
Other long-term assets8,340
Investments in associates63,106
Other financial assets163,463 24,030
Intangible assets101,526 162,263
Goodwill314,923 241,371
Total assets1,436,817 702,720
Current liabilities
Accounts payable and accrued liabilities89,571 15,386
Deferred revenue900 588
Current portion of long-term debt1,557 1,691
Current liabilities92,028 17,665
Long-term debt6,865 8,639
Deferred tax liability33,536 35,924
Other long-term liabilities61,150 766
Total liabilities193,579 62,994
Commitments and contingencies
Shareholders' equity
Share capital1,076,838 621,541
Other reserves127,418 23,415
Accumulated other comprehensive income46,166 16,098
Deficit(91,649)(21,296)
Equity attributable to Canopy Growth Corporation1,158,773 639,758
Non-controlling interests84,465 (32)
Total equity1,243,238 639,726
Total liabilities and equity $ 1,436,817 $ 702,720

Consolidated Statements of Oper

Consolidated Statements of Operations - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Income Statement [Abstract]
Revenue $ 77,948 $ 39,895
Inventory production costs expensed to cost of sales37,790 15,293
Gross margin before the undernoted40,158 24,602
Fair value changes in biological assets included in inventory sold and other inventory charges66,268 34,978
Unrealized gain on changes in fair value of biological assets(100,302)(49,090)
Gross margin74,192 38,714
Sales and marketing38,203 12,960
Research and development1,453 810
General and administration43,819 16,858
Acquisition-related costs3,406 7,369
Share-based compensation expense29,631 8,046
Share-based compensation expense related to acquisition milestones19,475 690
Depreciation and amortization20,486 6,064
Operating expenses156,473 52,797
Loss from operations(82,281)(14,083)
Share of loss on equity investments(1,473)(50)
Other income, net31,213 3,858
Other income29,740 3,808
Loss before income taxes(52,541)(10,275)
Income tax (expense) recovery(1,593)2,703
Net loss(54,134)(7,572)
Net income (loss) attributable to:
Canopy Growth Corporation(70,353)(7,521)
Non-controlling interests16,219 (51)
Net loss $ (54,134) $ (7,572)
Earnings per share, basic and diluted
Net loss per share: $ (0.40) $ (0.06)
Weighted average number of outstanding common shares:177,301,767 118,989,713

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Statement Of Comprehensive Income [Abstract]
Net loss $ (54,134) $ (7,572)
Fair value changes on available for sale financial assets38,673 18,328
Exchange differences on translating foreign operations410 198
Income tax(4,982)(2,428)
Total other comprehensive income34,101 16,098
Comprehensive income (loss)(20,033)8,526
Comprehensive income (loss) attributable to:
Canopy Growth Corporation(40,285)8,577
Non-controlling interests20,252 (51)
Comprehensive income (loss) $ (20,033) $ 8,526

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in ThousandsTotalCanopy Rivers CorporationShare capitalShare-based reserveWarrantsOwnership changesOwnership changesCanopy Rivers CorporationExchange diffrencesFair value changes, net of taxDeficitNon-controlling interestsNon-controlling interestsCanopy Rivers Corporation
Balance at Mar. 31, 2016 $ 123,785 $ 131,080 $ 5,804 $ 676 $ (13,775)
Balance, Shares at Mar. 31, 201698,818,213
Equity financings and private placements $ 123,186 123,186
Equity financings and private placements, Shares22,617,500
Issuance of shares from acquisitions $ 364,889 353,214 11,675
Issuance of shares for acquisition, Shares36,138,911
Exercise of warrants $ 126 195 607 (676)
Exercise of warrants, Shares213,104
Exercise of ESOP stock options $ 6,961 11,036 (4,075)
Exercise of ESOP stock options, Shares4,010,865
Non-controlling interests from acquisitions $ 19 $ 19
Other share issuances $ 2,191 2,830 (639)
Other share issuances, Shares388,669
Fair value changes on available for sale investments, net of tax $ 15,900 $ 15,900
Share-based compensation10,043 10,043
Net loss(7,572)(7,521)(51)
Other comprehensive income198 $ 198
Balance at Mar. 31, 2017 $ 639,726 621,541 23,415 198 15,900 (21,296)(32)
Balance, Shares at Mar. 31, 2017162,187,262
Equity financings and private placements $ 461,017 390,752 70,265
Equity financings and private placements, Shares27,782,491
Issuance of shares from acquisitions $ 32,240 30,248 689 1,303
Issuance of shares for acquisition, Shares4,515,879
Exercise of warrants $ 770 1,883 (1,113)
Exercise of warrants, Shares207,297
Exercise of ESOP stock options $ 11,053 19,197 (8,144)
Exercise of ESOP stock options, Shares3,912,946
Non-controlling interests from acquisitions $ 4,889 4,889
Other share issuances $ 4,220 9,795 (5,575)
Other share issuances, Shares715,106
Share-based compensation $ 47,597 47,597
Other share issue costs(206)(206)
Tax benefit associated with share issue costs3,628 3,628
Non-controlling interest arising from Canopy Rivers $ 55,722 $ (55) $ 55,777
Additional non-controlling interest relating to share-based payment3,579 3,579
Ownership change arising from Canopy Rivers investment in Vert Mirabel(964) $ (964)
Net loss(54,134)(70,353)16,219
Other comprehensive income34,101 410 29,658 4,033
Balance at Mar. 31, 2018 $ 1,243,238 $ 1,076,838 $ 57,982 $ 70,455 $ (1,019) $ 608 $ 45,558 $ (91,649) $ 84,465
Balance, Shares at Mar. 31, 2018199,320,981

Consolidated Statements of Cha6

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) $ in Thousands12 Months Ended
Mar. 31, 2018CAD ($)
Share issue costs $ 2,448
Canopy Rivers Corporation
Share issue costs $ 2,448

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Operating
Net loss $ (54,134) $ (7,572)
Adjustments for:
Depreciation of property, plant and equipment8,725 4,146
Amortization of intangible assets11,761 1,918
Share of loss in equity investments1,473 50
Fair value changes in biological assets included in inventory sold and other inventory charges66,268 34,978
Unrealized gain on changes in fair value of biological assets(100,302)(49,090)
Share-based compensation51,177 10,043
Non-cash acquisition costs1,333
Loss on disposal of property, plant and equipment and intangible assets1,285 661
Other assets(1,853)
Non-cash other income and expense(38,779)(5,702)
Income tax (recovery) expense1,593 (2,703)
Increase in fair value of acquisition consideration related liabilities1,193
Non-cash interest and FX impact on assets(201)
Changes in non-cash operating working capital items(28,519)(16,348)
Net cash used in operating activities(81,506)(27,093)
Investing
Purchases and deposits of property, plant and equipment and assets in process(176,037)(29,391)
Purchases of intangible assets and intangibles in process(2,132)(141)
Proceeds on disposals of property and equipment75 37
Purchases of restricted investments(118)(300)
Proceeds on assets classified as held for sale7,000
Investments in associates(26,179)
Investments in other financial assets(22,439)
Net cash inflow (outflow) on acquisition of subsidiaries(3,753)11,193
Net cash used in investing activities(223,583)(18,602)
Financing
Proceeds from issuance of common shares and warrants470,670 130,276
Payment of share issue costs(10,008)(8,066)
Proceeds from issuance of shares by Canopy Rivers, net of share issue costs of $2,44854,876
Proceeds from exercise of stock options11,053 6,961
Proceeds from exercise of warrants770 126
Issuance of long-term debt3,500
Increase in finance lease obligations(317)260
Repayment of long-term debt(1,195)(959)
Net cash provided by financing activities525,849 132,098
Net cash inflow220,760 86,403
Cash and cash equivalents, beginning of year101,800 15,397
Cash and cash equivalents, end of year $ 322,560 $ 101,800

Consolidated Statements of Cas8

Consolidated Statements of Cash Flows (Paranthetical) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Statement Of Cash Flows [Abstract]
Share issue costs $ 2,448 $ 2,448

Description of Business

Description of Business12 Months Ended
Mar. 31, 2018
Disclosure Of Business Description [Abstract]
Description of Business1.
Description of business Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario with its common shares listed on the TSX, under the trading symbol “WEED” and as of May 24, 2018 on the NYSE, under the trading symbol “CGC”. References in these consolidated financial statements to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its direct and indirect subsidiaries. The principal activities of the Company are the growing, possession and sale of cannabis as regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) in Canada. The Company is also expanding to jurisdictions outside of Canada where federally lawful and regulated including subsidiaries which operate in Europe, Latin America and the Caribbean. Through its subsidiary Canopy Rivers Corporation (“Canopy Rivers”), the Company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector, where federally lawful.

Basis of Presentation

Basis of Presentation12 Months Ended
Mar. 31, 2018
Disclosure Of Basis Of Presentation [Abstract]
Basis of Presentation2.
Basis of presentation Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). These consolidated financial statements were approved by the Board of Directors and authorized for issue by the Board of Directors on June 27, 2018. Subsidiaries These consolidated financial statements are comprised of the financial results of the Company and its subsidiaries, which are the entities over which Canopy Growth has control. An investor controls an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and can affect those returns through its power over the investee. Non-controlling interests in the equity of Canopy Growth’s subsidiaries are shown separately in equity in the consolidated statements of financial position. The table below lists the Company’s subsidiaries that are consolidated in these financial statements and the ownership interest held by non-controlling interests.
2.
Basis of presentation (continued) Subsidiaries (continued)
Subsidiaries
Defined as
Non-controlling interests
Tweed Inc.
Tweed
-
Tweed Farms Inc.
Tweed Farms
-
Bedrocan Canada Inc.
Bedrocan Canada
-
Spectrum Cannabis Canada Ltd. (formerly Mettrum Ltd.)
Spectrum Cannabis
-
Tweed Grasslands Cannabis Inc.
Tweed Grasslands
-
Les Serres Vert Cannabis
Vert Mirabel
33.3%
Spot Therapeutics Inc.
Spot
-
Vert Cannabis Inc.
Vert Cannabis
-
2344823 Ontario Inc. d/b/a Bodystream
Bodystream
-
Apollo Applied Research Inc. and Apollo CRO Inc.
together "Apollo"
-
Mettrum Hempworks Inc.
Mettrum Hempworks
-
Groupe H.E.M.P.CA
Group H.E.M.P.
25%
Spectrum Health Corp. (formerly Mettrum Health Corp.)
Spectrum Health
-
10252832 Canada Inc
Edmonton
-
9388036 Canada Inc.
9388036 Canada
-
10663824 Canada Inc.
Alberta
-
80694 Newfoundand and Labrador Inc.
Newfoundland
-
Spektrum Cannabis GmbH
Spektrum Cannabis
-
Canopy LATAM Corporation
LATAM
-
Spectrum Chile SpA
Spectrum Chile
15%
Grow House JA Limited
Tweed JA
51%
Spectrum Cannabis Denmark Aps
Spectrum Cannabis Denmark
-
Spectrum Polska Sp
Spectrum Polska
-
Spectrum Cannabis Australia PTY Ltd.
Spectrum Australia
-
Spectrum Cannabis Italia srl
Spectrum Italy
-
Canopy Rivers Corporation
Canopy Rivers
68.5%
Refer to Note 14 for additional information on subsidiaries of the Company with non-controlling interests. Business combinations Acquisitions of subsidiaries and businesses are accounted for using the acquisition method. The Company measures goodwill as the fair value of the consideration transferred, including the recognized amount of any non-controlling interest in the acquiree, less the net recognized amount of the identifiable assets and liabilities assumed, all measured as of the acquisition date. Any excess of the fair value of the net assets acquired over the assumed consideration paid is a gain on business acquisition and is recognized as a gain in the Statement of Operations. The Company elects on a transaction-by-transaction basis whether to measure non-controlling interest at its fair value or at its proportionate share of the recognized amount of the identifiable net assets, at the acquisition date. Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.
2.
Basis of presentation (continued) Joint operations A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, related to the arrangement. Joint control is the contractually agreed sharing of control of an arrangement which exists only when decisions about the relevant activities require unanimous consent of parties sharing control. The Company recognizes only its assets, liabilities and share of the results of operations of the joint operation. The assets, liabilities and results of joint operations are included within the respective line items of the Consolidated Statements of Financial Position, Consolidated Statements of Operations, Consolidated Statements of Comprehensive Income (Loss), Consolidated Statements of Changes in Shareholders Equity and Consolidated Statements of Cash Flows. Refer to Note 13 for additional information on the Company’s joint operation. Investments in associates Associates are entities over which the Company exercises significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but without control or joint control over those policies. The Company accounts for associates using the equity method of accounting. Interests in associates accounted for using the equity method are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s interest in an associate is adjusted for the Company’s share of comprehensive income and distributions of the investee. The carrying value of associates is assessed for impairment at each balance sheet date. Refer to Note 15 for additional information on associates of the Company. Basis of measurement These consolidated financial statements have been prepared in Canadian dollars on a historical cost basis except for biological assets, assets classified as held for sale, available for sale investments, other long-term liabilities and derivatives, which are measured at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether the price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date Fair value measurements are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs). The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. Further information on fair value measurements is available in Notes 5, 10(c) and 28. Classification of expenses The expenses within the statements of operations and comprehensive income (loss) are presented by function. Refer to Note 22 for details of expenses by nature.

Significant Accounting Policies

Significant Accounting Policies12 Months Ended
Mar. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Significant Accounting Policies3.
Significant accounting policies (a) Foreign currency translation All figures presented in the consolidated financial statements and tabular disclosures to the consolidated financial statements are reflected in Canadian dollars, which is the functional currency of the Company. Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising from the acquisition, are translated in Canadian dollars at year-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in equity. (b) Biological assets The Company’s biological assets consist of cannabis plants. With the exception of depreciation, which is directly expensed in the period and presented separately in the Consolidated Statement of Operations, the Company capitalizes the direct and indirect costs incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest. The Company then measures the biological assets at fair value less cost to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. The net unrealized gains or losses arising from changes in fair value less cost to sell during the year are included in the results of operations of the related year. Seeds are measured at fair value. (c) Inventory Inventories of harvested work-in-process and finished goods are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories for resale and supplies and consumables are valued at the lower of costs and net realizable value, with cost determined using the average cost basis. (d) Property, plant and equipment Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Depreciation is provided on a straight-line basis over the following terms:
Computer equipment
2-3 years
Office/lab equipment
3-5 years
Furniture and fixtures
3-10 years
Warehouse equipment
5-15 years
Production equipment
3-30 years
Leasehold improvements
3-20 years
Building and improvements
20-40 years
Greenhouse and improvements
20-25 years An asset’s residual value, useful life and depreciation method are reviewed during each financial year and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item are determined by comparing the proceeds from disposal with the carrying amount of the item and recognized in profit or loss. Assets under capital lease are amortized according to their asset category. Assets in process are transferred to the appropriate asset class when available for use and depreciation of the assets commences at that point.
3.
Significant accounting policies (continued) (e) Finite-lived and indefinite-lived intangible assets Finite-lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms:
Domain name
5 years
Health Canada licenses
Useful life of facility or lease term
Distribution channel
5 years
Import license
4 years
Software
3 years The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives are comprised of acquired product rights and brand name which are carried at cost less accumulated impairment losses. (f) Impairment of long-lived assets Long-lived assets, including property, plant and equipment and intangible assets are reviewed for impairment at each statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss equal to the amount by which the carrying amount exceeds the recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously. (g) Goodwill Goodwill represents the excess of the price paid for the acquisition of an entity over the fair value of the net identifiable tangible and intangible assets and liabilities acquired. Goodwill is allocated to the CGU or CGUs to which it relates. Currently, the Company has one reportable segment. The Company has determined that the goodwill associated with all acquisitions belongs to this segment as this is the lowest level at which management monitors goodwill. Goodwill is measured at historical cost and is evaluated for impairment annually in the fourth quarter or more often if events or circumstances indicate there may be an impairment. CGUs have been grouped for purposes of impairment testing. Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs to sell and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in income in the period in which the impairment is identified. Impairment losses on goodwill are not subsequently reversed. (h) Leased assets The Company leases some items of property, plant and equipment. A lease of property, plant and equipment is classified as a capital lease if it transfers substantially all the risks and rewards incidental to ownership to the Company. A lease of property, plant and equipment is classified as an operating lease whenever the terms of the lease do not transfer substantially all of the risks and rewards of ownership to the lessee. Lease payments are recognized as an expense on a straight-line basis over the lease term, except where another systematic basis is more representative of the time pattern in which the economic benefits are consumed.
3.
Significant accounting policies (continued) (i) Assets held for sale Assets and liabilities held for disposal are no longer depreciated and are presented separately in the statement of financial position at the lower of their carrying amount and fair value less costs to sell. An asset is regarded as held for sale if its carrying amount will be recovered principally through a sale transaction, rather than through continuing use. For this to be the case, the asset must be available for immediate sale and its sale must be highly probable. (j) Revenue recognition Revenue is recognized at the fair value of consideration received or receivable. Revenue from the sale of goods is recognized when all the following conditions have been satisfied:

the Company has transferred to the buyer the significant risks and rewards of ownership of the goods;

the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;

the amount of revenue can be measured reliably;

it is probable that the economic benefits associated with the transaction will flow to the entity; and

the costs incurred or to be incurred in respect of the transaction can be measured reliably. (k) Research and development Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized in profit or loss as incurred. (l) Income taxes The Company uses the liability method to account for income taxes. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities for accounting purposes, and their respective tax bases. Deferred income tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and are reviewed at the end of each reporting period. (m) Share-based compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share based payments granted to non-employees the compensation expense is measured at the fair value of the good and services received except where the fair value cannot be estimated in which case it is measured at the fair value of the equity instruments granted. The fair value of share-based compensation to non-employees is periodically re-measured until counterparty performance is complete, and any change therein is recognized over the period and in the same manner as if the Company had paid cash instead of paying with or using equity instruments. Consideration paid by employees or non-employees on the exercise of stock options is recorded as share capital and the related share-based compensation is transferred from share-based reserve to share capital.
3.
Significant accounting policies (continued) (n) Earnings (loss) per share The Company presents basic and diluted earnings (loss) per share data for its common shares. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise warrants and share options issued. (o) Financial instruments Financial assets The Company initially recognizes financial assets at fair value on the date that they are originated. All financial assets (including assets designated at fair value through profit or loss, “FVTPL”) are recognized initially on the date at which the Company becomes a party to the contractual provisions of the instrument. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability. The Company classifies its financial assets as financial assets at FVTPL, available for sale (“AFS”) financial assets or loans and receivables. Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value. Subsequent to initial recognition loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. AFS financial assets are non-derivatives that are either designated as AFS or are not classified as loans and receivables or financial assets at FVTPL. AFS financial assets are stated at fair value at the end of each reporting period. The fair value is determined in the manner described in Note 28. Changes in the carrying amount of AFS monetary financial assets relating to changes in foreign currency rates, interest income calculated using the effective interest method and dividends on AFS equity investments are recognized in profit or loss. Other changes in the carrying amount of AFS financial assets are recognized in other comprehensive income (“OCI”). When the investment is disposed of or is determined to be impaired, the cumulative gain or loss previously accumulated in OCI is reclassified to profit or loss. AFS equity investments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured are measured at cost less any identified impairment losses at the end of each reporting period. Financial liabilities The Company initially recognizes financial liabilities at fair value on the date that they are originated. All financial liabilities (including liabilities designated at FVTPL) are recognized initially on the date at which the Company becomes a party to the contractual provisions of the instrument. The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. The Company classifies its financial liabilities as either financial liabilities at FVTPL or other liabilities. Subsequent to initial recognition other liabilities are measured at amortized cost using the effective interest method. Financial liabilities at fair value are stated at fair value with changes being recognized in profit or loss.
3.
Significant accounting policies (continued) (o) Financial instruments (continued) Classification of financial instruments The Company classifies its financial assets and liabilities depending on the purpose for which the financial instruments were acquired, their characteristics, and management intent as outlined below:
Classification
Cash and cash equivalents
FVTPL
Accounts receivable
Loans and receivable
Restricted investments
Loans and receivable
Other financial assets
Available for sale financial assets, Loans and
receivables and FVTPL
Accounts payable and accrued liabilities
Other liabilities
Long-term debt
Other liabilities
BC Tweed and Vert Mirabel put liability
FVTPL
Acquisition consideration related liabilities
FVTPL Effective interest method The effective interest method is a method of calculating the amortized cost of a financial instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Transaction costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss. Impairment of financial assets Financial assets, other than those classified at FVTPL, are assessed for indicators of impairment at the end of the reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. (p) Critical judgments in applying accounting policies The following are the critical judgments, apart from those involving estimations (refer to (q) below), that have the most significant effect on the amounts recognized in the financial statements. Business combinations Judgment is used in determining whether an acquisition is a business combination or an asset acquisition. Judgement is also required to assess whether the amounts paid on achievement of milestones represents contingent consideration or compensation for post-acquisition services. Judgment is also required to assess whether contingent consideration should be classified as equity or a liability. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with IAS 39, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss.
3.
Significant accounting policies (continued) (p) Critical judgments in applying accounting policies (continued) Control, joint control or level of influence When determining the appropriate basis of accounting for the Company’s interests in affiliates, the Company makes judgments about the degree of influence that it exerts directly or through an arrangement over the investees’ relevant activities. Information about these judgments is included in Note 12,15 and 16. Accounting for joint operation Judgment was used to determine whether the joint venture agreement described in Note 13 should be accounted for as a joint operation or a joint venture. Given the Company has rights to substantially all the economic benefits of the arrangement, through its obligation to purchase all of the output of BC Tweed, and also has an obligation for the liabilities of the arrangement the Company has concluded it will be accounted for as a joint operation. The Company will recognize its share of assets and liabilities and revenue and expenses in its consolidated financial statements on the basis of the Company’s proportionate share of BC Tweed’s output, being 100%. (q) Critical The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Biological assets and inventory In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, average or expected selling prices and list prices, expected yields for the cannabis plants, and oil conversion factors. In calculating final inventory values, management compares the inventory cost to estimated net realizable value. Further information on estimates used in determining the fair value of biological assets is contained in Note 5. Estimated useful lives and depreciation and amortization of property, plant and equipment and intangible assets Depreciation and amortization of property, plant and equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets. Share-based compensation In calculating the share-based compensation expense, key estimates such as the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company’s stock price and the risk free interest rate are used. To calculate the share-based compensation expense related to key employee performance milestones associated with the terms of an acquisition, the Company must estimate the number of shares that will be earned and when they will be issued based on estimated discounted probabilities. Fair value measurements Certain of the Company’s assets and liabilities are measured at fair value. In estimating fair value the Company uses market-observable data to the extent it is available. In certain cases where Level 1 inputs are not available the Company will engage third party qualified valuers to perform the valuation. Information about the valuation techniques and inputs used in determining the fair value of biological assets is disclosed in Note 5, the retained interest in Agripharm in Note 10(c) and financial assets and liabilities in Note 28.
3.
Significant accounting policies (continued) (r) New and revised IFRS in issue but not yet effective IFRS 15 Revenue from Contracts with Customers IFRS 15 was issued by the IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. On April 12, 2016, the IASB published final clarifications to IFRS 15 with respect to identifying performance obligations, principal versus agent considerations, and licensing. The Company will adopt IFRS 15 effective April 1, 2018. The Company is currently completing its assessment of the impact of this new standard. IFRS 9 Financial Instruments ("IFRS 9") IFRS 9 was issued by the IASB in November 2009 and October 2010 and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Financial liabilities are classified in a similar manner as under IAS 39. The Company will adopt IFRS 9 effective April 1, 2018. The Company is currently completing its assessment of the impact of this new standard. IFRS 16 Leases (“IFRS 16”) IFRS 16 was issued by the IASB in January 2016 and specifies the requirements to recognize, measure, present and disclose leases. IFRS 16 is effective for the Company for its annual period ending March 31, 2020 with early adoption permitted. The Company is continuing to assess the impact of this new standard on its financial position and financial performance.

Amounts Receivable

Amounts Receivable12 Months Ended
Mar. 31, 2018
Trade And Other Current Receivables [Abstract]
Amounts Receivable4.
amounts receivable Amounts receivable was comprised of:
March 31,
March 31,
2018
2017
Accounts receivable
$
5,863
$
2,794
Commodity tax receivable
15,262
2,769
Interest receivable
300
252
Total amounts receivable
$
21,425
$
5,815

Biological Assets

Biological Assets12 Months Ended
Mar. 31, 2018
Disclosure Of Detailed Information About Biological Assets [Abstract]
Biological Assets5.
Biological assets The Company’s biological assets consists of seeds and cannabis plants. The continuity of biological assets for the years ended March 31, 2018 and 2017 was as follows:
March 31,
March 31,
2018
2017
Balance, beginning of year
$
14,725
$
5,321
Purchases of seeds
271
70
Acquired biological assets
-
1,691
Disposed biological assets due to disposal of consolidated entity (Note 10(c))
(1,430
)
-
Unrealized gain on changes in fair value of biological assets
100,302
49,090
Increase in biological assets due to capitalized costs
17,309
11,983
Transferred to inventory upon harvest
(114,829
)
(53,430
)
Balance, end of year
$
16,348
$
14,725
5.
Biological assets (continued) Biological assets are valued in accordance with IAS 41 and are presented at their fair values less costs to sell up to the point of harvest. The Company’s biological assets are primarily cannabis plants, and because there is no actively traded commodity market for plants or dried product, the valuation of these biological assets is obtained using valuation techniques where the inputs are based upon unobservable market data (Level 3). The valuation of biological assets is based on a market approach where fair value at the point of harvest is estimated based on selling prices less the costs to sell at harvest. For in process biological assets, the fair value at point of harvest is adjusted based on the stage of growth. As at March 31, 2018, on average, the biological assets were 12% complete as to the next expected harvest date, compared to a 43% average stage of completion as at March 31, 2017. The significant unobservable inputs and their range of values are noted in the table below:
Unobservable Inputs
Range
Sensitivity
Estimated Yield per Plant – varies by strain and is obtained through historical growing results (trailing 6-months moving average) or grower estimate if historical results are not available.
25 grams/plant to 400 grams/plant
A slight increase in the estimated yield per plant would result in a significant increase in fair value, and vice versa.
Listed Selling Price of Dry Cannabis – varies by strain and is obtained through listed selling prices or estimated selling prices if historical results are not available.
$6 to $12/gram
A slight increase in the estimated selling price per strain would result in a significant increase in fair value, and vice versa.

Inventory

Inventory12 Months Ended
Mar. 31, 2018
Classes Of Inventories [Abstract]
Inventory6.
Inventory Inventory was comprised of the following items:
March 31,
March 31,
2018
2017
Dry Cannabis
Finished goods
$
14,114
$
2,478
Work-in-process
51,309
33,418
65,423
35,896
Cannabis Oils
Finished goods
9,624
2,085
Work-in-process
20,574
5,492
30,198
7,577
Capsules - Finished goods
2,705
-
Seeds - Finished goods
63
74
2,768
74
98,389
43,547
Product for resale (vaporizers and other)
571
1,017
Supplies and consumables
2,647
1,417
$
101,607
$
45,981
Inventories expensed during the year ended March 31, 2018, was $92,683 (year ended March 31, 2017 - $39,210). The fair value changes in biological assets included in inventory sold and other inventory charges of $66,268 consists of fair value changes in biological assets included in inventory sold of $40,509 and other inventory charges of $25,759. Included in other inventory charges is a net realizable value adjustment for anticipated price changes of $8,431 and inventory write-offs of $7,903.

Prepaid Expenses and Other Asse

Prepaid Expenses and Other Assets12 Months Ended
Mar. 31, 2018
Prepaid Expenses And Other Assets [Abstract]
Prepaid Expenses and Other Assets7.
PREPAID EXPENSES AND OTHER ASSETS The Company’s prepaid expenses and other assets consists of the following:
March 31,
March 31,
2018
2017
Prepaid packaging
$
8,774
$
-
Prepaid expenses
7,358
2,934
Prepaid deposits
842
-
Restricted short-term investments
664
550
Other assets
2,199
801
$
19,837
$
4,285
Other long-term assets of $8,340 includes deposits on property, plant and equipment amounting to $6,487 and a lease payment of $1,853 which is being amortized over the term of the lease.

Assets Classified as Held for S

Assets Classified as Held for Sale12 Months Ended
Mar. 31, 2018
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners [Abstract]
Assets Classified as Held for Sale8.
ASSETS CLASSIFIED AS HELD FOR SALE The assets classified as held for sale represented a non-strategic facility that was sold on September 13, 2017, for $7,000 which equated to its carrying amount after adjusting for the deferred tax liability of $820. The Company has agreed to provide transitional services to the purchaser and has entered into a three-year supply agreement to provide medical cannabis and cannabis extracts to the purchaser.

Property, Plant and Equipment

Property, Plant and Equipment12 Months Ended
Mar. 31, 2018
Disclosure Of Property Plant And Equipment [Abstract]
Property, Plant and Equipment9.
Property, plant and equipment A continuity of property, plant and equipment for the year ended March 31, 2018 is as follows:
COST
Balance at
Disposal of
Balance at
April 1,
Additions from
consolidated
Transfers/
March 31,
2017
Additions
acquisitions
entity
disposals
2018
Computer equipment
$
4,181
$
1,219
$
-
$
(101
)
$
942
$
6,241
Office/lab equipment
831
626
-
(16
)
279
1,720
Furniture and fixtures
875
348
109
-
49
1,381
Production equipment
11,132
4,511
468
(2,619
)
15,272
28,764
Leasehold improvements
17,155
338
-
-
4,989
22,482
Building and improvements
43,449
3,799
-
(5,066
)
25,331
67,513
Greenhouse and improvements
3,528
106
-
-
461
4,095
Land and improvements
2,397
5,728
345
-
-
8,470
Warehouse equipment
-
138
-
-
29
167
Assets in process
19,302
201,509
5,164
-
(48,977
)
176,998
Total
$
102,850
$
218,322
$
6,086
$
(7,802
)
$
(1,625
)
$
317,831
ACCUMULATED DEPRECIATION
Balance at
Disposal of
Balance at
April 1,
consolidated
Transfers/
March 31,
2017
Depreciation
entity
disposals
2018
Computer equipment
$
889
$
1,043
$
(31
)
$
(1
)
$
1,900
Office/lab equipment
82
404
(5
)
(2
)
479
Furniture and fixtures
82
137
-
(1
)
218
Production equipment
1,038
2,539
(587
)
(260
)
2,730
Leasehold improvements
1,930
1,510
-
12
3,452
Building and improvements
2,182
2,920
(217
)
(64
)
4,821
Greenhouse and improvements
358
155
-
-
513
Land and improvements
19
11
-
-
30
Warehouse equipment
-
6
-
-
6
Total
6,580
8,725
(840
)
(316
)
14,149
Net book value
$
96,270
$
303,682
9.
Property, plant and equipment (continued) During the year ended March 31, 2018, the assets in process additions were $201,509 of which $71,155, $64,813, and $43,847 related to the expansion or growing operations at both BC locations, Smiths Falls Ontario, and Niagara-on-the-Lake, respectively. The remaining $21,694 was for ongoing projects at the Company’s other subsidiaries. On September 7, 2017, the Company acquired the parcel of land including an operational greenhouse adjacent to its current greenhouse facility in Niagara-on-the Lake. The purchase price of $8,865 was partially settled through the payment on closing of $6,000 cash and the issuance of 111,366 common shares with a value of $1,003. The balance will be paid through the issuance of common shares to a value of $2,000 calculated at the 5-day volume weighted average price (“VWAP”) on the earlier of the completion of the facility’s renovation and September 7, 2018. The value to be paid was discounted to arrive at the initial present value of the obligation of $1,862. The Company also capitalized $71 of acquisition costs. The newly acquired greenhouse is undergoing improvements and is recorded in assets in process. A continuity of property, plant and equipment for the year ended March 31, 2017 is as follows:
COST
Balance at
Balance at
April 1,
Additions from
Transfers/
March 31,
2016
Additions
acquisitions
disposals
2017
Computer equipment
$
958
$
886
$
313
$
2,024
$
4,181
Office/lab equipment
935
536
408
(1,048
)
831
Furniture and fixtures
2,428
1,343
26
(2,922
)
875
Production equipment
1,543
1,668
3,789
4,132
11,132
Leasehold improvements
37,620
2,972
229
(23,666
)
17,155
Building and improvements
136
6,551
12,449
24,313
43,449
Greenhouse and improvements
2,951
-
-
577
3,528
Land and improvements
723
420
1,000
254
2,397
Warehouse equipment
-
-
-
-
-
Assets in process
403
18,771
5,138
(5,010
)
19,302
Total
47,697
33,147
23,352
(1,346
)
102,850
ACCUMULATED DEPRECIATION
Balance at
Balance at
April 1,
Transfers/
March 31,
2016
Depreciation
disposals
2017
Computer equipment
$
255
$
516
$
118
$
889
Office/lab equipment
157
266
(341
)
82
Furniture and fixtures
223
356
(497
)
82
Production equipment
139
279
620
1,038
Leasehold improvements
1,714
2,455
(2,239
)
1,930
Building and improvements
14
156
2,012
2,182
Greenhouse and improvements
211
118
29
358
Land and improvements
-
-
19
19
Warehouse equipment
-
-
-
-
Total
2,713
4,146
(279
)
6,580
Net book value
$
44,984
$
96,270
The $23,666 cost adjustment from leasehold improvements is largely due to improvements which were made to the facility in Smiths Falls Ontario which were transferred to building and improvements upon acquisition on January 13, 2017. On January 13, 2017, the Company acquired the 472,000 square foot property at 1 Hershey Drive that currently houses Canopy Growth’s headquarters and the Tweed production facilities for $7,163, including transaction costs of $179, from Tweed Hershey Drive Inc. (“Tweed Hershey”). Tweed Hershey was related through common ownership (the Company’s CEO and Chairman is a significant shareholder of Tweed Hershey). The purchase price was partially settled with the issuance of 94,397 of the Company’s common shares with a value of $858 and the rent deposit of $450. The shares were subject to a 4-month lockup. The remainder was paid in cash on closing. The portion of the facility that is not currently being used by the Company has been recorded in assets in process.
9.
Property, plant and equipment (continued) Of the $1,346 net cost disposals/adjustments, $632 was transferred to intangibles as these amounts were composed of software. Refer to Note 11. During the year ended March 31, 2017, the assets in process additions were $18,771 of which $15,997 related principally to the expansion or growing operations at Tweed in Smiths Falls Ontario.

Acquistions and Disposals

Acquistions and Disposals12 Months Ended
Mar. 31, 2018
Disclosure Of Business Combinations [Abstract]
Acquistions and Disposals10.
acquistions and disposalS
(a)
Acquisitions completed in Fiscal 2018 The following table summarizes the balance sheet impact on the acquisition date of the Company’s business combinations that occurred in the period ended March 31, 2018:
Tweed Grasslands
Tweed JA
Odense
Vert Mirabel
Other acquisitions
(i)
(ii)
(iii)
(iv)
(v)
Cash and cash equivalents
$
59
$
125
$
-
$
-
$
7
Amounts receivable
16
-
-
-
14
Subscription receivable
-
3,669
-
-
-
Inventory
-
-
173
-
-
Prepaids and other assets
6
-
-
-
107
Property, plant and equipment
1,446
182
3,990
-
468
Goodwill
29,736
1,835
-
5,625
1,562
Accounts payable and accrued
-
liabilities
(336
)
(29
)
-
-
(143
)
Deferred tax liability
-
-
(297
)
-
-
Net assets
30,927
5,782
3,866
5,625
2,015
Non-controlling interests
-
(2,013
)
-
(2,839
)
-
Net assets acquired
$
30,927
$
3,769
$
3,866
$
2,786
$
2,015
Consideration paid in cash
$
450
$
100
$
3,228
$
-
$
166
Consideration paid in shares
6,381
-
-
-
1,850
Future cash consideration
-
3,669
-
-
-
Other consideration
2,382
-
-
3,750
-
Contingent consideration
21,714
-
-
-
-
Total consideration
$
30,927
$
3,769
$
3,228
$
3,750
$
2,016
Consideration paid in cash
$
(450
)
$
(100
)
$
(3,228
)
$
-
$
(166
)
Less: Cash and cash equivalents
acquired
59
125
-
-
7
Net cash (outflow) inflow
$
(391
)
$
25
$
(3,228
)
$
-
$
(159
)
Acquisition-related costs
expensed
$
302
$
24
$
33
$
54
$
213
Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill arising on these acquisitions are expected to be deductible for tax purposes.
10.
acquistions and disposalS (continued) (i) Tweed Grasslands Cannabis Inc. (formerly rTrees) On May 1, 2017, the Company purchased 100% of the issued and outstanding shares of rTrees Producers Inc. (“rTrees”), a late-stage ACMPR applicant based in Yorkton, Saskatchewan. On June 30, 2017, rTrees changed its name to Tweed Grasslands Cannabis Inc (“Tweed Grasslands”). The consideration for the transaction included 3,494,505 common shares issued to former shareholders of rTrees, of which 2,795,604 common shares were to be held in escrow and will be either released to the former shareholders of rTrees upon the satisfaction of certain specific license achievement, or released to the Company for cancellation. The 698,901 shares released on closing were recorded at an issue price of $9.13 per share for consideration of $6,381. The shares being held in escrow were recorded as equity based contingent consideration. The achievement of milestones was assessed probabilities by management which were then discounted to present value in order to derive a fair value of the contingent consideration. In aggregate, the amount of contingent consideration is up to $25,524 with a fair value of $21,714 at the acquisition date. All the milestones were achieved in fiscal 2018 and the shares were released from escrow. Other consideration included $1,079 of replacement options and $1,303 of replacement warrants. There was also an effective settlement of a note receivable of $450 for total consideration of $30,927. For the year ended March 31, 2018, rTrees contributed a loss of $1,565. (ii) Tweed JA On September 6, 2017, the Company subscribed for 49% of the issued and outstanding shares of Grow House JA Limited (now operating as Tweed JA), for $3,769 payable in cash. Tweed JA is a Jamaican company that had received a provisional license to cultivate and sell medical cannabis. As of March 31, 2018, $2,000 of the subscription price has been advanced and the balance of the subscription price will be advanced based on funding milestones. Through the shareholder agreement, the Company has rights that allow it to direct the relevant activities of Tweed JA such that the Company has control, and Tweed JA is consolidated in these financial statements. The non-controlling interest recognized at the acquisition date was recorded at its proportionate share of the identifiable net assets. For the year ended March 31, 2018, Tweed JA contributed a loss of $391. (iii) Spectrum Cannabis Denmark ApS and acquisition of Odense operation On September 20, 2017, the Company formed Spectrum Cannabis Denmark ApS (“Spectrum Denmark”). Spectrum Denmark will produce, cultivate and distribute medical cannabis products in Denmark. Spectrum Denmark will also seek to establish operations in other jurisdictions in Europe where federally lawful and regulated. The Company owns 62% of the issued shares of Spectrum Denmark and Danish Cannabis ApS (“Danish Cannabis”) owns the remaining 38% of shares. Upon achievement of defined milestones, Danish Cannabis has a right to exchange its shares in Spectrum Denmark for a maximum of 1,906,214 common shares of the Company. On issuance, the shares are subject to either a three or six month restriction on trading. If after 4 years, the defined milestones are not met then the Company will be entitled to purchase any remaining interest of Danish Cannabis in Spectrum Denmark for up to $6,000. The shares are being provided in exchange for the services that the principals of Danish Cannabis are providing to Spectrum Denmark and are being accounted for as share-based compensation expense. The fair value on the grant date of September 20, 2017, of $18,805 was estimated by discounting the quoted price of the shares to reflect the restriction on trading using a put option pricing model. The Company is amortizing the expense over the estimated vesting period. For the year ended March 31, 2018, the Company recorded $7,206 in share-based compensation related to these shares. On December 5, 2017, Spectrum Denmark purchased a 40,000 square meter operating greenhouse facility in Odense, Denmark (“Odense”) from a liquidator for cash consideration of $3,228. This transaction was accounted for as a business combination and generated a bargain purchase gain of $ 638 which is included in Other income and expense. Excluding the impact of the bargain purchase gain for the year ended March 31, 2018, Odense contributed a loss of $1,772. The accounting for the acquisition of Odense was only provisionally determined at December 31, 2017. The Company has now completed its final assessment of the accounting for this transaction.
10.
acquistions and disposalS (continued) (iv) Vert Mirabel On December 18, 2017, the Company, Canopy Rivers and Les Serres Stephane Bertrand Inc. (“Bertrand”) formed a new company, Les Serres Vert Cannabis Inc. (“Vert Mirabel”). Bertrand was a large-scale greenhouse operator in Mirabel, Quebec. The Company owns 40.7%, Canopy Rivers 26% and Bertrand owns 33.3% of the common shares of Vert Mirabel. Vert Mirabel will lease from Bertrand its 700,000-square foot greenhouse which will be retrofitted for cannabis production. Vert Mirabel has an option to acquire the property for a term of ten years from the date Vert Mirabel receives its sales and cultivation license under ACMPR. The purchase price for acquiring the property is $20 million (this price will increase by 3% per year from the License Date with a minimum purchase price of $23 million if exercised within five years of signing this agreement). The Company has the option to purchase from Bertrand its interest in Vert Mirabel and Bertrand has the option to sell its interest in Vert Mirabel to the Company in exchange for shares in the Company equal to the fair value of their interest in Vert Mirabel on the date of exercise. The call and put options are exercisable only on specific dates – the 5 th th Through its direct and indirect voting rights, the Company controls Vert Mirabel. The greenhouse operation transferred by Bertrand meets the definition of a business and will be accounted for as a business combination. The Vert Mirabel Put Liability represents the consideration paid by Canopy for acquiring control of this greenhouse operation. The Company has agreed to purchase from Vert Mirabel 100% of the cannabis produced for a fixed price during an initial term of two years and thereafter, for a price computed with reference to the market price and has also guaranteed a minimum level of income for Vert Mirabel under this agreement. The offtake agreement terminates upon acquisition of the property by Vert Mirabel. Upon termination of the offtake agreement, Vert Mirabel will agree to provide the Company with a right of first offer to the cannabis produced by Vert Mirabel. Canopy Rivers has committed to contribute up to $15,000 in cash, in exchange for Class A Preferred Shares with cumulative preferred dividends at a rate of 18%. Of this amount, $750 was advanced on closing. The Company will issue to Bertrand $2,750 of common stock in four equal tranches upon achievement of various milestones. These payments will be accounted for as share-based compensation expense. The fair value on the grant date of December 18, 2018, of $2,599 was estimated by discounting the value of the shares. The Company is amortizing the expense over the estimated vesting period. For the year ended March 31, 2018, the Company recorded $1,131 in share-based compensation related to these shares. Excluding the increase in the Vert Mirabel Put Liability f or the year ended March 31, 2018, Vert Mirabel contributed a loss of $1,411. Acquisition related costs of $54 were recognized as an expense for the year ended March 31, 2018.
10.
acquistions and disposalS (continued) (v) Other fiscal 2018 acquisitions On August 28, 2017, the Company purchased 100% of the issued and outstanding shares of Spot Therapeutics Inc. (“Spot”), an ACMPR applicant based in Fredericton, New Brunswick. At closing, the Company issued 111,669 common shares to the shareholders of Spot which were recorded at an issue price of $8.90 per common share for consideration of $993. A second tranche payment which is estimated to be $907 will be satisfied by the issuance of additional common shares calculated using the VWAP for 20 days preceding satisfaction of tranche conditions. The payment is contingent on the performance of future services and the achievement of certain licensing and operational milestones. The second tranche payment will be treated as share-based compensation and the present value of $844 will be amortized rateably over the expected vesting period. On January 24, 2018, the Company acquired certain assets, intellectual property, and assumed various lease contracts relating to Green Hemp Industries Ltd ("Green Hemp"), a veteran hemp farm operator based in Saskatchewan. The consideration for the transaction included 24,577 common shares issued to Green Hemp. The 24,577 shares released on closing were recorded at an issue price of $34.87 per share for consideration of $857. Other consideration included a cash payment of $166 for total consideration of $1,023. A second tranche payment of 24,577 is contingent on the performance of future services and the achievement of certain milestones. This tranche will be treated as share-based compensation and the expense of $857 will be amortized rateably over the expected vesting period.
(b)
Acquisitions completed in Fiscal 2017 The following table summarizes the balance sheet impact on the acquisition date of the Company’s business combinations that occurred in the period ended March 31, 2017:
Mettrum
MedCann GmbH
Other acquisitions
(i)
(ii)
(iii)
Cash and cash equivalents
$
12,309
$
-
$
15
Amounts receivable
2,140
5
-
Biological assets
1,691
-
-
Inventory
5,022
137
-
Prepaids and other assets
1,184
102
24
Assets classified as held for sale
7,000
-
-
Property, plant and equipment
22,451
336
565
Intangible assets
131,009
784
12
Goodwill
207,081
9,209
4,024
Accounts payable and accrued liabilities
(5,663
)
(107
)
(115
)
Debt
(3,576
)
-
-
Other liabilities
(768
)
-
-
Deferred tax liability
(29,546
)
(60
)
-
Net assets
350,334
10,406
4,525
Non-controlling interests
-
-
(19
)
Net assets acquired
$
350,334
$
10,406
$
4,506
Consideration paid in cash
$
-
$
-
$
1,131
Consideration paid in shares
337,511
9,720
2,124
Other consideration
12,823
-
-
Contingent consideration
-
688
1,251
Total consideration
$
350,334
$
10,408
$
4,506
Consideration paid in cash
$
-
$
-
$
(1,131
)
Less: Cash and cash equivalents
acquired
12,309
-
15
Net cash (outflow) inflow
$
12,309
$
-
$
(1,116
)
Acquisition-related costs expensed
$
5,190
$
372
$
163
10.
acquistions and disposalS (continued)
(b)
Acquisitions completed in Fiscal 2017 (continued) Goodwill arose in these acquisitions because the cost of acquisition included a control premium. In addition, the consideration paid for the combination reflected the benefit of expected revenue growth and future market development, along with the assembled work force for Mettrum. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill arising on these acquisitions are expected to be deductible for tax purposes. (i) Mettrum (renamed Spectrum Cannabis Canada) On January 31, 2017, the Company purchased 100% of the issued and outstanding shares of Mettrum Ltd. (“Mettrum”), a producer and vendor of medical cannabis. Subsequent to year end, Mettrum Ltd. changed its name to Spectrum Cannabis Canada Ltd (“Spectrum Cannabis Canada”). The transaction was accounted for as a business combination. The consideration for the transaction was 34,265,042 shares issued at a price of $9.85 per share which totaled $337,511, less cash acquired of $12,309. Other consideration included $11,663 of replacement stock options, other share based payments of $480 and an effective settlement of accounts receivable of $680 for total consideration of $350,334. Mettrum shares and replacement options were exchanged at a ratio of 0.7132 Mettrum shares to 1 Canopy Growth share. Acquisition related costs of $5,190 were recognized as an expense in the year ended March 31, 2017, $1,000 of which was satisfied by issuing 83,822 common shares at $11.93 per share. For the year ended March 31, 2017, Mettrum accounted for $4,053 in net loss since January 31, 2017. This amount included $2,659 of unrealized gain on changes in fair value of biological assets and revenues of $3,033. Had the business combination been effected at April 1, 2016, management estimates that the revenue of the Company would have been $15,428 higher and the net loss after income taxes of the Company would have increased by $12,673 for the year ended March 31, 2017. Additional purchase consideration included replacement options and other stock based compensation offered to employees and directors of Mettrum including amounts provided to employees who were former shareholders of Apollo and Bodystream (refer to Note 20(c)). Prior to the acquisition of Mettrum, the Company had accounts receivable of $680 from Mettrum. As a result of the business combination the preexisting relationship is effectively settled. The Company has increased the consideration transferred to account for this effective settlement. (ii) MedCann GmbH (renamed Spektrum Cannabis GmbH) On December 12, 2016, the Company purchased 100% of the issued and outstanding shares of MedCann GmbH, a German-based pharmaceutical importer and distributor who has successfully placed Tweed-branded cannabis strains in German pharmacies. Subsequent to the acquisition, MedCann GmbH Pharma and Nutraceuticals changed its name to Spektrum Cannabis GmbH. In connection with the acquisition of MedCann GmbH, the Company will issue up to 1,165,272 common shares to former shareholders of MedCann GmbH, of which 674,631 were released on closing for consideration of $6,746 and 490,641 common shares will be held in escrow and either (i) released to the former shareholders of Medcann GmbH upon the satisfaction of certain milestones, or (ii) released to the Company for cancellation. The shares to be issued based on license achievements were accounted for as equity classified contingent consideration. Management assessed the probability and timing of achievement then discounted to present value using a put option pricing model in order to derive a fair value of the contingent consideration of $3,660. In aggregate, the amount of contingent consideration is up to $4,906 and the fair value was $3,660 at the acquisition date based on the expected timing of achievement. On November 23, 2017 the Company released 367,981 of the shares being held in escrow. As of March 31, 2018, 122,660 remain in escrow. For the year ended March 31, 2017, MedCann GmbH accounted for $542 in net loss from December 12, 2016 to March 31, 2017, which included revenues of $35.
10.
acquistions and disposalS (continued) (ii) MedCann GmbH (renamed Spektrum Cannabis GmbH) (continued) Had the business combination been effected at April 1, 2016, management estimates that the revenue of the Company would have been $106 higher and the net loss after income taxes of the Company would have increased by $462 for the year ended March 31, 2017. (iii) Other fiscal 2017 acquisitions On November 1, 2016, the Company purchased 100% of the issued and outstanding shares of Vert Médical Inc. – Green Medical Inc., a Quebec-based company that began its application for federal government approval to produce medical cannabis in 2013. On acquisition, the entity was amalgamated as Vert Cannabis Inc. (“Vert”). In connection with the acquisition of Vert, the Company paid $498 and will issue up to 294,900 common shares to former shareholders of Vert, of which 58,978 were released on closing for consideration of $413 and 235,922 common shares were held in escrow and will be released to the former shareholders of Vert upon the satisfaction of certain milestones. The shares to be issued based on license achievements were accounted for as equity classified contingent consideration. Management assessed the probability and timing of achievement and then discounted to present value using a put option pricing model. In aggregate, the amount of contingent consideration is up to $1,651 and the fair value was $1,251 at November 1, 2016. In January 2018, 147,453 shares were released from escrow. As of March 31, 2018, 88,469 remain in escrow. On November 1, 2016, the Company purchased 75% of the issued and outstanding shares of Hemp.CA. Through the acquisition, the Company obtained a hemp production license and Hemp.CA brands and digital properties. In connection with the acquisition of Hemp.CA, the Company paid $595 and will issue up to 258,037 common shares to former shareholders of Hemp.CA, of which 129,021 were issued on closing and 129,016 common shares were to be held in escrow until April 1, 2017. The common shares held in escrow were discounted to present value and amounted to $808 at November 1, 2016. In total, the consideration for the transaction was $2,344 which included $338 in cash, $295 paid on March 30, 2017, $903 in common shares issued and $808 in common shares held in escrow. On April 1, 2017, the Company released the remaining 129,016 common shares held in escrow in relation to the Hemp.CA purchase. The non-controlling interest (25% ownership interest in Hemp) recognized at acquisition date was recorded at their proportionate share of the identifiable net assets.
(c)
Disposal of Consolidated Entity Agripharm Corp. (“Agripharm’) holds the lease and a Health Canada license for a facility at Creemore, Ontario. Prior to December 1, 2017, Agripharm was a wholly-owned subsidiary of the Company. On December 1, 2017, the Company’s interest in Agripharm was diluted from 100% to 40% under an arrangement whereby Green House Holdings North America Inc. and National Concessions Group Inc. granted exclusive royalty-free licenses in Canada to certain proprietary technology, trademarks, genetics, know-how and other intellectual property to Agripharm in exchange for shares of Agripharm. At the same time, Agripharm entered into an agreement to sublicense these licenses to the Company, as permitted under the arrangement.
10.
ACQUISTIONS AND DISPOSALS (CONTINUED) (c) Disposal of Consolidated Entity (continued) Following this transaction, the Company no longer controls Agripharm and the Company derecognized the assets and liabilities of Agripharm from its consolidated financial statements at their carrying amounts. Goodwill of $2,259 was allocated to Agripharm on the basis of the relative values of Agripharm on the date control was lost and the Company as a whole. The derecognized assets and liabilities on November 30, 2017, were as follows:
Cash and cash equivalents
$
(17
)
Amounts receivable
158
Inventory
21
Biological assets
1,430
Prepaids and other assets
451
Property, plant and equipment
6,962
Intangible assets
26,282
Goodwill
2,259
Accounts payable and accrued liabilities
(1,194
)
Capital lease obligations
(1,073
)
Deferred tax liability
(5,699
)
Net assets disposed
$
29,580
Fair value of retained interest
38,400
Gain on disposal of consolidated entity
$
8,820
The gain calculated on the derecognition of Agripharm’s assets and liabilities is the difference between the carrying amounts of the derecognized assets and liabilities of Agripharm and the fair value of consideration received, being the fair value of the Company’s retained interest in Agripharm. The fair value of this interest was estimated to be $38,400 which was determined using a discounted cash flow approach. The most significant inputs to the fair value measurement are the discount rate, expectations about future prices and capacity of the facility. Through its ownership and other rights, the Company continues to have significant influence over Agripharm and will account for its retained interest in Agripharm using the equity method of accounting. The investment will initially be recognized at its fair value and adjusted thereafter to recognize the Company’s share of net income or loss and other comprehensive income. Transaction costs of $311 have been included in the carrying value of the investment. The Company will record its share of net income or loss one quarter in arrears with adjustments for any significant transactions. To the extent that there are differences between the fair value of the assets and liabilities of Agripharm and the book value of these assets and liabilities that would impact earnings the Company has accounted for these differences in its equity earnings in the investee. The Company also entered into an agreement with Agripharm whereby Agripharm has committed to sell up to 100% of the output produced by Agripharm to the Company, subject to the right of Agripharm to sell up to 25% of its products directly in its own physical brick-and-mortar retail locations, if permitted by applicable law. The price to be paid is cost plus a percentage of profit margin. Contemporaneously with entering into the above agreement, Canopy Rivers committed to advance up to $20,000 to Agripharm under a repayable debenture and royalty agreement. Under the repayable debenture and royalty agreement, Canopy Rivers will receive a royalty for a term of 20 years. The repayable debenture and royalty is being accounted for as one instrument and is classified as loans and receivables and is being measured at amortized cost. To date, $3,000 has been advanced under the royalty agreement and $nil advanced under the repayable debenture.
10.
ACQUISTIONS AND DISPOSALS (CONTINUED) (c) Disposal of Consolidated Entity (continued) As part of the consideration for entering into the repayable debenture and royalty agreement, Canopy Rivers also received a warrant to acquire 4% of Agripharm for $5,000. The warrant expires the later of November 16, 2020, or two years after Agripharm becomes a public company. The warrant represents a derivative financial instrument that is initially measured at fair value and subsequently measured to its fair value at the end of each reporting period, with changes in fair value recorded through profit or loss. On initial recognition the fair value of the warrant was estimated as $586 using a Black-Scholes model. The fair value of the warrant was recorded as a reduction to the $3,000 receivable under the royalty agreement which resulted in the residual amount of $2,414 being allocated to the royalty receivable. Estimated future cash flows to be received under the repayable debenture and royalty agreement will be discounted back to the amounts advanced to Agripharm by Canopy Rivers, net of the warrant received, at the effective interest rate. Amounts received by Agripharm will be allocated to reduce the principal amount owing and interest payments based on the effective interest rate. Estimated future cash flows will be updated at each reporting date based on the most recent information available.

Intangible Assets And Goodwill

Intangible Assets And Goodwill12 Months Ended
Mar. 31, 2018
Disclosure Of Intangible Assets [Abstract]
Intangible Assets And Goodwill11.
Intangible assets and goodwill A continuity of the intangible assets for the year ended March 31, 2018 is as follows:
COST
Balance at
Additions
Balance at
April 1,
from
Disposals/
Exchange
March 31,
2017
Additions
acquisitions
adjustments
differences
2018
Health Canada licenses
$
92,200
$
-
$
-
$
(27,600
)
$
-
$
64,600
Distribution channel
38,900
-
-
-
-
38,900
Product rights
28,000
-
-
(28,000
)
-
-
Brand
3,410
-
2,632
-
-
6,042
Import license
795
-
-
-
46
841
Software
1,197
117
-
143
(2
)
1,455
Domain name
54
-
-
-
-
54
Intangibles in process
92
1,646
600
(194
)
-
2,144
Internally generated intangibles in process
-
326
-
-
-
326
Total
$
164,648
$
2,089
$
3,232
$
(55,651
)
$
44
$
114,362
ACCUMULATED AMORTIZATION
Balance at
Balance at
April 1,
Disposals/
Exchange
March 31,
2017
Amortization
adjustments
differences
2018
Health Canada licenses
$
985
$
2,957
$
(1,318
)
$
-
$
2,624
Distribution channel
1,000
8,077
-
-
9,077
Import license
57
155
-
7
219
Software
305
557
-
1
863
Domain name
38
15
-
-
53
Total
2,385
11,761
(1,318
)
8
12,836
Net book value
$
162,263
$
101,526
A significant disposal of intangible assets in the period related to the disposal of Agripharm which resulted in a net derecognition of the related Health Canada License of $26,282. Refer to Note 10 (c).
11.
Intangible assets and goodwill (continued) The product rights were acquired as part of the acquisition of Bedrocan Canada Inc. that was completed in August 2015. On July 14, 2017 Bedrocan Canada Inc., a wholly owned subsidiary of the Company, commenced arbitration proceedings against Bedrocan International BV (“Bedrocan International”) seeking performance of Bedrocan International’s contractual obligations under the licensing and distribution agreement between the parties. During the fourth quarter of fiscal 2018 the Company initiated settlement negotiations with Bedrocan International which would include the orderly termination of the licensing and distribution agreement. As a result of these developments management has estimated that the recoverable amount for these product rights would be minimal and an impairment loss of $28,000 has been recognized in the Consolidated Statements of Operations within Other Income. On February 7, 2018, the Company acquired a brand, certain technology, and lab equipment in exchange for the issuance of 117,253 common shares with a value of $3,239. The Company capitalized $43 of acquisition costs related to this transaction. Lab equipment of $50 was recorded to property plant, and equipment with the remaining $3,232 recorded to intangible assets. Under the terms of the transaction, the sellers will receive additional shares up to a value of $1,065 if certain milestones are met. This variable consideration will be recorded if and when these milestones are achieved. On closing of the transaction the sellers entered in to consulting agreements with the Company. As additional consideration for entering in to these agreements they will receive shares to a value of $1,127, based on the 5 day VWAP at the time the shares are issued, which will be recorded as share based compensation expense over the term of the agreements. A continuity of the intangible assets for the year ended March 31, 2017 is as follows:
COST
Balance at
Additions
Balance at
April 1,
from
Disposals/
Exchange
March 31,
2016
Additions
acquisitions
adjustments
differences
2017
Health Canada licenses
$
4,000
$
-
$
88,200
$
-
$
-
$
92,200
Distribution Channel
-
-
38,900
-
-
38,900
Product rights
28,000
-
-
-
-
28,000
Brand
-
-
3,410
-
-
3,410
Import license
-
-
779
-
16
795
Software
-
49
516
632
-
1,197
Domain name
54
-
-
-
-
54
Intangibles in process
-
92
-
-
-
92
Total
32,054
141
131,805
632
16
164,648
ACCUMULATED AMORTIZATION
Balance at
Balance at
April 1,
Disposals/
Exchange
March 31,
2016
Amortization
adjustments
differences
2017
Health Canada licenses
$
166
$
819
$
-
$
-
$
985
Distribution Channel
-
1,000
-
-
1,000
Import license
-
57
-
-
57
Software
-
31
274
-
305
Domain name
27
11
-
-
38
Total
193
1,918
274
-
2,385
Net book value
$
31,861
$
162,263
11.
Intangible assets and goodwill (continued) The net change in goodwill is as follows:
As at March 31, 2016
$
20,866
Additions from acquisitions of subsidiaries
10(b)
220,314
Exchange differences
191
As at March 31, 2017
241,371
Additions from acquisitions of subsidiaries
10(a)
38,758
Additions from acquisition of joint operation
13
36,400
Disposal of consolidated entity
10(c)
(2,259
)
Exchange differences
653
As at March 31, 2018
$
314,923

Formation of Canopy Rivers

Formation of Canopy Rivers12 Months Ended
Mar. 31, 2018
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Formation of Canopy Rivers12.
FORMATION OF CANOPY RIVERS On May 12, 2017, the Company advanced $20,000 in the form of a convertible debenture to a newly formed subsidiary company, Canopy Rivers. Other investors advanced $953 of seed capital to purchase 19,066,667 Class B common shares, including $503 that was advanced by certain employees of the Company and a consultant, where the Company provided a share purchase loan which was used to pay for the Class B common shares. On June 16, 2017, Canopy Rivers completed a Class B common share offering for aggregate gross proceeds of $36,899 at which time the convertible debenture including interest of $57 was converted into Class A common shares of Canopy Rivers. This included shares with a value of $668 that were issued in exchange for services. Share issue costs net of the related tax benefit were $1,709. Through these Class A common shares, the Company’s ownership interest in Canopy Rivers was 34.1%, and represented 91.2% of the voting rights. The voting rights allow the Company to direct the relevant activities of Canopy Rivers such that the Company has control over Canopy Rivers and Canopy Rivers is consolidated in these financial statements. The difference between the consideration paid by investors to acquire the non-controlling interests and the net assets acquired of $1,065 has been recorded as a decrease to equity attributable to the parent. Under the share purchase loan, the Company’s recourse is limited to the shares purchased by the employees and the individual. Accordingly, it is accounted for as a grant of options to acquire 8.7% of Canopy Rivers at $0.05 per Class B common share. The shares treated as options will be considered exercised on the repayment of the loan. The shares purchased by employees and the consultant have been placed in trust and vest in 3 equal tranches over 3 years if the employees remain as employees of the Company and the individual remains as a consultant and the loan is repaid. In certain cases, there are also additional performance targets. The shares were measured at fair value on May 12, 2017 using a Black-Scholes model and will be expensed over their vesting period. Shares issued to non-employees will be remeasured until their performance is complete. Where there are performance conditions in addition to service requirements, the Company has estimated the number of shares it expects to vest and is amortizing the expense over the expected vesting period. For the year ended March 31, 2018, the Company recorded $3,090 in share-based compensation expense related to this arrangement with a corresponding increase to non-controlling interests. During fiscal 2018 Canopy Rivers granted 3,475,000 options to purchase Class B common shares to employees of the Company and 2,440,000 options to purchase Class B common shares to consultants of the Company. The options have an exercise price of $0.60 per Class B common shares and are exercisable in increments, with one third being exercisable on each of the first, second and third anniversaries from the date of grant. The expiry date of the options ranges from December 4, 2022 to March 26, 2023. The options were measured at fair value at the date of issuance using a Black-Scholes model and will be expensed over their vesting period. Shares issued to non-employees will be remeasured until their performance is complete. For the year ended March 31, 2018, the Company recorded $489 in share-based compensation expense related to this arrangement with a corresponding increase to non-controlling interests.
12.
FORMATION OF CANOPY RIVERS (CONTINUED) On January 8, 2018 Canopy Rivers completed a non-brokered private placement of 23,636,365 Class B common shares for aggregate proceeds of $26,000 including $5,141 invested by Canopy Growth. Canopy Rivers incurred and paid $738 in issuance costs related to this offering net of the associated tax benefit. Following this round Canopy Growth’s interest and voting rights were reduced to 31.5% and 89.1%, respectively. An amount of $1,047 has been recorded as an increase in the equity attributable to the parent which represents the change in the carrying amount of the non-controlling interest as a result of the difference between the consideration paid and the net assets acquired and the dilution of Canopy’s ownership interest.

Joint Operations

Joint Operations12 Months Ended
Mar. 31, 2018
Disclosure Of Joint Operations [Abstract]
Joint Operations13.
JOINT OPERATION On October 10, 2017, the Company entered into a definitive joint venture agreement with a large-scale greenhouse operator (the “Partner”) to form a new company, BC Tweed Joint Venture Inc. (“BC Tweed”). BC Tweed is 66.67% owned by the Company and 33.33% owned by the Partner. Since the decisions over relevant activities are jointly determined the Company has concluded that the Company and the Partner have joint control over BC Tweed. As part of the transaction, BC Tweed agreed to lease from the Partner a 1.3 million square feet greenhouse facility located on a 55-acre parcel of land in British Columbia (“BC lease 1”). In December 2017, BC Tweed agreed to lease and develop a second greenhouse of 1.7 million square feet (“BC lease 2”) from the Partner. BC Tweed intends to retrofit the facilities for cannabis production and obtain the necessary sales and cultivation licenses under ACMPR. The Partner has the option to sell its interest in BC Tweed, in whole or in part, to the Company. This put option is exercisable only on specific dates following the license date – the 4th anniversary of the sales license date, then at the 6th, 8th, 10th and 12th anniversaries. The put option is accounted for as a liability of the Company (“BC Tweed Put Liability”) and is recorded on the Statements of Financial Position in Other long-term liabilities and is subsequently measured at fair value with changes in fair value recorded in net income in the period in which they arise. On acquisition date the fair value of the BC Tweed Put Liability was estimated to be $36,400 using a discounted cash flow approach by estimating the expected future cash flows and applying a discount rate to arrive at the present value of the put option’s strike price. On March 31, 2018 the BC Tweed Put Liability was estimated to be $56,300 and the increase of $19,900 was recorded in the Statement of Operations (Note 21). For further information on valuation techniques and significant unobservable inputs used to estimate the fair value refer to Note 28. The greenhouse operation transferred by the Partner meets the definition of a business and will be accounted for as a business combination. The BC Tweed Put Liability represents the consideration paid by Canopy for acquiring its interest in this greenhouse operation and the Company will recognize a liability equal to the present value of the BC Tweed put option strike price. To fund the development of BC Tweed, the Company will contribute, in multiple tranches, an aggregate of $20,000 in cash, of which approximately $1,000 was advanced at closing in exchange for Class A preferred shares with cumulative preferred dividends with a dividend rate of 24%. To the extent that BC Tweed requires funding beyond the initial $20,000 in cash, the Company has committed to provide additional funding in the form of preferred shares with prime rate plus 3% cumulative preferred dividends that will rank in seniority to the Class A preferred shares. The Company is obligated to purchase from BC Tweed 100% of the cannabis produced for a fixed price per gram for the first two years of the agreement and thereafter at a price that is computed with reference to the market price and has also guaranteed a minimum level of income for BC Tweed under this agreement. At March 31, 2018, the Company has advanced $79,879 to BC Tweed for preferred shares. The Company will upon various milestones being achieved issue 310,316 common shares over two tranches and a further $2,750 of common shares of the Company in two additional tranches to the Partner. These payments will be accounted for as share-based compensation expense. The grant date fair value of the share-based compensation was $6,731. The Company is amortizing the expense over the estimated vesting period. In the year ended March 31, 2018, the Company recorded $5,001 in share-based compensation related to these shares.
13.
JOINT OPERATION (CONTINUED) As part of the transaction, BC Tweed entered into call/put option agreements with the Partner to acquire all of the limited partnership units of the limited partnerships which hold the greenhouses and related property. BC Tweed has the right to exercise the call options for a term of seven years from the respective license dates of the facilities. The put option can only be exercised if BC Tweed exercises the call option (and gives the Partner the ability to receive the option price in Class B preferred shares of BC Tweed as opposed to cash). The purchase price for acquiring the limited partnership units of the entity which owns the BC lease 1 property is $28,000 less any and all liabilities of the limited partnership (this price will increase by 3% per year from the license date with further increases of 8% per year starting after the fifth anniversary from the license date until the end of the call/put option period, as applicable). The purchase price for acquiring the limited partnership units of the entity which owns the BC lease 2 property is $45,000 less any and all liabilities of the limited partnership (this price will increase by 3% per year from the license date with further increases of 8% per year starting after the fifth anniversary from the license date until the end of the call/put option period, as applicable). Since these options represent options to acquire the limited partnership units, the options will be accounted for as derivative financial instruments which will be recognized initially and subsequently at fair value through profit or loss. At inception and March 31, 2018, the fair value of these options is $nil as the exercise price of the option approximates the fair value of the limited partnership units. BC Tweed also entered into a management services agreement with the Partner. Excluding the increase in the put liability and the partner expense paid to the Partner f or the year ended March 31, 2018 BC Tweed contributed a loss of $19,907. Acquisition related costs of $641 were recognized as an expense in the year ended March 31, 2018.

Non-controlling Interests

Non-controlling Interests12 Months Ended
Mar. 31, 2018
Non Controlling Interests [Abstract]
Non-controlling Interests14.
Non-controlling Interests The following table presents the summarized financial information about the Company’s subsidiaries that have non-controlling interests. This information represents amounts before intercompany eliminations.
As at March 31, 2018
Canopy Rivers
Tweed JA
Vert Mirabel
Cash and cash equivalents
$
46,299
$
12
$
508
Amounts receivable
519
-
650
Subscription receivable
-
1,769
-
Prepaid expenses and other assets
2
-
94
Investments in associates
13,225
-
-
Other financial assets
57,491
-
-
Property, plant and equipment
2,610
1,677
6,818
Preferred shares
5,455
-
-
Goodwill
-
1,939
5,625
Accounts payable and accrued liabilities
(4,705
)
(451
)
(3,940
)
Other current liabilities
-
-
(88
)
Other long-term liabilities
-
-
(5,455
)
Deferred tax liability
(4,502
)
-
-
Non-controlling interests
(80,844
)
(1,686
)
(2,155
)
Equity attributable to Canopy Growth
$
35,550
$
3,260
$
2,057
14.
Non-controlling Interests (CONTINUED) The net change in the non-controlling interests is as follows:
Canopy Rivers
Tweed JA
Vert Mirabel
Other non- material interests 1
Total
As at March 31, 2016
$
-
$
-
$
-
$
-
$
-
Net(loss)/income
-
-
-
(51
)
(51
)
Acquisitions
-
-
-
19
19
As at March 31, 2017
-
-
-
(32
)
(32
)
Net (loss)/income
17,490
(366
)
(721
)
(184
)
16,219
Other comprehensive income
3,998
39
-
(4
)
4,033
Share-based compensation
3,579
-
-
-
3,579
Acquisitions and ownership changes 2
55,777
2,013
2,876
-
60,666
As at March 31, 2018
$
80,844
$
1,686
$
2,155
$
(220
)
$
84,465
1 2

Investments in Associates

Investments in Associates12 Months Ended
Mar. 31, 2018
Disclosure Of Significant Investments In Associates [Abstract]
Investments in Associates15.
Investments In ASSOCIATES The following table outlines changes in the investments in associates that are accounted for using the equity method. In accordance with IAS 28 Investments in Associates and Joint Ventures in cases where the Company does not have the same reporting date as its associates the Company will account for its investment one quarter in arrears. Accordingly the figures in the following tables are based on values at December 31, 2017 with adjustments for any significant transactions.
Participating
Balance at
Share of net
Balance at
share
March 31,
(loss)/
Interest
March 31,
Entity
Instrument
Note
2017
Additions
income
income
2018
Agripharm
shares
10(c)
40.0
%
$
-
$
38,711
$
(232
)
$
-
$
38,479
TerrAscend
shares
15(i)
24.0
%
-
16,978
(66
)
-
16,912
Radicle
convertible debenture
15(ii)
23.8
%
-
5,000
(136
)
(110
)
4,754
CHI
shares
15(iii)
43.0
%
-
4,000
(1,039
)
-
2,961
Bedrocan Brasil
shares
15(iv)
39.8
%
-
-
-
-
-
Entourage
shares
15(iv)
40.0
%
-
-
-
-
-
$
-
$
64,689
$
(1,473
)
$
(110
)
$
63,106
The following table presents current and non-current assets, current and non-current liabilities as well as revenues and profit or loss of the Company’s investments in associates:
Current
Non-current
Current
Non-current
Entity
assets
assets
liabilities
liabilities
Revenue
Loss 1
Agripharm
$
4,671
$
90,716
$
1,391
$
10,896
$
-
$
(557
)
TerrAscend
53,693
15,369
1,692
-
-
(6,805
)
Radicle
2,576
4,382
94
7,174
-
(506
)
CHI
12,160
123
364
-
-
(3,949
)
Bedrocan Brasil
659
-
34
-
-
(162
)
Entourage
1,749
224
2,056
-
-
(2,061
)
$
75,508
$
110,814
$
5,631
$
18,070
$
-
$
(14,040
) 1
15.
Investments In ASSOCIATES (CONTINUED)
(i)
TerrAscend Corp. (“TerrAscend”) is a publicly traded licensed producer under ACMPR. On December 8, 2017, the Company subscribed for 9,545,456 units of TerrAscend directly, and 9,545,456 units indirectly through its subsidiary Canopy Rivers, for $1.10 per unit. Each unit included one common share of TerrAscend and one common share purchase warrant. The warrants are exercisable until December 8, 2020 at $1.10 per common share. The Company has allocated the purchase price to the shares and warrants based on their relative fair values, in the amount of $13,460 and $7,540 respectively. On November 27, 2017, the Company acquired an additional 1,740,000 common shares of TerrAscend directly and 1,740,000 shares indirectly through its subsidiary Canopy Rivers under a block trade at a price of $1.00 per share. Following these transactions, the Company directly and indirectly owns 24% of the issued and outstanding shares of TerrAscend and the Company has concluded it has significant influence over TerrAscend and will account for its investment in these common shares using the equity method. Costs of $38 have been capitalized to the cost of the investment. The warrants represent a derivative financial instrument that is initially measured at fair value in other financial assets and subsequently remeasured to its fair value at the end of each reporting period with changes in fair value through profit or loss. TerrAscend has agreed to sell the Company approximately 25% of its current production for a term of 2 years upon receiving its license to sell cannabis, renewal annually for an additional one-year term.
(ii)
Radicle Medical Marijuana Inc. (“Radicle”) is an ACMPR applicant. Canopy Rivers has entered into funding arrangements with Radicle and its affiliates whereby they have committed to invest $5,000 in the form of a convertible debenture and $5,000 in a repayable debenture and has also entered into a royalty agreement with Radicle. The debentures bear interest at 5%, payable quarterly in cash, and are due at the earlier of 24 months or the date Radicle receives a sales license and are secured against all of its assets. Assuming Radicle receives a sales license before maturity, the convertible debenture automatically converts into common shares and the repayable debenture will convert into the royalty interest. Under the royalty agreement, Canopy Rivers will receive a royalty for a term of 20 years. To date $5,000 has been advanced under the convertible debenture and $3,000 has been advanced under the repayable debenture. The convertible debenture is convertible into 23.8% of the common shares and this interest, together with other rights provided under the agreements, give Canopy Rivers significant influence over the investee and Canopy Rivers is accounting for the investment using the equity method. The repayable debenture and royalty agreement is being accounted for as one instrument and is classified as loans and receivables and being measured at amortized cost. Canopy Growth also entered into an agreement with Radicle whereby they have committed to sell a specified portion of their output to Canopy Growth.
(iii)
Canopy Health Innovations (“CHI”) was formed in December 2016 to act as a cannabis research incubator. On December 21, 2016, CHI closed an initial round of financing for gross proceeds of approximately $7,000. Following this investment, the Company had a 46.15% ownership interest in CHI, however had a $nil balance at March 31, 2017. During the quarter ended September 30, 2017, CHI closed a second round of financing for $8,842 which included $4,000 invested by the Company. The Company’s ownership interest is currently 43.0%.
(iv)
Bedrocan Brasil S.A. (“Bedrocan Brasil”) was formed in September 2016 to facilitate the importation of Bedrocan International's proprietary standardized cannabis varieties and the Company’s know-how into the Brazilian market. At the same time, the Company partnered with Entourage Phytolab S.A. (“Entourage”) to develop cannabis-based pharmaceutical medical products for the Brazilian and international markets. The Company currently holds a 39.762% interest in Bedrocan Brasil and 39.990% interest in Entourage, however has a $nil balance at March 31, 2018.

Other Financial Assets

Other Financial Assets12 Months Ended
Mar. 31, 2018
Disclosure Of Financial Assets [Abstract]
Other Financial Assets16.
Other Financial Assets The following table outlines changes in other financial assets. Additional details on how fair value is calculated is included in Note 28.
Balance at
Balance at
Accounting
March 31,
Interest
March 31,
Entity
Instrument
Note
method
2017
Additions
FVTOCI 1
FVTPL
revenue
2018
TerrAscend
warrants
15(i)
FVTPL
$
-
$
7,540
$
-
$
67,614
$
-
$
75,154
AusCann
shares
16(i)
FVOCI
18,328
1,214
19,544
-
-
39,086
AusCann
options
16(i)
FVTPL
5,702
-
-
4,785
-
10,487
JWC
shares
16(ii)
FVTOCI
-
3,863
6,728
-
-
10,591
JWC
warrants
16(ii)
FVTPL
112
702
-
814
JWC
royalty interest
16(ii)
amortized cost
-
2,500
-
-
162
2,662
Agripharm
royalty interest
10(c)
amortized cost
-
2,414
-
-
(88
)
2,326
Agripharm
warrants
10(c)
FVTPL
-
586
-
(139
)
-
447
Vapium
shares
16(iii)
cost
-
1,210
-
-
-
1,210
Radicle
repayable debenture
15(ii)
amortized cost
-
3,000
-
-
75
3,075
HydRx
shares
16(iv)
FVTOCI
-
12,401
-
-
12,401
HydRx
warrants
16(iv)
FVTPL
-
-
-
5,210
-
5,210
$
24,030
$
22,439
$
38,673
$
78,172
$
149
$
163,463
1 Changes in fair value through other comprehensive income (“FVTOCI”)
(i)
AusCann Group Holdings Ltd. (“AusCann”), operates in Australia's medical cannabis industry and is listed on the Australian Stock Exchange. The Company holds 29,865,000 ordinary shares of AusCann, which represents 11% of the issued and outstanding shares at March 31, 2018, and 7,677,639 options. Of the currently held shares, 27,465,000 have been placed in escrow until February 3, 2019. The options are exercisable at AUD$ 0.20 and expire on January 19, 2020. Any shares received on exercise of the options will also be held in escrow until February 3, 2019. For the year ended March 31, 2017, a gain of $15,900 (net of $2,428 in taxes) was recorded relating to the AusCann shares in fair value changes on available for sale financial assets and a gain of $5,702 was recorded on the AusCann options in other income (expense).
(ii)
James E. Wagner Cultivation Ltd. (“JWC”) is an ACMPR applicant. During the quarter ended September 30, 2017, Canopy Rivers acquired 37,000 common shares and 5,000 warrants for $3,975, advanced $2,500 under a repayable debenture and also entered into a royalty agreement with JWC. The repayable debenture bears interest at 8%, payable quarterly in cash, and is due at the earlier of 18 months or the date the applicant receives a sales license and is secured by the assets of the applicant. As JWC received a sales license before maturity, the principal amount drawn under the repayable debenture automatically converted into a royalty interest. Under the terms of the royalty agreement, the Company will receive a royalty per gram of applicable JWC cannabis production for a term of The repayable debenture and royalty agreement is being accounted for as one instrument and is classified as loans and receivables and being measured at amortized cost. The carrying value approximates its fair value. The common shares represent an 14.7% ownership interest in JWC. JWC is a private company and prior to March 31, 2018, the fair value of the Company’s equity interest could not be reliably measured and the common shares and warrants were carried at their cost of $3,863 and $112, respectively. Subsequent to year end, JWC completed a financing that provided a measure of the fair value of the common shares and warrants and the shares and warrants were adjusted to their fair value of $10,591 and $814, respectively. The difference between their carrying amount of the shares and this fair value was recorded in other comprehensive income and the difference between the carrying amount of the warrants and this fair value for the warrants. Canopy Growth also entered into agreements with JWC whereby they have committed to sell a specified portion of their output to Canopy Growth.
16.
Other Financial Assets (CONTINUED)
(iii)
Vapium Incorporated (“Vapium”) is a company that designs and engineers portable vaporizer devices. On September 29, 2017, the Company acquired a 9.93% ownership interest for a cash investment of $960. On November 27, 2017, the Company exercised an option to acquire additional shares for $250 and increased its ownership to 12.24%. Vapium is a private company and the fair value of the instrument is not reliably determinable such that the investment is being carried at cost.
(iv)
HydRx Farms Ltd. (“HydRx”), operates as Scientus Pharma Inc. The Company holds 3,100,307 shares and 1,860,680 warrants in the HydRx which represents a 8.7% ownership interest. HydRx is a private company and prior to February 2018 the fair value of the Company’s equity interest could not be reliably measured and the common shares and warrants were carried at their cost amount of $nil. In the quarter ended March 31, 2018 the Company completed a financing that provided a measure of the fair value of the common shares and warrants and the shares and warrants were adjusted to their fair value of $12,401 and $5,210, respectively. The difference between their carrying amount of the shares and this fair value was recorded in other comprehensive income and the difference between the carrying amount of the warrants and the fair value of the warrants was recorded in other income (expense).

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities12 Months Ended
Mar. 31, 2018
Accounts Payable And Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities17.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
March 31,
March 31,
2018
2017
Trade payables
$
46,175
$
5,661
Accrued liabilities
43,396
9,725
Total accounts payable and accrued liabilities
$
89,571
$
15,386
The accounts payable and accrued liabilities balance of $89,571 (2017 – $15,386) is comprised of amounts for property, plant and equipment of $62,034 (2017 – $2,804), professional fees of $7,391 (2017 – $1,642), compensation related liabilities of $5,747 (2017 – $2,349), and other miscellaneous liabilities of $14,399 (2017 – 8,591).

Long-term Debt and Other Long-T

Long-term Debt and Other Long-Term Liabilities12 Months Ended
Mar. 31, 2018
Borrowings [Abstract]
Long-term Debt and Other Long-Term Liabilities18.
Long-term debt AND other Long-TERM LIABILITIES
(a)
Long-term debt
March 31,
March 31,
Maturity Date
2018
2017
Mortgage payable with a five-year term and amortization period of seven years bearing an annual interest rate of 4.9%
August 1, 2021
$
2,777
$
3,210
Mortgage payable with a five-year term and amortization period of seven years bearing an annual interest rate of 5.3%
December 1, 2019
1,089
1,345
Mortgage payable with a five-year term and amortization period of seven years bearing an annual interest rate of 4.8%
December 1, 2020
2,648
2,994
Term loan at 10% interest with monthly repayment
October 1, 2024
1,564
1,724
Finance lease obligations with interest rates between 5.9%-17.1%, and terms between 2-5 years, liens against the related leased equipment
344
1,057
8,422
10,330
Less: current portion
(1,557
)
(1,691
)
Long-term portion
$
6,865
$
8,639
The mortgage with a maturity date of August 1, 2021 is secured by a first charge mortgage on the Tweed Farms property, a first position on a Tweed Farms general security agreement and a specific security interest, backed by a corporate guarantee from the Company. The mortgage with a maturity date of December 1, 2019 is secured by a first charge on the Tweed Farms property. In respect of the mortgage with a maturity date of December 1, 2020, the mortgage is secured by a first charge on the Mettrum Bowmanville property. The mortgages payable, all with Farm Credit Canada, a Canadian Crown Corporation can be prepaid at any time but is subject to a prepayment fee equal to the greater of (a) three months’ interest on the amount being prepaid or (b) the amount of interest lost by the lender over the remaining term of the loan on the amount being prepaid. The Company also has revolving lines of credit for up to $5,500 with Farm Credit Corporation, with variable interest rates based on the CIBC prime rate plus 1.2% with a 5 year term and interest only payments on drawn amounts, but is payable on demand or may be prepaid at any time at the option of the Company. The lines of credit are subject to disbursement conditions related to capital expenditures at Tweed Farms and Mettrum. The lines of credit were undrawn as at March 31, 2018 and March 31, 2017. The term loan was added to the existing lease agreement for the Toronto facilities and is held by a related party. The loan accrues interest at 10% annually and is payable over the initial ten-year term of the amended lease to October 1, 2024 by way of additional monthly rent of $27, which includes principal and interest payments.
18.
Long-term debt AND other Long-TERM LIABILITIES (CONTINUED) Principal repayments required on the long-term debt in the next five fiscal years are as follows:
2019
$
1,547
2020
2,048
2021
2,537
2022
1,588
2023
263
Thereafter
439
$
8,422
(b)
Other long-term liabilities At March 31, 2018 other long-term liabilities of $61,150 is comprised of the BC Tweed Put Liability (Note 13) with a fair value of $56,300 and the Vert Mirabel Put Liability (Note 10(a)(iv)) with a fair value of $4,850.

Reconciliation of Liabilities A

Reconciliation of Liabilities Arising From Financing Activities12 Months Ended
Mar. 31, 2018
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Abstract]
Reconciliation of Liabilities Arising From Financing Activities19.
ReconcIliation of liabilities arising from financing activities
Non-cash changes
April 1,
Acquisition/
March 31,
2017
Cash flows
Disposal
New leases
2018
Long-term borrowings
$
9,273
$
(1,195
)
$
-
$
-
$
8,078
Finance lease obligations
1,057
(336
)
(396
)
19
344
Long-term debt
$
10,330
$
(1,531
)
$
(396
)
$
19
$
8,422
Non-cash changes
April 1,
Acquisition/
March 31,
2016
Cash flows
Disposal
New leases
2017
Long-term borrowings
$
3,457
$
2,813
$
3,003
$
-
$
9,273
Finance lease obligations
565
(12
)
504
-
1,057
Long-term debt
$
4,022
$
2,801
$
3,507
$
-
$
10,330

Share Capital

Share Capital12 Months Ended
Mar. 31, 2018
Disclosure Of Classes Of Share Capital [Abstract]
Share Capital20.
Share capital (a) Authorized An unlimited number of common shares.
(i)
Equity Raises During fiscal 2018 the Company completed the following equity financings:
Number of Shares
Share Capital
Equity financing - February 7, 2018 - net of share issue costs of $8,615
5,800,000
$
192,065
Equity investment from Greenstar - November 2, 2017 - net of share issue costs of $707
18,876,901
173,765
Equity financing - July 21, 2017 - net of share issue costs of $78
3,105,590
24,922
Total equity raise share issuances
27,782,491
$
390,752
20.
Share capital (CONTINUED) During fiscal 2017 the Company completed the following equity financings:
Number of Shares
Share Capital
Equity private placement financing - March 22, 2017 - net of share issue costs of $90
2,500,000
$
24,160
Equity financing - December 22, 2016 - net of share issue costs of $3,886
5,662,000
56,131
Equity financing - August 24, 2016 - net of share issue costs of $2,407
9,453,000
32,096
Equity financing - April 15, 2016 - net of share issue costs of $707
5,002,500
10,799
Total equity raise share issuances
22,617,500
$
123,186
On November 2, 2017, Greenstar Canada Investment Limited Partnership, which is an affiliate of Constellation Brands, Inc., (“Greenstar”) acquired 18,876,901 common shares from treasury and 18,876,901 warrants in exchange for $244,990. The common shares have a hold period of four months and one day from the closing date. The warrants, each exercisable at $12.9783 per warrant for a common share expire May 2, 2020 and are exercisable in two equal tranches, with the first exercisable tranche date being August 1, 2018, and the second exercisable tranche date being February 1, 2019, provided at the time of exercising the warrants, the Company still owns the 18,876,901 common shares. The proceeds of the common share issuance were allocated to the common shares and warrants based on their relative fair values in the amount of $174,472 and $70,518, respectively. The fair value of the common shares was determined using the closing price on the day the share subscription closed, and the fair value of the warrants was determined using a Black-Scholes model. Share issuance costs of $707 were allocated to the common shares and $253 to the warrants.
(ii)
Acquisitions During fiscal 2018 the Company issued the following shares as a result of business combinations that occurred in the current or prior years:
Notes
Number of Shares
Share Capital
Share Based Reserve
Issuance of shares for rTrees acquisition - net of share issue costs of $69
10(a)(i)
3,494,505
$
28,026
$
1,079
Issuance of shares for Spot acquisition - net of share issue costs of $9
10(a)(v)
111,669
984
-
Issuance of shares for Green Hemp acquisition - net of share issue costs of $9
10(a)(v)
24,577
848
-
Shares released from escrow related to the MedCann Access acquisition
240,678
390
(390
)
Shares released from escrow related to the Hemp.CA acquisition
10(b)(iii)
129,016
-
-
Shares released from escrow related to the Spektrum Cannabis GmbH acquisition
10(b)(ii)
367,981
-
-
Shares released from escrow related to the Vert Medical acquisition
10(b)(iii)
147,453
-
-
Total acquisition related share issuances
4,515,879
$
30,248
$
689
20.
Share capital (CONTINUED) During fiscal 2017 the Company issued the following shares as a result of business combinations that occurred in the current or prior years:
Notes
Number of Shares
Share Capital
Share Based Reserve
Issuance of shares for Mettrum acquisition - net of share issue costs of $997
10(b)(i)
34,265,042
$
336,514
$
12,143
Issuance of shares per Spektrum Cannabis GmbH acquisition
10(b)(ii)
674,631
10,406
-
Issuance of shares per Vert acquisition
10(b)(iii)
58,978
1,664
-
Issuance of shares per Hemp acquisition
10(b)(iii)
129,021
1,711
-
Shares released from escrow related to the MedCann Access acquisition
1,011,239
2,919
(468
)
Total acquisition related share issuances
36,138,911
$
353,214
$
11,675
During fiscal 2018, the Company released 240,678 (fiscal 2017 – 1,011,239) of the common shares held in escrow in relation to the fiscal 2016 MedCann Access acquisition as certain milestones of the acquisition had been met. In addition, 48,078 (fiscal 2017 – 1,149,892) escrowed shares were cancelled. No shares remain in escrow at March 31, 2018.
(iii)
Other During fiscal 2018 the Company other share issuances were comprised of:
Notes
Number of Shares
Share Capital
Share Based Reserve
Shares released from escrow to LBC Holdings, Inc.
87,836
$
1,297
$
(1,297
)
Shares issued to BC Tweed Partner for performance conditions
20(c)
155,158
1,880
(1,880
)
Shares issued for Apollo/Bodystream earnout
20(c)
243,493
2,398
(2,398
)
Issuance of shares for Niagara asset acquisition - net of share issue costs of $8
9
111,366
995
-
Issuance of shares for acquired intangible - net of share issue costs of $14
11
117,253
3,225
-
Total other share issuances
715,106
$
9,795
$
(5,575
) During fiscal 2017 the Company other share issuances were comprised of:
Number of Shares
Share Capital
Share Based Reserve
Shares released from escrow to LBC Holdings, Inc.
138,032
$
639
$
(639
)
Issuance of shares for 1 Hershey Drive purchase
9
94,397
858
-
Issuance of shares per service agreements
156,240
1,333
-
Total other share issuances
388,669
$
2,830
$
(639
) During fiscal 2018, 87,836 (fiscal 2017 – 138,032) common shares were released from escrow under the agreement with LBC Holdings, Inc., a company controlled by the artist known as Snoop Dogg. The remaining 25,097 common shares are escrowed for release, subject to meeting certain service criteria. During fiscal 2017, the Company issued 72,418 common shares to XIB consulting Inc. (“XIB), to assist the Company with corporate development initiatives and 83,822 common shares to satisfy $1,000 in acquisition costs related to the Mettrum acquisition.
20.
Share capital (CONTINUED)
(iv)
Warrants
Number of whole warrants
Average exercise price
Warrant value
Expiry date
Balance at March 31, 2017
-
$
-
$
-
Greenstar equity investment - net of warrant issue cost of $253
18,876,901
12.98
70,265
May 1, 2020
rTrees acquisition
242,408
3.83
1,302
April 30, 2018
Exercise of warrants
(207,297
)
3.72
(1,113
)
N/A
Balance at March 31, 2018
18,912,012
$
12.96
$
70,454
During the year ended March 31, 2018, 207,297 warrants were exercised at a weighted average price of $3.72 (March 31, 2017- 213,104 warrants at an average price of $0.59). (b) Omnibus plan On September 15, 2017, shareholders approved an Omnibus Incentive Plan (“Omnibus Plan”) pursuant to which it is able to issue share-based long-term incentives. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”) restricted share units (“RSUs”), deferred share units (“DSUs”), stock appreciation rights (“Stock Appreciation Rights”), restricted stock (“Restricted Stock”), performance awards (“Performance Awards”) or other stock based awards (collectively, the “Awards”), under the Omnibus Plan. In addition, shareholders also approved the 2017 Employee Stock Purchase Plan of the Company (the “Purchase Plan”). Under the Purchase Plan, the aggregate number of common shares that may be issued is 400,000, and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 200,000. Under the Omnibus Plan, the maximum number of shares issuable from treasury pursuant to Awards shall not exceed 10% of the total outstanding shares from time to time less the number of shares issuable pursuant to all other security-based compensation arrangements of the Company (being the existing employee stock option plan ("ESOP") and the Purchase Plan). The maximum number of common shares reserved for Awards is 19,955,721 at March 31, 2018. As of March 31, 2018, the only Awards issued have been options under the ESOP, and no shares have been issued under the Purchase Plan as it has not yet been implemented. The ESOP is administered by the Board of Directors of the Company who establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Options under the Plan generally remain exercisable in increments with 1/3 being exercisable on each of the first, second and third anniversaries from the date of grant, and has expiry dates set at six years from issuance. The Board of Directors has the discretion to amend general vesting provisions and the term of any award, subject to limits contained in the Plan.
20.
Share capital (CONTINUED) The following is a summary of the changes in the Company’s ESOP options during the period:
Options issued
Weighted average exercise price
Balance outstanding at March 31, 2016
8,446,182
$
2.05
Options granted
4,337,701
6.23
Replacement options issued as a result of the Mettrum acquisition
2,417,102
2.35
Options exercised
(4,010,865
)
1.74
Options forfeited/cancelled
(1,146,008
)
2.78
Balance outstanding at March 31, 2017
10,044,112
$
3.97
Options granted
12,832,237
16.50
Replacement options issued as a result of the rTrees acquisition
224,433
3.18
Options exercised
(3,912,946
)
2.82
Options forfeited/cancelled
(1,942,001
)
9.32
Balance outstanding at March 31, 2018
17,245,835
$
12.95
The following is a summary of the outstanding stock options as at March 31, 2018:
Options Outstanding
Options Exercisable
Number Outstanding at March 31, 2018
Weighted Average Remaining Contractual Life (years)
Range of Exercise Prices
Number Exercisable at March 31, 2018
Range of Exercise Prices
3,471,904
3.41
$0.56 - $3.78
1,569,274
$0.56 - $3.78
5,731,691
5.13
$3.79 - $8.51
577,665
$3.79 - $8.51
2,712,240
4.91
$8.52 - $11.76
536,254
$8.52 - $11.76
1,540,000
5.67
$11.77 - $27.94
16,667
$11.77 - $27.94
3,790,000
5.88
$27.95 - $33.66
-
$27.95 - $33.66
17,245,835
4.96
2,699,860
At March 31, 2018, the weighted average exercise price of options outstanding and options exercisable was $12.95 and $4.55, respectively. The Company recorded $21,278 in share-based compensation expense related to options issued to employees for the year ended March 31, 2018 (for the year ended March 31, 2017 - $7,650) and $4,774 in share-based compensation expense related to options issued to contractors. The fiscal 2018 compensation expense includes an amount related to 420,000 options being provided in exchange for services which are subject to performance conditions.
20.
Share capital (CONTINUED) In determining the amount of share-based compensation related to options issued during the year, the Company used the Black-Scholes option pricing model to establish the fair value of options granted during the year ended March 31, 2018 and 2017 on their measurement date by applying the following assumptions:
March 31,
March 31,
2018
2017
(Weighted average)
(Range)
Risk-free interest rate
1.54%
0.50% - 1.94%
Expected life of options (years)
3 - 5
1 - 6
Expected annualized volatility
64%
55% - 70%
Expected forfeiture rate
11%
7%
Expected dividend yield
nil
nil
Black-Scholes value of each option
$
8.88
$0.20 - $6.09
Volatility was estimated by using the historical volatility of the Company and other companies that the Company considers comparable that have trading and volatility history prior to the Company becoming public. Beginning the fourth quarter of Fiscal 2017, the Company began using its own historical volatility. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate was based on the zero coupon Canada government bonds with a remaining term equal to the expected life of the options. The Company recorded $3,579 (March 31, 2017 – $ During fiscal 2018, 3,912,946 ESOP options were exercised ranging in price from $0.43 to $11.71 for gross proceeds of $11,053. (c) Share-based compensation expense related to acquisition and asset purchase milestones Share-based compensation expense related to acquisition milestones is comprised of:
Compensation expense
Notes
Released during fiscal 2018
Remaining shares to be issued on completion of milestones*
March 31, 2018
March 31, 2017
Apollo/Bodystream
(i)
243,493
1,941,804
$
5,095
$
690
Spektrum Cannabis GmBH
(ii)
-
23,570
349
-
Spot
10(a)(v)
-
30,658
330
-
Spectrum Denmark
10(a)(iii)
-
1,906,214
7,206
-
BC Tweed
13
155,158
240,061
5,001
-
Vert Mirabel
10(a)(iv)
-
84,903
1,131
-
Green Hemp
10(a)(v)
-
24,567
167
-
Intellectual property acquisition
11
-
33,804
196
-
$
19,475
$
690
20.
Share capital (CONTINUED)
(i)
The obligation for share-based compensation owing to former shareholders of Apollo Applied Research Inc., and Apollo CRO Inc. (together “Apollo”) and 2344823 Ontario Inc., operating as Bodystream (“Bodystream”) was assumed by the Company in fiscal 2017 on the acquisition of Mettrum Health Corp. and its subsidiaries (“Mettrum”). The maximum number of Company shares that would be issued with respect to the Apollo and Bodystream agreements is 1,111,702 and 1,073,595 shares, respectively. The Company has estimated the number of shares it expects to vest and is amortizing the expense over the expected vesting period based on the fair value of the shares on the acquisition date.
(ii)
The share-based compensation expense is related to a bonus that will be paid to a former shareholder of Spektrum Cannabis GmbH within two years of the acquisition date if certain performance targets are met and the shareholder remains as an employee. (d) Other share based payments The Company also recorded a gain of $14 for the year ended March 31, 2018 (expense for the year ended March 31, 2017 - $396) in share-based compensation expense for escrowed shares issued on the acquisition of MedCann Access that were related to employment. These shares were measured at fair value at the date of grant and expensed over their vesting period. In addition, the Company recorded share based payments of $1,151 (for the year ended March 31, 2017 - $1,307) related to shares provided in exchange for sales and marketing services. The Company has determined that the sales and marketing services received are best measured by reference to the fair value of the equity granted as the services are rendered. This expense is recorded in sales and marketing expenses. On October 20, 2017, the Company agreed to issue 79,717 common shares in payment of royalties. The Company will record the expense over the subsequent year. The Company recorded an expense of $920 in cost of sales for the fiscal year ended March 31, 2018 related to this arrangement (March 31, 2017 – $

Other Income (Expense)

Other Income (Expense)12 Months Ended
Mar. 31, 2018
Analysis Of Income And Expense [Abstract]
Other Income (Expense)21.
OTHER INCOME (EXPENSE)
March 31,
March 31,
Notes
2018
2017
Fair value changes on financial assets
16
$
78,172
$
5,702
Impairment of product rights
11
(28,000
)
-
Fair value increase in BC Tweed Put Liability and Vert Mirabel Put Liability
10(a),13
(21,000
)
-
Gain on disposal of consolidated entity
10(c)
8,820
-
Bargain purchase gain
10(iii)
638
Partner expense
(4,995
)
-
Gain/loss disposal of property, plant and equipment
(1,181
)
-
Increase in fair value of acquisition consideration related liabilities
-
(1,193
)
Other expense, net
(1,241
)
(651
)
Total other income, net
$
31,213
$
3,858
The partner expense represents a distribution to the Partner of BC Tweed.

Expenses by Nature

Expenses by Nature12 Months Ended
Mar. 31, 2018
Expense By Nature [Abstract]
Expenses by Nature22.
Expenses by nature Operating expenses are presented on the face of the consolidated statements of operations using a classification based on the functions “Cost of sales (recovery),” “Sales and marketing,” “Research and development,” and “General and administration.” The Company also presents other material operating expenses separately as they were deemed to be items of dissimilar function.
22.
Expenses by nature (continued) Operating expenses totalled $160,229 and $53,978 for the years ended March 31, 2018 and 2017. Total operating expenses were distributed by nature as follows:
March 31,
March 31,
2018
2017
Employee compensation and benefits
$
49,971
$
21,726
Raw materials used and consumables
13,286
8,105
Other costs of sales
12,340
5,603
Net valuation gains related to inventory and biological assets
(53,652
)
(25,555
)
Share-based compensation
51,177
10,043
Acquisition-related costs
3,406
7,369
Depreciation and amortization
20,486
6,064
Legal and professional fees
10,370
2,947
Royalties
3,110
1,416
Consultants
12,385
3,391
Facility expenses
12,669
3,087
Patient assistance
7,365
2,913
Marketing and promotion
3,835
2,314
Office expenses
6,454
1,986
Travel and other employee expenses
5,141
1,672
Bank and payment processor fees
1,886
897
Total
$
160,229
$
53,978

Earnings Per Share

Earnings Per Share12 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share23.
Earnings per share Net income per common share represents the net income attributable to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing the applicable net income by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the period. As at March 31, 2018 and 2017, all instruments were anti-dilutive.

Income Taxes

Income Taxes12 Months Ended
Mar. 31, 2018
Disclosure Of Income Taxes [Abstract]
Income Taxes24.
INCOME TAXES Income tax expense varies from the amount that would be computed by applying the basic federal and provincial tax rates to loss before income taxes, shown as follows:
March 31, 2018
March 31, 2017
Loss from operations
(52,541
)
(10,275
)
Expected tax rate
26.5
%
26.5
%
Expected tax benefit resulting from loss
$
13,923
$
2,723
Non-deductible expenses
(19,310
)
(2,156
)
Increase in unrecognized temporary differences
(5,506
)
2,258
Non-taxable portion of capital gains and losses
9,421
-
Other
(121
)
(122
)
Income tax (expense) recovery
$
(1,593
)
$
2,703
Deferred income taxes reflect the impact of loss carry forwards and of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws.
24.
INCOME TAXES (CONTINUED) The effect of temporary differences and loss carryforwards that give rise to significant portions of the deferred tax liability, which has been recognized during the year ended March 31, 2018 are as follows:
March 31, 2017
Recognized in profit or loss
Recognized in equity
Recognized in other comprehensive income
Disposal of consolidated entity
Business combinations and assets held for sale
March 31, 2018
Deferred tax asset
Loss carryforwards
$
30,494
$
5,677
$
-
$
-
$
(1,014
)
$
-
$
35,157
Other
829
-
4,511
-
-
-
5,340
31,323
5,677
4,511
-
(1,014
)
-
40,497
Deferred tax liability
Fixed assets
(1,126
)
3,577
-
-
(263
)
(1,117
)
1,071
Intangibles
(42,703
)
10,310
-
-
6,965
-
(25,428
)
Biological assets
(20,615
)
(9,460
)
-
-
295
-
(29,780
)
Investments
(3,184
)
(13,558
)
-
(5,124
)
-
-
(21,866
)
Other long-term liabilities
-
2,783
-
-
-
-
2,783
Other
381
(922
)
-
-
(284
)
12
(813
)
(67,247
)
(7,270
)
-
(5,124
)
6,713
(1,105
)
(74,033
)
Net deferred taxes
$
(35,924
)
$
(1,593
)
$
4,511
$
(5,124
)
$
5,699
$
(1,105
)
$
(33,536
) The effect of temporary differences and loss carryforwards that give rise to significant portions of the deferred tax liability, which has been recognized during the year ended March 31, 2017 are as follows:
March 31, 2016
Recognized in profit or loss
Recognized in goodwill
Recognized in other comprehensive income
Liabilities associated with asset held for sale
March 31, 2017
Deferred tax asset
Loss carryforwards
$
9,100
$
15,332
$
6,062
$
-
$
-
$
30,494
Other
224
(62
)
667
-
-
829
9,324
15,270
6,729
-
-
31,323
Deferred tax liability
Fixed assets
(1,097
)
132
(161
)
-
-
(1,126
)
Intangibles
(8,436
)
479
(34,746
)
-
-
(42,703
)
Asset held for sale
-
-
(820
)
-
820
-
Biological assets
(7,201
)
(12,529
)
(885
)
-
-
(20,615
)
Investments
-
(756
)
-
(2,428
)
-
(3,184
)
Other
(3
)
107
277
-
-
381
(16,737
)
(12,567
)
(36,335
)
(2,428
)
820
(67,247
)
Net deferred taxes
$
(7,413
)
$
2,703
$
(29,606
)
$
(2,428
)
$
820
$
(35,924
) The unrecognized temporary differences of the Company are comprised of:
March 31, 2018
March 31, 2017
Losses carried forward
$
30,041
$
2,792
Intangibles assets and fixed asset
-
9,906
Total
$
30,041
$
12,698
24.
INCOME TAXES (CONTINUED) The Company has the following non-capital losses available to reduce future years' taxable income which expires as follows:
2030
$
40
2031
123
2032
376
2033
3,195
2034
7,258
2035
18,196
2036
29,806
2037
29,202
2038
79,301
Foreign - indefinite
3,900
$
171,397

Related Parties

Related Parties12 Months Ended
Mar. 31, 2018
Disclosure Of Transactions Between Related Parties [Abstract]
Related Parties25.
Related parties Key management personnel compensation Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the entity, directly or indirectly. The key management personnel of the Company are the members of the Company’s executive management team and Board of Directors, who control approximately 5% of the outstanding shares of the Company. Compensation provided to key management is as follows:
March 31, 2018
March 31, 2017
Short-term employee benefits
$
3,746
$
1,420
Share-based compensation
5,786
1,535
$
9,532
$
2,955
As of March 31, 2018, in the event that executive officers employment agreements were terminated by the Company, other than due to a material breach of their employment agreements or in the event the Company becomes insolvent: the CEO is entitled to a severance amount equal to nine months of compensation based on the monthly contract work fee or $300 in aggregate and all other Executive officers are entitled to a severance amount equal to at least thirty four week’s annual base salary and in some cases, inclusive of their annual bonus. Related party transactions On January 13, 2017, the Company acquired the entire building and land, known as 1 Hershey Drive, Smiths Falls, Ontario, from Tweed Hershey which was related through common ownership (the Company’s CEO and chairman is a significant shareholder of the lessor) (refer to Note 8). The Company had previously been leasing a portion of this facility from Tweed Hershey. For the year ended March 31, 2017 up until January 13, 2017, the acquisition date, the expense incurred under this lease including base rent and operating costs was $2,118. The Company leases premises for the two Bedrocan facilities in Toronto from a company controlled by a director of Canopy Growth Corporation. The leases expire on October 15, 2018 (with 3 separate options to renew for an additional period of 5 years) and August 31, 2024. Included in the expenses for the year ended March 31, 2018 for rent and operating costs was $2,686 (for the year ended March 31, 2017 - $785). In addition to the leased premises, consulting services of $159 was also provided to the Company (March 31, 2017 - $nil). The Company had $137 owing in accounts payable and accrued liabilities at March 31, 2018 (March 31, 2017 - $nil).
25.
Related parties (CONTINUEd) The Company leases premises for the Mettrum Hempworks Inc. (“Hempworks”) production facility located in Barrie, Ontario from the former founder and shareholder of Hempworks and former officer of Mettrum, now an employee and shareholder of the Company. The lease has a term of five (5) years with an expiration date of March 31, 2020 together with one (1) extension term of five (5) years. The lease has an identical term and extension term (each expiring one (1) day earlier). Included in the expenses for the year ended March 31, 2018 for rent and operating costs was $131 (for the year ended March 31, 2017 from the date of the Mettrum acquisition - $8). At March 31, 2018, the Company had $24 owing related to rent associated with these leased premises (March 31, 2017 - $8). All amounts exclude HST. The CEO is providing consulting services to the Company at $55 per quarter and is eligible for up to an annual $300 bonus, representing his sole cash compensation. For the year ended March 31, 2018 consulting expenses including travel totaled $531 (for the year ended March 31, 2017 - $400). The Company had $375 owing in accounts payable and accrued liabilities at March 31, 2018 (March 31, 2017 - $255). All amounts exclude HST. The Company currently has a loan payable to a director of the Company. Included in interest expense for the year ended March 31, 2018 was an amount of $169 (for the year ended March 31, 2017 - $179). At March 31, 2018, the loan balance was $1,564 (March 31, 2017 - $1,724) (refer to Note 18). During the year ended March 31, 2018, $708 was expensed in director’s fees (for the year ended March 31, 2017 - $223). The Company had $nil owing in accounts payable and accrued liabilities to directors at March 31, 2018 (March 31, 2017 - $nil). Pursuant to the share purchase agreement with Hemp.CA, the Company entered into a lease for the Vert and Hemp.CA properties with a shareholder of Hemp.CA who for a period of time following the acquisition was an employee of Canopy. The lease was to expire on November 1, 2036 and the Company had two automatic renewal terms of 10 years each. As of March 31, 2018, the related lease was cancelled and the expense incurred under the lease including base rent, operating costs, and cancellation costs were $84 since acquisition. These transactions are in the normal course of operations and are measured at the exchange amounts being the amounts agreed to by the parties.

Commitments and Contingencies

Commitments and Contingencies12 Months Ended
Mar. 31, 2018
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies26.
Commitments and contingencies (a) The Company leases production and retail space under operating leases which range in expiration from April 2018 to October 2037 and also has royalty, equipment and other commitments with varying terms. All production and retail operating leases have optional renewal terms that the Company may exercise at its option. (b) Future commitments which include minimum lease and royalty payments due in each of the next five years are as follows:
2019
$
21,767
2020
21,712
2021
21,017
2022
21,076
2023
19,366
Thereafter
85,200
$
190,138
(c) In March 2015, a claim was commenced against Canopy Growth Corporation by the former CEO for $330 in specified damages for breach of contract and wrongful dismissal. The litigation process will continue into the foreseeable future unless settled. No amount has been recorded in the consolidated financial statements since the amount cannot be reliably measured at this point. (d) Prior to its acquisition by the Company, Mettrum had initiated voluntary Type III recalls for products where trace amounts of an unauthorized pesticide was found to have been applied in certain Mettrum products. A Type III recall refers to a situation in which the use of, or exposure to, a product is not likely to cause any adverse health consequences. In March 2017, two separate class action lawsuits relating to the Mettrum recalls were initiated naming Mettrum Health Corp. as respondent.
26.
Commitments and contingencies (CONTINUED) The proposed action seeks damages for the proposed class of individuals who purchased the products affected by the recall. The Company and its insurers are contesting the litigation. The litigation process will continue into the foreseeable future before the class action suit is certified by the court and unless settled out of court. No amount has been recorded in the consolidated financial statements since the amount cannot be reliably measured at this point.

Supplementary Cash Flow Informa

Supplementary Cash Flow Information12 Months Ended
Mar. 31, 2018
Disclosure Of Cash Flow Statement [Abstract]
Supplementary Cash Flow Information27.
Supplementary cash flow information The changes items are as follows:
March 31,
March 31,
2018
2017
Amounts receivable
$
(15,738
)
$
(2,184
)
Prepaid expenses and other assets
(15,770
)
(1,493
)
Biological assets and inventory
(24,493
)
(12,270
)
Accounts payable and accrued liabilities
27,130
(200
)
Deferred revenue
312
55
Other liabilities
40
(256
)
Total
$
(28,519
)
$
(16,348
) Non-cash transactions Excluded from the March 31, 2018 consolidated statements of cash flows was a total of $49,679 in accounts payable and accrued liabilities as follows: $49,627 of property, plant and equipment and assets in process purchases and $52 of share issue costs. Included for the March 31, 2018 consolidated statements of cash flows is a total of $3,860 in accounts payable and accrued liabilities as follows: $3,770 of property, plant and equipment and assets in process purchases and $90 of share issue costs. Excluded from the March 31, 2017 consolidated statements of cash flows was a total of $3,860 in accounts payable and accrued liabilities as follows: $3,770 of property, plant and equipment and assets in process purchases and $90 of share issue costs. Included for the March 31, 2017 consolidated statements of cash flows was a total of $946 in accounts payable and accrued liabilities as follows: $877 of property, plant and equipment and assets in process purchases and $69 of share issue costs. Cash and cash equivalents consist of the following:
March 31,
March 31,
2018
2017
Cash
$
322,560
$
16,700
Short-term guaranteed investment certificates
-
85,100
Total cash and cash equivalents
$
322,560
$
101,800

Financial Instruments

Financial Instruments12 Months Ended
Mar. 31, 2018
Disclosure Of Financial Instruments [Abstract]
Financial Instruments28.
Financial instruments (a) Market risk Market risk is defined as the risk that the fair value or future cash flows of a financial instrument held by the Company will fluctuate because of changes in market prices. Market risk includes the risk of changes in interest rates, currency exchange rates and changes in market prices due to other factors including changes in equity prices.
(i)
Currency risk As at March 31, 2018, less than 2% of the Company’s financial assets (as at March 31, 2017 – 1%) and less than 3% of the Company’s financial liabilities (as at March 31, 2017 – 1%) for which cash flows are denominated in a foreign currency. The Company has very limited currency risk. No other financial assets and liabilities are denominated in a foreign currency.
28.
Financial instruments (CONTINUED)
(ii)
Interest rate risk The Company may invest surplus cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. Currently the Company’s short-term investments and restricted investments consist of $65,395 in guaranteed investment certificates which have fixed rates of interest. Interest rate risk on the long-term debt and capital lease obligations is limited due to the fact that they are both fixed rate of interest instruments. The Company is exposed to the risk that changes in interest rate will impact the fair value of financial instruments whose cash flows are fixed in nature.
(i)
Other market risk The Company holds financial assets in the form of shares, warrants and options that are measured at FVTPL and FVOCI. The Company is exposed to equity price risk on these financial assets. (b) Credit risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s trade accounts receivable. The Company is exposed to credit-related losses in the event of non-performance by the counterparties. The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk, but has limited risk due to the fact that the majority of sales are transacted with credit cards. Trade accounts receivable are reported net of an allowance for doubtful accounts of $78. The carrying amount of cash and cash equivalents , short-term restricted investments and amounts receivable represents the maximum exposure to credit risk and at March 31, 2018, this amounted to $344,659 (2017 - $108,165). Since the inception of the Company, no losses have been suffered in relation to cash held by the bank. As at March 31, 2018, the Company’s aging of receivables was approximately as follows:
March 31, 2018
March 31, 2017
0-60 days
$
5,683
$
2,137
61-120 days
258
909
Total
$
5,941
$
3,046
The Company’s accounts receivable are primarily driven by sales to government agencies and credit card processors and timing of bill payments. At March 31, 2018, the receivables from government agencies and credit card processor and bill payment receivables accounted for 19% and 42%, respectively, of trade accounts receivable (2017 - 55% and 30%, respectively). (c) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements. During the year ended March 31, 2018, the Company completed several equity financings for gross cash proceeds of $470,670.
28.
Financial instruments (CONTINUED) In addition to the commitments disclosed in Note 17, the Company is obligated to the following contractual maturities of undiscounted cash flows:
As at March 31, 2018
Carrying amount
Contractual cash flows
Year 1
Years 2 - 3
Years 4 and after - 5
Accounts payable and accrued liabilities
$
89,571
$
89,571
$
89,571
$
-
$
-
Long-term debt
8,422
9,522
1,899
5,082
2,541
Total
$
97,993
$
99,093
$
91,470
$
5,082
$
2,541
(d) Fair value of financial assets and liabilities that are measured at fair value on a recurring basis The following table summarizes the valuation techniques and key inputs used in the fair value measurement of level 2 financial instruments:
Financial asset/financial liability
Valuation techniques and key inputs
Key inputs
AusCann shares
Put option pricing model
Quoted prices in active market
AusCann options
Black-Scholes option pricing model
Quoted prices in active market
TerrAscend warrants
Black-Scholes option pricing model
Quoted prices in active market The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of level 3 financial instruments
Financial asset/financial liability
Valuation techniques
Significant unobservable inputs
Relationship of unobservable inputs to fair value
JWC warrants
Black-Scholes option pricing model
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
JWC shares
Market approach
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
HydRx shares
Market approach
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
HydRx warrants
Black-Scholes option pricing model
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
Agripharm warrant
Black-Scholes option pricing model
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
BC Tweed and Vert Mirabel put liability
Discounted cash flow
Discount rate
Increase or decrease in discount rate will result in a decrease or increase in fair value
Future wholesale price and production levels
Increase in future wholesale price and production levels will result in an increase in fair value
BC Tweed call option liability
Market approach
Appraised value of property
Increase or decrease in value will result in a increase or decrease in fair value
28.
Financial instruments (CONTINUED) During the year, there were no transfers of amounts between levels. (e) Fair value of financial assets and liabilities that are not measured at fair value but fair value disclosures are required The carrying values of cash, short-term investments, and restricted investments and accounts payable and accrued liabilities approximate their fair values due to their short-term to maturity. The fair value of the JWC repayable debenture, Agripharm royalty interest, Radicle repayable debenture, and mortgage payables

Segmented Information

Segmented Information12 Months Ended
Mar. 31, 2018
Disclosure Of Operating Segments [Abstract]
Segmented Information29.
Segmented information The Company operates in one segment, the production and sale of medical cannabis. All property, plant and equipment and intangible assets are located in Canada, except for $6,242 which is located outside of Canada. All revenues were principally generated in Canada during the year ended March 31, 2018, except for $3,746, related to exported medical cannabis generated outside of Canada (for the year ended March 31, 2017 - $35).

Capital Management

Capital Management12 Months Ended
Mar. 31, 2018
Disclosure Of Financial Risk Management [Abstract]
Capital Management30.
Capital management The Company’s objective is to maintain sufficient capital base so as to maintain investor, creditor and customer confidence and to sustain future development of the business and provide the ability to continue as a going concern. Management defines capital as the Company’s shareholders’ equity and debt. The Board of Directors does not establish quantitative return on capital criteria for management; but rather promotes year over year sustainable profitable growth. The Company currently has not paid any dividends to its shareholders. As at March 31, 2018 total managed capital was comprised of shareholders’ equity and debt of $1,251,660 (March 31, 2017 - $650,056). There were no changes in the Company’s approach to capital management during the year. The Company is subject to externally imposed restrictions related to covenants on its mortgage payable (refer to Note 18).

Subsequent Events

Subsequent Events12 Months Ended
Mar. 31, 2018
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Subsequent Events31.
Subsequent events (a) Strategic agreement with LiveWell On April 2, 2018, the Company entered into a strategic agreement with LiveWell Foods Canada Inc. (“LiveWell”) and Artiva Inc. (“Artiva”). Artiva is an ACMPR applicant operating as a subsidiary of LiveWell. This strategic agreement represents an amendment to the original investment agreement that the parties entered into on November 22, 2017. Under the terms of the amended agreement, in exchange for strategic support services and for the offering of financial support, on April 15, 2018 Canopy Growth was issued 5,487,642 common shares and Canopy Rivers was issued 5,487,642 common shares of LiveWell which represents a 10% equity interest in LiveWell. An additional 5,487,642 common shares were placed in escrow and will be released to the Company on the achievement of certain milestones. LiveWell has the option to draw on up to $20,000 of debt financing from Canopy Rivers (subject to the completion of certain milestones). (b) Investment in Civilized On April 17, 2018, the Company announced that Canopy Rivers had entered in to a strategic investment and collaboration agreement with Civilized Worldwide Inc. (“Civilized”) pursuant to which Canopy Rivers, will invest $5,000 in Civilized via a debenture that is convertible into common shares of Civilized, and the companies will work together on various online, media and event mandates relating to the cannabis industry. Canopy Rivers also received common share purchase warrants of Civilized with a total exercise price of $3,500 and a 24-month expiry.
31.
Subsequent events (CONTINUED) (c) Investment in Good Leaf, Inc. On April 23, 2018, the Company invested $5,478 in Good Leaf, Inc. in exchange for 674,709 Series A-1 preferred shares and warrants to acquire 139,432 common shares. The warrants are exercisable at a price of $0.01 per share for a period of 7 years. Following the transaction the Company’s ownership interest in Good Leaf, Inc. is 8.8% on a fully diluted basis. (d) Creation of joint venture On May 7, 2018, Canopy Rivers entered into a joint venture with principals and operators of a leading North American greenhouse produce company, to finance and support the development and operation of a retrofitted 1.2 million square foot greenhouse for cannabis cultivation in Leamington, Ontario. (e) Option to acquire production assets On May 9, 2018 the Company entered into lease agreement for the lease of production assets and issued 332,009 common shares with a value of approximately $10,000 in exchange for an option to purchase the building from the landlord. The Company also provided a loan of $10,000 to the landlord which will be used by the landlord to assist with the construction of the building. (f) Agreement to acquire non-controlling interest(s) in CHI On May 15, 2018 the Company announced that it had entered in to a definitive arrangement agreement (“Arrangement Agreement”) pursuant to which the Company will acquire all of the non-controlling interests in CHI. Pursuant to the Arrangement Agreement, shareholders of CHI will receive 0.3790 common shares of the Company for each common share of CHI held (the “Exchange Ratio”). In addition, Canopy Growth will issue options to purchase common shares of the Company in exchange for options previously issued by CHI and Canopy Animal Health based on the Exchange Ratio. In aggregate Canopy Growth will issue 3,037,771 common shares, having a value of $91,573, along with options having an aggregate “in-the-money” value of $9,688 for aggregate consideration of $101,261. The transaction, which is expected to close on or before August 2018, will be undertaken by way of a plan of arrangement and is subject to a number of approvals. (g) Acquisition of Daddy Cann Lesotho PTY Ltd. On May 17, 2018 the Company acquired Daddy Cann Lesotho PTY Ltd., trading as Highlands (“Highlands”). Based in the Kingdom of Lesotho, Highlands holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and its resin. As consideration the Company issued 666,362 common shares in the capital of the Company on closing and, subject to meeting certain milestones, the Company will issue up to an additional 333,281 common shares for a total of up to 999,643 common shares. The total value of the consideration payable by the Company under the terms of the agreement is approximately $28.8 million. (h) Bedrocan product rights On June 11, 2018 the Company announced that it had reached an agreement with Bedrocan International Under the terms of the Agreement, the Company will decrease and then end the production and sale of Bedrocan products within the calendar year. Canopy Growth will retain the licensed production facility, licensed sales facility, and all associated licenses owned and operated by Bedrocan Canada. Management will redeploy these facilities, free of the current royalty structure and fixed production practices. During the year ended March 31, 2018 the Company recorded an impairment loss in connection with these product rights in anticipation of the orderly termination of this agreement (Note 11).
31.
Subsequent events (continued) (i) Convertible debt financing In June 2018, the Company issued $600,000 convertible senior notes, including the over-allotment option of $100,000. The notes are general unsecured, senior obligations of Canopy Growth and interest will be payable semi-annually in arrears at a rate of 4.25% annually. The initial conversion rate for the notes will be 20.7577 common shares of the Company per $1 principal amount of notes, subject to potential adjustments. The initial conversion rate is equivalent to an initial conversion Prior to January 15, 2023, the notes will be convertible at the option of holders only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the business day immediately preceding the maturity date. Upon conversion, the notes may be settled in cash, common shares of Canopy Growth or a combination of cash and common shares of Canopy Growth, at the election of Canopy Growth. Canopy Growth may not redeem the notes prior to July 20, 2021, except in the event of certain changes in Canadian tax law. Canopy Growth may redeem for cash all or any portion of the notes, at its option, on or after July 20, 2021 if the last reported sale price of Canopy Growth’s common shares for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on the trading day immediately preceding the date on which Canopy Growth provides notice of redemption has been at least 130% of the conversion price then in effect on each such trading day. Redemptions of notes in either case shall be at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If Canopy Growth undergoes a fundamental change, holders of the notes will have the right to require Canopy Growth to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. Canopy Growth will also be required, in certain circumstances, to increase the conversion rate for a holder who elects to convert its notes in connection with certain corporate events or during the related redemption period.

Comparative amounts

Comparative amounts12 Months Ended
Mar. 31, 2018
Comparative Amounts [Abstract]
Comparative Amounts32. COMPARATIVE AMOUNTS Certain comparative amounts have been reclassified to conform to the current presentation.

Significant Accounting Polici41

Significant Accounting Policies (Policies)12 Months Ended
Mar. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Foreign currency translation(a) Foreign currency translation All figures presented in the consolidated financial statements and tabular disclosures to the consolidated financial statements are reflected in Canadian dollars, which is the functional currency of the Company. Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising from the acquisition, are translated in Canadian dollars at year-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income and accumulated in equity.
Biological assets(b) Biological assets The Company’s biological assets consist of cannabis plants. With the exception of depreciation, which is directly expensed in the period and presented separately in the Consolidated Statement of Operations, the Company capitalizes the direct and indirect costs incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest. The Company then measures the biological assets at fair value less cost to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. The net unrealized gains or losses arising from changes in fair value less cost to sell during the year are included in the results of operations of the related year. Seeds are measured at fair value.
Inventory(c) Inventory Inventories of harvested work-in-process and finished goods are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories for resale and supplies and consumables are valued at the lower of costs and net realizable value, with cost determined using the average cost basis.
Property, plant and equipment(d) Property, plant and equipment Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Depreciation is provided on a straight-line basis over the following terms:
Computer equipment
2-3 years
Office/lab equipment
3-5 years
Furniture and fixtures
3-10 years
Warehouse equipment
5-15 years
Production equipment
3-30 years
Leasehold improvements
3-20 years
Building and improvements
20-40 years
Greenhouse and improvements
20-25 years An asset’s residual value, useful life and depreciation method are reviewed during each financial year and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item are determined by comparing the proceeds from disposal with the carrying amount of the item and recognized in profit or loss. Assets under capital lease are amortized according to their asset category. Assets in process are transferred to the appropriate asset class when available for use and depreciation of the assets commences at that point.
Finite-lived and indefinite-lived intangible assets3.
Significant accounting policies (continued) (e) Finite-lived and indefinite-lived intangible assets Finite-lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms:
Domain name
5 years
Health Canada licenses
Useful life of facility or lease term
Distribution channel
5 years
Import license
4 years
Software
3 years The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives are comprised of acquired product rights and brand name which are carried at cost less accumulated impairment losses.
Impairment of long-lived assets(f) Impairment of long-lived assets Long-lived assets, including property, plant and equipment and intangible assets are reviewed for impairment at each statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss equal to the amount by which the carrying amount exceeds the recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.
Goodwill(g) Goodwill Goodwill represents the excess of the price paid for the acquisition of an entity over the fair value of the net identifiable tangible and intangible assets and liabilities acquired. Goodwill is allocated to the CGU or CGUs to which it relates. Currently, the Company has one reportable segment. The Company has determined that the goodwill associated with all acquisitions belongs to this segment as this is the lowest level at which management monitors goodwill. Goodwill is measured at historical cost and is evaluated for impairment annually in the fourth quarter or more often if events or circumstances indicate there may be an impairment. CGUs have been grouped for purposes of impairment testing. Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs to sell and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in income in the period in which the impairment is identified. Impairment losses on goodwill are not subsequently reversed.
Leased assets(h) Leased assets The Company leases some items of property, plant and equipment. A lease of property, plant and equipment is classified as a capital lease if it transfers substantially all the risks and rewards incidental to ownership to the Company. A lease of property, plant and equipment is classified as an operating lease whenever the terms of the lease do not transfer substantially all of the risks and rewards of ownership to the lessee. Lease payments are recognized as an expense on a straight-line basis over the lease term, except where another systematic basis is more representative of the time pattern in which the economic benefits are consumed.
Assets held for sale3.
Significant accounting policies (continued) (i) Assets held for sale Assets and liabilities held for disposal are no longer depreciated and are presented separately in the statement of financial position at the lower of their carrying amount and fair value less costs to sell. An asset is regarded as held for sale if its carrying amount will be recovered principally through a sale transaction, rather than through continuing use. For this to be the case, the asset must be available for immediate sale and its sale must be highly probable.
Revenue recognition(j) Revenue recognition Revenue is recognized at the fair value of consideration received or receivable. Revenue from the sale of goods is recognized when all the following conditions have been satisfied:

the Company has transferred to the buyer the significant risks and rewards of ownership of the goods;

the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;

the amount of revenue can be measured reliably;

it is probable that the economic benefits associated with the transaction will flow to the entity; and

the costs incurred or to be incurred in respect of the transaction can be measured reliably.
Research and development(k) Research and development Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized in profit or loss as incurred.
Income taxes(l) Income taxes The Company uses the liability method to account for income taxes. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities for accounting purposes, and their respective tax bases. Deferred income tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and are reviewed at the end of each reporting period.
Share-based compensation(m) Share-based compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share based payments granted to non-employees the compensation expense is measured at the fair value of the good and services received except where the fair value cannot be estimated in which case it is measured at the fair value of the equity instruments granted. The fair value of share-based compensation to non-employees is periodically re-measured until counterparty performance is complete, and any change therein is recognized over the period and in the same manner as if the Company had paid cash instead of paying with or using equity instruments. Consideration paid by employees or non-employees on the exercise of stock options is recorded as share capital and the related share-based compensation is transferred from share-based reserve to share capital.
Earnings (loss) per share3.
Significant accounting policies (continued) (n) Earnings (loss) per share The Company presents basic and diluted earnings (loss) per share data for its common shares. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise warrants and share options issued.
Financial instruments(o) Financial instruments Financial assets The Company initially recognizes financial assets at fair value on the date that they are originated. All financial assets (including assets designated at fair value through profit or loss, “FVTPL”) are recognized initially on the date at which the Company becomes a party to the contractual provisions of the instrument. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability. The Company classifies its financial assets as financial assets at FVTPL, available for sale (“AFS”) financial assets or loans and receivables. Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value. Subsequent to initial recognition loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. AFS financial assets are non-derivatives that are either designated as AFS or are not classified as loans and receivables or financial assets at FVTPL. AFS financial assets are stated at fair value at the end of each reporting period. The fair value is determined in the manner described in Note 28. Changes in the carrying amount of AFS monetary financial assets relating to changes in foreign currency rates, interest income calculated using the effective interest method and dividends on AFS equity investments are recognized in profit or loss. Other changes in the carrying amount of AFS financial assets are recognized in other comprehensive income (“OCI”). When the investment is disposed of or is determined to be impaired, the cumulative gain or loss previously accumulated in OCI is reclassified to profit or loss. AFS equity investments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured are measured at cost less any identified impairment losses at the end of each reporting period. Financial liabilities The Company initially recognizes financial liabilities at fair value on the date that they are originated. All financial liabilities (including liabilities designated at FVTPL) are recognized initially on the date at which the Company becomes a party to the contractual provisions of the instrument. The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. The Company classifies its financial liabilities as either financial liabilities at FVTPL or other liabilities. Subsequent to initial recognition other liabilities are measured at amortized cost using the effective interest method. Financial liabilities at fair value are stated at fair value with changes being recognized in profit or loss.
3.
Significant accounting policies (continued) (o) Financial instruments (continued) Classification of financial instruments The Company classifies its financial assets and liabilities depending on the purpose for which the financial instruments were acquired, their characteristics, and management intent as outlined below:
Classification
Cash and cash equivalents
FVTPL
Accounts receivable
Loans and receivable
Restricted investments
Loans and receivable
Other financial assets
Available for sale financial assets, Loans and
receivables and FVTPL
Accounts payable and accrued liabilities
Other liabilities
Long-term debt
Other liabilities
BC Tweed and Vert Mirabel put liability
FVTPL
Acquisition consideration related liabilities
FVTPL Effective interest method The effective interest method is a method of calculating the amortized cost of a financial instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Transaction costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss. Impairment of financial assets Financial assets, other than those classified at FVTPL, are assessed for indicators of impairment at the end of the reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected.
Critical judgments in applying accounting policies and estimates(p) Critical judgments in applying accounting policies The following are the critical judgments, apart from those involving estimations (refer to (q) below), that have the most significant effect on the amounts recognized in the financial statements. Business combinations Judgment is used in determining whether an acquisition is a business combination or an asset acquisition. Judgement is also required to assess whether the amounts paid on achievement of milestones represents contingent consideration or compensation for post-acquisition services. Judgment is also required to assess whether contingent consideration should be classified as equity or a liability. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as a liability is remeasured at subsequent reporting dates in accordance with IAS 39, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss.
3.
Significant accounting policies (continued) (p) Critical judgments in applying accounting policies (continued) Control, joint control or level of influence When determining the appropriate basis of accounting for the Company’s interests in affiliates, the Company makes judgments about the degree of influence that it exerts directly or through an arrangement over the investees’ relevant activities. Information about these judgments is included in Note 12,15 and 16. Accounting for joint operation Judgment was used to determine whether the joint venture agreement described in Note 13 should be accounted for as a joint operation or a joint venture. Given the Company has rights to substantially all the economic benefits of the arrangement, through its obligation to purchase all of the output of BC Tweed, and also has an obligation for the liabilities of the arrangement the Company has concluded it will be accounted for as a joint operation. The Company will recognize its share of assets and liabilities and revenue and expenses in its consolidated financial statements on the basis of the Company’s proportionate share of BC Tweed’s output, being 100%. (q) Critical The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Biological assets and inventory In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, average or expected selling prices and list prices, expected yields for the cannabis plants, and oil conversion factors. In calculating final inventory values, management compares the inventory cost to estimated net realizable value. Further information on estimates used in determining the fair value of biological assets is contained in Note 5. Estimated useful lives and depreciation and amortization of property, plant and equipment and intangible assets Depreciation and amortization of property, plant and equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets. Share-based compensation In calculating the share-based compensation expense, key estimates such as the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company’s stock price and the risk free interest rate are used. To calculate the share-based compensation expense related to key employee performance milestones associated with the terms of an acquisition, the Company must estimate the number of shares that will be earned and when they will be issued based on estimated discounted probabilities. Fair value measurements Certain of the Company’s assets and liabilities are measured at fair value. In estimating fair value the Company uses market-observable data to the extent it is available. In certain cases where Level 1 inputs are not available the Company will engage third party qualified valuers to perform the valuation. Information about the valuation techniques and inputs used in determining the fair value of biological assets is disclosed in Note 5, the retained interest in Agripharm in Note 10(c) and financial assets and liabilities in Note 28.
New and revised IFRS in issue but not yet effective3.
Significant accounting policies (continued) (r) New and revised IFRS in issue but not yet effective IFRS 15 Revenue from Contracts with Customers IFRS 15 was issued by the IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. On April 12, 2016, the IASB published final clarifications to IFRS 15 with respect to identifying performance obligations, principal versus agent considerations, and licensing. The Company will adopt IFRS 15 effective April 1, 2018. The Company is currently completing its assessment of the impact of this new standard. IFRS 9 Financial Instruments ("IFRS 9") IFRS 9 was issued by the IASB in November 2009 and October 2010 and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Financial liabilities are classified in a similar manner as under IAS 39. The Company will adopt IFRS 9 effective April 1, 2018. The Company is currently completing its assessment of the impact of this new standard. IFRS 16 Leases (“IFRS 16”) IFRS 16 was issued by the IASB in January 2016 and specifies the requirements to recognize, measure, present and disclose leases. IFRS 16 is effective for the Company for its annual period ending March 31, 2020 with early adoption permitted. The Company is continuing to assess the impact of this new standard on its financial position and financial performance.

Basis of Presentation (Tables)

Basis of Presentation (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Basis Of Presentation [Abstract]
Disclosure of company’s subsidiaries and ownership interest held by non-controlling interestsSubsidiaries
Defined as
Non-controlling interests
Tweed Inc.
Tweed
-
Tweed Farms Inc.
Tweed Farms
-
Bedrocan Canada Inc.
Bedrocan Canada
-
Spectrum Cannabis Canada Ltd. (formerly Mettrum Ltd.)
Spectrum Cannabis
-
Tweed Grasslands Cannabis Inc.
Tweed Grasslands
-
Les Serres Vert Cannabis
Vert Mirabel
33.3%
Spot Therapeutics Inc.
Spot
-
Vert Cannabis Inc.
Vert Cannabis
-
2344823 Ontario Inc. d/b/a Bodystream
Bodystream
-
Apollo Applied Research Inc. and Apollo CRO Inc.
together "Apollo"
-
Mettrum Hempworks Inc.
Mettrum Hempworks
-
Groupe H.E.M.P.CA
Group H.E.M.P.
25%
Spectrum Health Corp. (formerly Mettrum Health Corp.)
Spectrum Health
-
10252832 Canada Inc
Edmonton
-
9388036 Canada Inc.
9388036 Canada
-
10663824 Canada Inc.
Alberta
-
80694 Newfoundand and Labrador Inc.
Newfoundland
-
Spektrum Cannabis GmbH
Spektrum Cannabis
-
Canopy LATAM Corporation
LATAM
-
Spectrum Chile SpA
Spectrum Chile
15%
Grow House JA Limited
Tweed JA
51%
Spectrum Cannabis Denmark Aps
Spectrum Cannabis Denmark
-
Spectrum Polska Sp
Spectrum Polska
-
Spectrum Cannabis Australia PTY Ltd.
Spectrum Australia
-
Spectrum Cannabis Italia srl
Spectrum Italy
-
Canopy Rivers Corporation
Canopy Rivers
68.5%

Significant Accounting Polici43

Significant Accounting Policies (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Schedule of Useful Lives of Property, Plant and EquipmentProperty, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Depreciation is provided on a straight-line basis over the following terms:
Computer equipment
2-3 years
Office/lab equipment
3-5 years
Furniture and fixtures
3-10 years
Warehouse equipment
5-15 years
Production equipment
3-30 years
Leasehold improvements
3-20 years
Building and improvements
20-40 years
Greenhouse and improvements
20-25 years
Schedule of Useful Lives of Finite-Lived Intangible AssetsFinite-lived intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms:
Domain name
5 years
Health Canada licenses
Useful life of facility or lease term
Distribution channel
5 years
Import license
4 years
Software
3 years

Amounts Receivable (Tables)

Amounts Receivable (Tables)12 Months Ended
Mar. 31, 2018
Trade And Other Current Receivables [Abstract]
Summary of Amounts ReceivableAmounts receivable was comprised of:
March 31,
March 31,
2018
2017
Accounts receivable
$
5,863
$
2,794
Commodity tax receivable
15,262
2,769
Interest receivable
300
252
Total amounts receivable
$
21,425
$
5,815

Biological Assets (Tables)

Biological Assets (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Reconciliation Of Changes In Biological Assets [Abstract]
Disclosure of continuity of biological assetsThe Company’s biological assets consists of seeds and cannabis plants. The continuity of biological assets for the years ended March 31, 2018 and 2017 was as follows:
March 31,
March 31,
2018
2017
Balance, beginning of year
$
14,725
$
5,321
Purchases of seeds
271
70
Acquired biological assets
-
1,691
Disposed biological assets due to disposal of consolidated entity (Note 10(c))
(1,430
)
-
Unrealized gain on changes in fair value of biological assets
100,302
49,090
Increase in biological assets due to capitalized costs
17,309
11,983
Transferred to inventory upon harvest
(114,829
)
(53,430
)
Balance, end of year
$
16,348
$
14,725
Summary of Significant Unobservable Inputs and Range of ValuesThe significant unobservable inputs and their range of values are noted in the table below:
Unobservable Inputs
Range
Sensitivity
Estimated Yield per Plant – varies by strain and is obtained through historical growing results (trailing 6-months moving average) or grower estimate if historical results are not available.
25 grams/plant to 400 grams/plant
A slight increase in the estimated yield per plant would result in a significant increase in fair value, and vice versa.
Listed Selling Price of Dry Cannabis – varies by strain and is obtained through listed selling prices or estimated selling prices if historical results are not available.
$6 to $12/gram
A slight increase in the estimated selling price per strain would result in a significant increase in fair value, and vice versa.

Inventory (Tables)

Inventory (Tables)12 Months Ended
Mar. 31, 2018
Classes Of Inventories [Abstract]
Schedule of InventoryInventory was comprised of the following items:
March 31,
March 31,
2018
2017
Dry Cannabis
Finished goods
$
14,114
$
2,478
Work-in-process
51,309
33,418
65,423
35,896
Cannabis Oils
Finished goods
9,624
2,085
Work-in-process
20,574
5,492
30,198
7,577
Capsules - Finished goods
2,705
-
Seeds - Finished goods
63
74
2,768
74
98,389
43,547
Product for resale (vaporizers and other)
571
1,017
Supplies and consumables
2,647
1,417
$
101,607
$
45,981

Prepaid Expenses and Other As47

Prepaid Expenses and Other Assets (Tables)12 Months Ended
Mar. 31, 2018
Prepaid Expenses And Other Assets [Abstract]
Schedule of Prepaid Expenses and Other AssetsThe Company’s prepaid expenses and other assets consists of the following:
March 31,
March 31,
2018
2017
Prepaid packaging
$
8,774
$
-
Prepaid expenses
7,358
2,934
Prepaid deposits
842
-
Restricted short-term investments
664
550
Other assets
2,199
801
$
19,837
$
4,285

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Property Plant And Equipment [Abstract]
Schedule of Property Plant and EquipmentA continuity of property, plant and equipment for the year ended March 31, 2018 is as follows:
COST
Balance at
Disposal of
Balance at
April 1,
Additions from
consolidated
Transfers/
March 31,
2017
Additions
acquisitions
entity
disposals
2018
Computer equipment
$
4,181
$
1,219
$
-
$
(101
)
$
942
$
6,241
Office/lab equipment
831
626
-
(16
)
279
1,720
Furniture and fixtures
875
348
109
-
49
1,381
Production equipment
11,132
4,511
468
(2,619
)
15,272
28,764
Leasehold improvements
17,155
338
-
-
4,989
22,482
Building and improvements
43,449
3,799
-
(5,066
)
25,331
67,513
Greenhouse and improvements
3,528
106
-
-
461
4,095
Land and improvements
2,397
5,728
345
-
-
8,470
Warehouse equipment
-
138
-
-
29
167
Assets in process
19,302
201,509
5,164
-
(48,977
)
176,998
Total
$
102,850
$
218,322
$
6,086
$
(7,802
)
$
(1,625
)
$
317,831
ACCUMULATED DEPRECIATION
Balance at
Disposal of
Balance at
April 1,
consolidated
Transfers/
March 31,
2017
Depreciation
entity
disposals
2018
Computer equipment
$
889
$
1,043
$
(31
)
$
(1
)
$
1,900
Office/lab equipment
82
404
(5
)
(2
)
479
Furniture and fixtures
82
137
-
(1
)
218
Production equipment
1,038
2,539
(587
)
(260
)
2,730
Leasehold improvements
1,930
1,510
-
12
3,452
Building and improvements
2,182
2,920
(217
)
(64
)
4,821
Greenhouse and improvements
358
155
-
-
513
Land and improvements
19
11
-
-
30
Warehouse equipment
-
6
-
-
6
Total
6,580
8,725
(840
)
(316
)
14,149
Net book value
$
96,270
$
303,682
A continuity of property, plant and equipment for the year ended March 31, 2017 is as follows:
COST
Balance at
Balance at
April 1,
Additions from
Transfers/
March 31,
2016
Additions
acquisitions
disposals
2017
Computer equipment
$
958
$
886
$
313
$
2,024
$
4,181
Office/lab equipment
935
536
408
(1,048
)
831
Furniture and fixtures
2,428
1,343
26
(2,922
)
875
Production equipment
1,543
1,668
3,789
4,132
11,132
Leasehold improvements
37,620
2,972
229
(23,666
)
17,155
Building and improvements
136
6,551
12,449
24,313
43,449
Greenhouse and improvements
2,951
-
-
577
3,528
Land and improvements
723
420
1,000
254
2,397
Warehouse equipment
-
-
-
-
-
Assets in process
403
18,771
5,138
(5,010
)
19,302
Total
47,697
33,147
23,352
(1,346
)
102,850
ACCUMULATED DEPRECIATION
Balance at
Balance at
April 1,
Transfers/
March 31,
2016
Depreciation
disposals
2017
Computer equipment
$
255
$
516
$
118
$
889
Office/lab equipment
157
266
(341
)
82
Furniture and fixtures
223
356
(497
)
82
Production equipment
139
279
620
1,038
Leasehold improvements
1,714
2,455
(2,239
)
1,930
Building and improvements
14
156
2,012
2,182
Greenhouse and improvements
211
118
29
358
Land and improvements
-
-
19
19
Warehouse equipment
-
-
-
-
Total
2,713
4,146
(279
)
6,580
Net book value
$
44,984
$
96,270

Acquistions and Disposals (Tabl

Acquistions and Disposals (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Business Combinations [Abstract]
Summary of Balance Sheet Impact on Acquisition Date(a)
Acquisitions completed in Fiscal 2018 The following table summarizes the balance sheet impact on the acquisition date of the Company’s business combinations that occurred in the period ended March 31, 2018:
Tweed Grasslands
Tweed JA
Odense
Vert Mirabel
Other acquisitions
(i)
(ii)
(iii)
(iv)
(v)
Cash and cash equivalents
$
59
$
125
$
-
$
-
$
7
Amounts receivable
16
-
-
-
14
Subscription receivable
-
3,669
-
-
-
Inventory
-
-
173
-
-
Prepaids and other assets
6
-
-
-
107
Property, plant and equipment
1,446
182
3,990
-
468
Goodwill
29,736
1,835
-
5,625
1,562
Accounts payable and accrued
-
liabilities
(336
)
(29
)
-
-
(143
)
Deferred tax liability
-
-
(297
)
-
-
Net assets
30,927
5,782
3,866
5,625
2,015
Non-controlling interests
-
(2,013
)
-
(2,839
)
-
Net assets acquired
$
30,927
$
3,769
$
3,866
$
2,786
$
2,015
Consideration paid in cash
$
450
$
100
$
3,228
$
-
$
166
Consideration paid in shares
6,381
-
-
-
1,850
Future cash consideration
-
3,669
-
-
-
Other consideration
2,382
-
-
3,750
-
Contingent consideration
21,714
-
-
-
-
Total consideration
$
30,927
$
3,769
$
3,228
$
3,750
$
2,016
Consideration paid in cash
$
(450
)
$
(100
)
$
(3,228
)
$
-
$
(166
)
Less: Cash and cash equivalents
acquired
59
125
-
-
7
Net cash (outflow) inflow
$
(391
)
$
25
$
(3,228
)
$
-
$
(159
)
Acquisition-related costs
expensed
$
302
$
24
$
33
$
54
$
213
The following table summarizes the balance sheet impact on the acquisition date of the Company’s business combinations that occurred in the period ended March 31, 2017:
Mettrum
MedCann GmbH
Other acquisitions
(i)
(ii)
(iii)
Cash and cash equivalents
$
12,309
$
-
$
15
Amounts receivable
2,140
5
-
Biological assets
1,691
-
-
Inventory
5,022
137
-
Prepaids and other assets
1,184
102
24
Assets classified as held for sale
7,000
-
-
Property, plant and equipment
22,451
336
565
Intangible assets
131,009
784
12
Goodwill
207,081
9,209
4,024
Accounts payable and accrued liabilities
(5,663
)
(107
)
(115
)
Debt
(3,576
)
-
-
Other liabilities
(768
)
-
-
Deferred tax liability
(29,546
)
(60
)
-
Net assets
350,334
10,406
4,525
Non-controlling interests
-
-
(19
)
Net assets acquired
$
350,334
$
10,406
$
4,506
Consideration paid in cash
$
-
$
-
$
1,131
Consideration paid in shares
337,511
9,720
2,124
Other consideration
12,823
-
-
Contingent consideration
-
688
1,251
Total consideration
$
350,334
$
10,408
$
4,506
Consideration paid in cash
$
-
$
-
$
(1,131
)
Less: Cash and cash equivalents
acquired
12,309
-
15
Net cash (outflow) inflow
$
12,309
$
-
$
(1,116
)
Acquisition-related costs expensed
$
5,190
$
372
$
163
Summary of Derecognized Assets And Liabilities Related To Deconsolidation Of SubsidiariesThe derecognized assets and liabilities on November 30, 2017, were as follows:
Cash and cash equivalents
$
(17
)
Amounts receivable
158
Inventory
21
Biological assets
1,430
Prepaids and other assets
451
Property, plant and equipment
6,962
Intangible assets
26,282
Goodwill
2,259
Accounts payable and accrued liabilities
(1,194
)
Capital lease obligations
(1,073
)
Deferred tax liability
(5,699
)
Net assets disposed
$
29,580
Fair value of retained interest
38,400
Gain on disposal of consolidated entity
$
8,820

Intangible Assets And Goodwill

Intangible Assets And Goodwill (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Intangible Assets [Abstract]
Schedule of Continuity of Intangible AssetsA continuity of the intangible assets for the year ended March 31, 2018 is as follows:
COST
Balance at
Additions
Balance at
April 1,
from
Disposals/
Exchange
March 31,
2017
Additions
acquisitions
adjustments
differences
2018
Health Canada licenses
$
92,200
$
-
$
-
$
(27,600
)
$
-
$
64,600
Distribution channel
38,900
-
-
-
-
38,900
Product rights
28,000
-
-
(28,000
)
-
-
Brand
3,410
-
2,632
-
-
6,042
Import license
795
-
-
-
46
841
Software
1,197
117
-
143
(2
)
1,455
Domain name
54
-
-
-
-
54
Intangibles in process
92
1,646
600
(194
)
-
2,144
Internally generated intangibles in process
-
326
-
-
-
326
Total
$
164,648
$
2,089
$
3,232
$
(55,651
)
$
44
$
114,362
ACCUMULATED AMORTIZATION
Balance at
Balance at
April 1,
Disposals/
Exchange
March 31,
2017
Amortization
adjustments
differences
2018
Health Canada licenses
$
985
$
2,957
$
(1,318
)
$
-
$
2,624
Distribution channel
1,000
8,077
-
-
9,077
Import license
57
155
-
7
219
Software
305
557
-
1
863
Domain name
38
15
-
-
53
Total
2,385
11,761
(1,318
)
8
12,836
Net book value
$
162,263
$
101,526
A continuity of the intangible assets for the year ended March 31, 2017 is as follows:
COST
Balance at
Additions
Balance at
April 1,
from
Disposals/
Exchange
March 31,
2016
Additions
acquisitions
adjustments
differences
2017
Health Canada licenses
$
4,000
$
-
$
88,200
$
-
$
-
$
92,200
Distribution Channel
-
-
38,900
-
-
38,900
Product rights
28,000
-
-
-
-
28,000
Brand
-
-
3,410
-
-
3,410
Import license
-
-
779
-
16
795
Software
-
49
516
632
-
1,197
Domain name
54
-
-
-
-
54
Intangibles in process
-
92
-
-
-
92
Total
32,054
141
131,805
632
16
164,648
ACCUMULATED AMORTIZATION
Balance at
Balance at
April 1,
Disposals/
Exchange
March 31,
2016
Amortization
adjustments
differences
2017
Health Canada licenses
$
166
$
819
$
-
$
-
$
985
Distribution Channel
-
1,000
-
-
1,000
Import license
-
57
-
-
57
Software
-
31
274
-
305
Domain name
27
11
-
-
38
Total
193
1,918
274
-
2,385
Net book value
$
31,861
$
162,263
Schedule of Net Change in Goodwill11.
Intangible assets and goodwill (continued) The net change in goodwill is as follows:
As at March 31, 2016
$
20,866
Additions from acquisitions of subsidiaries
10(b)
220,314
Exchange differences
191
As at March 31, 2017
241,371
Additions from acquisitions of subsidiaries
10(a)
38,758
Additions from acquisition of joint operation
13
36,400
Disposal of consolidated entity
10(c)
(2,259
)
Exchange differences
653
As at March 31, 2018
$
314,923

Non-controlling Interests (Tabl

Non-controlling Interests (Tables)12 Months Ended
Mar. 31, 2018
Non Controlling Interests [Abstract]
Summary of Financial Information About Company’s Subsidiaries Non-controlling InterestsThe following table presents the summarized financial information about the Company’s subsidiaries that have non-controlling interests. This information represents amounts before intercompany eliminations.
As at March 31, 2018
Canopy Rivers
Tweed JA
Vert Mirabel
Cash and cash equivalents
$
46,299
$
12
$
508
Amounts receivable
519
-
650
Subscription receivable
-
1,769
-
Prepaid expenses and other assets
2
-
94
Investments in associates
13,225
-
-
Other financial assets
57,491
-
-
Property, plant and equipment
2,610
1,677
6,818
Preferred shares
5,455
-
-
Goodwill
-
1,939
5,625
Accounts payable and accrued liabilities
(4,705
)
(451
)
(3,940
)
Other current liabilities
-
-
(88
)
Other long-term liabilities
-
-
(5,455
)
Deferred tax liability
(4,502
)
-
-
Non-controlling interests
(80,844
)
(1,686
)
(2,155
)
Equity attributable to Canopy Growth
$
35,550
$
3,260
$
2,057
Summary of Net Change In Non-controlling InterestsThe net change in the non-controlling interests is as follows:
Canopy Rivers
Tweed JA
Vert Mirabel
Other non- material interests 1
Total
As at March 31, 2016
$
-
$
-
$
-
$
-
$
-
Net(loss)/income
-
-
-
(51
)
(51
)
Acquisitions
-
-
-
19
19
As at March 31, 2017
-
-
-
(32
)
(32
)
Net (loss)/income
17,490
(366
)
(721
)
(184
)
16,219
Other comprehensive income
3,998
39
-
(4
)
4,033
Share-based compensation
3,579
-
-
-
3,579
Acquisitions and ownership changes 2
55,777
2,013
2,876
-
60,666
As at March 31, 2018
$
80,844
$
1,686
$
2,155
$
(220
)
$
84,465
1 2

Investments in Associates (Tabl

Investments in Associates (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Significant Investments In Associates [Abstract]
Summary of Changes in Investments in Associates Accounted for Using Equity MethodThe following table outlines changes in the investments in associates that are accounted for using the equity method. In accordance with IAS 28 Investments in Associates and Joint Ventures in cases where the Company does not have the same reporting date as its associates the Company will account for its investment one quarter in arrears. Accordingly the figures in the following tables are based on values at December 31, 2017 with adjustments for any significant transactions.
Participating
Balance at
Share of net
Balance at
share
March 31,
(loss)/
Interest
March 31,
Entity
Instrument
Note
2017
Additions
income
income
2018
Agripharm
shares
10(c)
40.0
%
$
-
$
38,711
$
(232
)
$
-
$
38,479
TerrAscend
shares
15(i)
24.0
%
-
16,978
(66
)
-
16,912
Radicle
convertible debenture
15(ii)
23.8
%
-
5,000
(136
)
(110
)
4,754
CHI
shares
15(iii)
43.0
%
-
4,000
(1,039
)
-
2,961
Bedrocan Brasil
shares
15(iv)
39.8
%
-
-
-
-
-
Entourage
shares
15(iv)
40.0
%
-
-
-
-
-
$
-
$
64,689
$
(1,473
)
$
(110
)
$
63,106
Summary of Investments in AssociatesThe following table presents current and non-current assets, current and non-current liabilities as well as revenues and profit or loss of the Company’s investments in associates:
Current
Non-current
Current
Non-current
Entity
assets
assets
liabilities
liabilities
Revenue
Loss 1
Agripharm
$
4,671
$
90,716
$
1,391
$
10,896
$
-
$
(557
)
TerrAscend
53,693
15,369
1,692
-
-
(6,805
)
Radicle
2,576
4,382
94
7,174
-
(506
)
CHI
12,160
123
364
-
-
(3,949
)
Bedrocan Brasil
659
-
34
-
-
(162
)
Entourage
1,749
224
2,056
-
-
(2,061
)
$
75,508
$
110,814
$
5,631
$
18,070
$
-
$
(14,040
) 1

Other Financial Assets (Tables)

Other Financial Assets (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Financial Assets [Abstract]
Summary of Changes in Other Financial AssetsThe following table outlines changes in other financial assets. Additional details on how fair value is calculated is included in Note 28.
Balance at
Balance at
Accounting
March 31,
Interest
March 31,
Entity
Instrument
Note
method
2017
Additions
FVTOCI 1
FVTPL
revenue
2018
TerrAscend
warrants
15(i)
FVTPL
$
-
$
7,540
$
-
$
67,614
$
-
$
75,154
AusCann
shares
16(i)
FVOCI
18,328
1,214
19,544
-
-
39,086
AusCann
options
16(i)
FVTPL
5,702
-
-
4,785
-
10,487
JWC
shares
16(ii)
FVTOCI
-
3,863
6,728
-
-
10,591
JWC
warrants
16(ii)
FVTPL
112
702
-
814
JWC
royalty interest
16(ii)
amortized cost
-
2,500
-
-
162
2,662
Agripharm
royalty interest
10(c)
amortized cost
-
2,414
-
-
(88
)
2,326
Agripharm
warrants
10(c)
FVTPL
-
586
-
(139
)
-
447
Vapium
shares
16(iii)
cost
-
1,210
-
-
-
1,210
Radicle
repayable debenture
15(ii)
amortized cost
-
3,000
-
-
75
3,075
HydRx
shares
16(iv)
FVTOCI
-
12,401
-
-
12,401
HydRx
warrants
16(iv)
FVTPL
-
-
-
5,210
-
5,210
$
24,030
$
22,439
$
38,673
$
78,172
$
149
$
163,463
1 Changes in fair value through other comprehensive income (“FVTOCI”)

Accounts Payable and Accrued 54

Accounts Payable and Accrued Liabilities (Tables)12 Months Ended
Mar. 31, 2018
Accounts Payable And Accrued Liabilities [Abstract]
Summary of Accounts Payable and Accrued LiabilitiesMarch 31,
March 31,
2018
2017
Trade payables
$
46,175
$
5,661
Accrued liabilities
43,396
9,725
Total accounts payable and accrued liabilities
$
89,571
$
15,386

Long-term Debt and Other Long55

Long-term Debt and Other Long-Term Liabilities (Tables)12 Months Ended
Mar. 31, 2018
Borrowings [Abstract]
Summary of Detailed Information About BorrowingsMarch 31,
March 31,
Maturity Date
2018
2017
Mortgage payable with a five-year term and amortization period of seven years bearing an annual interest rate of 4.9%
August 1, 2021
$
2,777
$
3,210
Mortgage payable with a five-year term and amortization period of seven years bearing an annual interest rate of 5.3%
December 1, 2019
1,089
1,345
Mortgage payable with a five-year term and amortization period of seven years bearing an annual interest rate of 4.8%
December 1, 2020
2,648
2,994
Term loan at 10% interest with monthly repayment
October 1, 2024
1,564
1,724
Finance lease obligations with interest rates between 5.9%-17.1%, and terms between 2-5 years, liens against the related leased equipment
344
1,057
8,422
10,330
Less: current portion
(1,557
)
(1,691
)
Long-term portion
$
6,865
$
8,639
Summary of Principal Repayments of Long-term Debt18.
Long-term debt AND other Long-TERM LIABILITIES (CONTINUED) Principal repayments required on the long-term debt in the next five fiscal years are as follows:
2019
$
1,547
2020
2,048
2021
2,537
2022
1,588
2023
263
Thereafter
439
$
8,422

Reconciliation of Liabilities56

Reconciliation of Liabilities Arising From Financing Activities (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Abstract]
Schedule of Reconciliation of Liabilities Arising From Financing ActivitiesNon-cash changes
April 1,
Acquisition/
March 31,
2017
Cash flows
Disposal
New leases
2018
Long-term borrowings
$
9,273
$
(1,195
)
$
-
$
-
$
8,078
Finance lease obligations
1,057
(336
)
(396
)
19
344
Long-term debt
$
10,330
$
(1,531
)
$
(396
)
$
19
$
8,422
Non-cash changes
April 1,
Acquisition/
March 31,
2016
Cash flows
Disposal
New leases
2017
Long-term borrowings
$
3,457
$
2,813
$
3,003
$
-
$
9,273
Finance lease obligations
565
(12
)
504
-
1,057
Long-term debt
$
4,022
$
2,801
$
3,507
$
-
$
10,330

Share Capital (Tables)

Share Capital (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Summary of Equity FinancingAn unlimited number of common shares.
(i)
Equity Raises During fiscal 2018 the Company completed the following equity financings:
Number of Shares
Share Capital
Equity financing - February 7, 2018 - net of share issue costs of $8,615
5,800,000
$
192,065
Equity investment from Greenstar - November 2, 2017 - net of share issue costs of $707
18,876,901
173,765
Equity financing - July 21, 2017 - net of share issue costs of $78
3,105,590
24,922
Total equity raise share issuances
27,782,491
$
390,752
20.
Share capital (CONTINUED) During fiscal 2017 the Company completed the following equity financings:
Number of Shares
Share Capital
Equity private placement financing - March 22, 2017 - net of share issue costs of $90
2,500,000
$
24,160
Equity financing - December 22, 2016 - net of share issue costs of $3,886
5,662,000
56,131
Equity financing - August 24, 2016 - net of share issue costs of $2,407
9,453,000
32,096
Equity financing - April 15, 2016 - net of share issue costs of $707
5,002,500
10,799
Total equity raise share issuances
22,617,500
$
123,186
Summary of Equity Issuances Related to AcquisitionsNotes
Number of Shares
Share Capital
Share Based Reserve
Issuance of shares for rTrees acquisition - net of share issue costs of $69
10(a)(i)
3,494,505
$
28,026
$
1,079
Issuance of shares for Spot acquisition - net of share issue costs of $9
10(a)(v)
111,669
984
-
Issuance of shares for Green Hemp acquisition - net of share issue costs of $9
10(a)(v)
24,577
848
-
Shares released from escrow related to the MedCann Access acquisition
240,678
390
(390
)
Shares released from escrow related to the Hemp.CA acquisition
10(b)(iii)
129,016
-
-
Shares released from escrow related to the Spektrum Cannabis GmbH acquisition
10(b)(ii)
367,981
-
-
Shares released from escrow related to the Vert Medical acquisition
10(b)(iii)
147,453
-
-
Total acquisition related share issuances
4,515,879
$
30,248
$
689
20.
Share capital (CONTINUED) During fiscal 2017 the Company issued the following shares as a result of business combinations that occurred in the current or prior years:
Notes
Number of Shares
Share Capital
Share Based Reserve
Issuance of shares for Mettrum acquisition - net of share issue costs of $997
10(b)(i)
34,265,042
$
336,514
$
12,143
Issuance of shares per Spektrum Cannabis GmbH acquisition
10(b)(ii)
674,631
10,406
-
Issuance of shares per Vert acquisition
10(b)(iii)
58,978
1,664
-
Issuance of shares per Hemp acquisition
10(b)(iii)
129,021
1,711
-
Shares released from escrow related to the MedCann Access acquisition
1,011,239
2,919
(468
)
Total acquisition related share issuances
36,138,911
$
353,214
$
11,675
Summary of Other Equity IssuancesDuring fiscal 2018 the Company other share issuances were comprised of:
Notes
Number of Shares
Share Capital
Share Based Reserve
Shares released from escrow to LBC Holdings, Inc.
87,836
$
1,297
$
(1,297
)
Shares issued to BC Tweed Partner for performance conditions
20(c)
155,158
1,880
(1,880
)
Shares issued for Apollo/Bodystream earnout
20(c)
243,493
2,398
(2,398
)
Issuance of shares for Niagara asset acquisition - net of share issue costs of $8
9
111,366
995
-
Issuance of shares for acquired intangible - net of share issue costs of $14
11
117,253
3,225
-
Total other share issuances
715,106
$
9,795
$
(5,575
) During fiscal 2017 the Company other share issuances were comprised of:
Number of Shares
Share Capital
Share Based Reserve
Shares released from escrow to LBC Holdings, Inc.
138,032
$
639
$
(639
)
Issuance of shares for 1 Hershey Drive purchase
9
94,397
858
-
Issuance of shares per service agreements
156,240
1,333
-
Total other share issuances
388,669
$
2,830
$
(639
)
Summary of Warrants(i)
Warrants
Number of whole warrants
Average exercise price
Warrant value
Expiry date
Balance at March 31, 2017
-
$
-
$
-
Greenstar equity investment - net of warrant issue cost of $253
18,876,901
12.98
70,265
May 1, 2020
rTrees acquisition
242,408
3.83
1,302
April 30, 2018
Exercise of warrants
(207,297
)
3.72
(1,113
)
N/A
Balance at March 31, 2018
18,912,012
$
12.96
$
70,454
Summary of Changes in ESOP Options20.
Share capital (CONTINUED) The following is a summary of the changes in the Company’s ESOP options during the period:
Options issued
Weighted average exercise price
Balance outstanding at March 31, 2016
8,446,182
$
2.05
Options granted
4,337,701
6.23
Replacement options issued as a result of the Mettrum acquisition
2,417,102
2.35
Options exercised
(4,010,865
)
1.74
Options forfeited/cancelled
(1,146,008
)
2.78
Balance outstanding at March 31, 2017
10,044,112
$
3.97
Options granted
12,832,237
16.50
Replacement options issued as a result of the rTrees acquisition
224,433
3.18
Options exercised
(3,912,946
)
2.82
Options forfeited/cancelled
(1,942,001
)
9.32
Balance outstanding at March 31, 2018
17,245,835
$
12.95
Summary of Outstanding Stock OptionsThe following is a summary of the outstanding stock options as at March 31, 2018:
Options Outstanding
Options Exercisable
Number Outstanding at March 31, 2018
Weighted Average Remaining Contractual Life (years)
Range of Exercise Prices
Number Exercisable at March 31, 2018
Range of Exercise Prices
3,471,904
3.41
$0.56 - $3.78
1,569,274
$0.56 - $3.78
5,731,691
5.13
$3.79 - $8.51
577,665
$3.79 - $8.51
2,712,240
4.91
$8.52 - $11.76
536,254
$8.52 - $11.76
1,540,000
5.67
$11.77 - $27.94
16,667
$11.77 - $27.94
3,790,000
5.88
$27.95 - $33.66
-
$27.95 - $33.66
17,245,835
4.96
2,699,860
Summary of Assumptions Used Following Black-Scholes Option Pricing Model to Establish Fair Value of Options20.
Share capital (CONTINUED) In determining the amount of share-based compensation related to options issued during the year, the Company used the Black-Scholes option pricing model to establish the fair value of options granted during the year ended March 31, 2018 and 2017 on their measurement date by applying the following assumptions:
March 31,
March 31,
2018
2017
(Weighted average)
(Range)
Risk-free interest rate
1.54%
0.50% - 1.94%
Expected life of options (years)
3 - 5
1 - 6
Expected annualized volatility
64%
55% - 70%
Expected forfeiture rate
11%
7%
Expected dividend yield
nil
nil
Black-Scholes value of each option
$
8.88
$0.20 - $6.09
Summary of Share-based Compensation Expense related to AcquisitionShare-based compensation expense related to acquisition milestones is comprised of:
Compensation expense
Notes
Released during fiscal 2018
Remaining shares to be issued on completion of milestones*
March 31, 2018
March 31, 2017
Apollo/Bodystream
(i)
243,493
1,941,804
$
5,095
$
690
Spektrum Cannabis GmBH
(ii)
-
23,570
349
-
Spot
10(a)(v)
-
30,658
330
-
Spectrum Denmark
10(a)(iii)
-
1,906,214
7,206
-
BC Tweed
13
155,158
240,061
5,001
-
Vert Mirabel
10(a)(iv)
-
84,903
1,131
-
Green Hemp
10(a)(v)
-
24,567
167
-
Intellectual property acquisition
11
-
33,804
196
-
$
19,475
$
690
20.
Share capital (CONTINUED)
(i)
The obligation for share-based compensation owing to former shareholders of Apollo Applied Research Inc., and Apollo CRO Inc. (together “Apollo”) and 2344823 Ontario Inc., operating as Bodystream (“Bodystream”) was assumed by the Company in fiscal 2017 on the acquisition of Mettrum Health Corp. and its subsidiaries (“Mettrum”). The maximum number of Company shares that would be issued with respect to the Apollo and Bodystream agreements is 1,111,702 and 1,073,595 shares, respectively. The Company has estimated the number of shares it expects to vest and is amortizing the expense over the expected vesting period based on the fair value of the shares on the acquisition date.
(ii)
The share-based compensation expense is related to a bonus that will be paid to a former shareholder of Spektrum Cannabis GmbH within two years of the acquisition date if certain performance targets are met and the shareholder remains as an employee.

Other Income (Expense) (Tables)

Other Income (Expense) (Tables)12 Months Ended
Mar. 31, 2018
Analysis Of Income And Expense [Abstract]
Summary of Other Income (Expense)March 31,
March 31,
Notes
2018
2017
Fair value changes on financial assets
16
$
78,172
$
5,702
Impairment of product rights
11
(28,000
)
-
Fair value increase in BC Tweed Put Liability and Vert Mirabel Put Liability
10(a),13
(21,000
)
-
Gain on disposal of consolidated entity
10(c)
8,820
-
Bargain purchase gain
10(iii)
638
Partner expense
(4,995
)
-
Gain/loss disposal of property, plant and equipment
(1,181
)
-
Increase in fair value of acquisition consideration related liabilities
-
(1,193
)
Other expense, net
(1,241
)
(651
)
Total other income, net
$
31,213
$
3,858
The partner expense represents a distribution to the Partner of BC Tweed.

Expenses by Nature (Tables)

Expenses by Nature (Tables)12 Months Ended
Mar. 31, 2018
Expense By Nature [Abstract]
Summary of Operating Expenses Distributed by NatureOperating expenses totalled $160,229 and $53,978 for the years ended March 31, 2018 and 2017. Total operating expenses were distributed by nature as follows:
March 31,
March 31,
2018
2017
Employee compensation and benefits
$
49,971
$
21,726
Raw materials used and consumables
13,286
8,105
Other costs of sales
12,340
5,603
Net valuation gains related to inventory and biological assets
(53,652
)
(25,555
)
Share-based compensation
51,177
10,043
Acquisition-related costs
3,406
7,369
Depreciation and amortization
20,486
6,064
Legal and professional fees
10,370
2,947
Royalties
3,110
1,416
Consultants
12,385
3,391
Facility expenses
12,669
3,087
Patient assistance
7,365
2,913
Marketing and promotion
3,835
2,314
Office expenses
6,454
1,986
Travel and other employee expenses
5,141
1,672
Bank and payment processor fees
1,886
897
Total
$
160,229
$
53,978

Income Taxes (Tables)

Income Taxes (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Income Taxes [Abstract]
Summary of Income Tax ExpenseIncome tax expense varies from the amount that would be computed by applying the basic federal and provincial tax rates to loss before income taxes, shown as follows:
March 31, 2018
March 31, 2017
Loss from operations
(52,541
)
(10,275
)
Expected tax rate
26.5
%
26.5
%
Expected tax benefit resulting from loss
$
13,923
$
2,723
Non-deductible expenses
(19,310
)
(2,156
)
Increase in unrecognized temporary differences
(5,506
)
2,258
Non-taxable portion of capital gains and losses
9,421
-
Other
(121
)
(122
)
Income tax (expense) recovery
$
(1,593
)
$
2,703
Summary of Effect of Temporary Differences and Loss CarryforwardsThe effect of temporary differences and loss carryforwards that give rise to significant portions of the deferred tax liability, which has been recognized during the year ended March 31, 2018 are as follows:
March 31, 2017
Recognized in profit or loss
Recognized in equity
Recognized in other comprehensive income
Disposal of consolidated entity
Business combinations and assets held for sale
March 31, 2018
Deferred tax asset
Loss carryforwards
$
30,494
$
5,677
$
-
$
-
$
(1,014
)
$
-
$
35,157
Other
829
-
4,511
-
-
-
5,340
31,323
5,677
4,511
-
(1,014
)
-
40,497
Deferred tax liability
Fixed assets
(1,126
)
3,577
-
-
(263
)
(1,117
)
1,071
Intangibles
(42,703
)
10,310
-
-
6,965
-
(25,428
)
Biological assets
(20,615
)
(9,460
)
-
-
295
-
(29,780
)
Investments
(3,184
)
(13,558
)
-
(5,124
)
-
-
(21,866
)
Other long-term liabilities
-
2,783
-
-
-
-
2,783
Other
381
(922
)
-
-
(284
)
12
(813
)
(67,247
)
(7,270
)
-
(5,124
)
6,713
(1,105
)
(74,033
)
Net deferred taxes
$
(35,924
)
$
(1,593
)
$
4,511
$
(5,124
)
$
5,699
$
(1,105
)
$
(33,536
)
The effect of temporary differences and loss carryforwards that give rise to significant portions of the deferred tax liability, which has been recognized during the year ended March 31, 2017 are as follows:
March 31, 2016
Recognized in profit or loss
Recognized in goodwill
Recognized in other comprehensive income
Liabilities associated with asset held for sale
March 31, 2017
Deferred tax asset
Loss carryforwards
$
9,100
$
15,332
$
6,062
$
-
$
-
$
30,494
Other
224
(62
)
667
-
-
829
9,324
15,270
6,729
-
-
31,323
Deferred tax liability
Fixed assets
(1,097
)
132
(161
)
-
-
(1,126
)
Intangibles
(8,436
)
479
(34,746
)
-
-
(42,703
)
Asset held for sale
-
-
(820
)
-
820
-
Biological assets
(7,201
)
(12,529
)
(885
)
-
-
(20,615
)
Investments
-
(756
)
-
(2,428
)
-
(3,184
)
Other
(3
)
107
277
-
-
381
(16,737
)
(12,567
)
(36,335
)
(2,428
)
820
(67,247
)
Net deferred taxes
$
(7,413
)
$
2,703
$
(29,606
)
$
(2,428
)
$
820
$
(35,924
)
Summary of Unrecognized Temporary DifferencesThe unrecognized temporary differences of the Company are comprised of:
March 31, 2018
March 31, 2017
Losses carried forward
$
30,041
$
2,792
Intangibles assets and fixed asset
-
9,906
Total
$
30,041
$
12,698
Non-Capital Losses Available to Reduce Future Years Taxable Income24.
INCOME TAXES (CONTINUED) The Company has the following non-capital losses available to reduce future years' taxable income which expires as follows:
2030
$
40
2031
123
2032
376
2033
3,195
2034
7,258
2035
18,196
2036
29,806
2037
29,202
2038
79,301
Foreign - indefinite
3,900
$
171,397

Related Parties (Tables)

Related Parties (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Transactions Between Related Parties [Abstract]
Summary of Key Management Personnel CompensationCompensation provided to key management is as follows:
March 31, 2018
March 31, 2017
Short-term employee benefits
$
3,746
$
1,420
Share-based compensation
5,786
1,535
$
9,532
$
2,955

Commitments and Contingencies (

Commitments and Contingencies (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Commitments And Contingencies [Abstract]
Schedule of Future Minimum Lease and Royalty PaymentsFuture commitments which include minimum lease and royalty payments due in each of the next five years are as follows:
2019
$
21,767
2020
21,712
2021
21,017
2022
21,076
2023
19,366
Thereafter
85,200
$
190,138

Supplementary Cash Flow Infor63

Supplementary Cash Flow Information (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Cash Flow Statement [Abstract]
Summary of Changes in Non-Cash Working CapitalThe changes items are as follows:
March 31,
March 31,
2018
2017
Amounts receivable
$
(15,738
)
$
(2,184
)
Prepaid expenses and other assets
(15,770
)
(1,493
)
Biological assets and inventory
(24,493
)
(12,270
)
Accounts payable and accrued liabilities
27,130
(200
)
Deferred revenue
312
55
Other liabilities
40
(256
)
Total
$
(28,519
)
$
(16,348
)
Summary of Cash and Cash EquivalentsCash and cash equivalents consist of the following:
March 31,
March 31,
2018
2017
Cash
$
322,560
$
16,700
Short-term guaranteed investment certificates
-
85,100
Total cash and cash equivalents
$
322,560
$
101,800

Financial Instruments (Tables)

Financial Instruments (Tables)12 Months Ended
Mar. 31, 2018
Disclosure Of Financial Instruments [Abstract]
Summary of Aging of ReceivablesAs at March 31, 2018, the Company’s aging of receivables was approximately as follows:
March 31, 2018
March 31, 2017
0-60 days
$
5,683
$
2,137
61-120 days
258
909
Total
$
5,941
$
3,046
Summary Contractual Maturities of Undiscounted Cash Flows28.
Financial instruments (CONTINUED) In addition to the commitments disclosed in Note 17, the Company is obligated to the following contractual maturities of undiscounted cash flows:
As at March 31, 2018
Carrying amount
Contractual cash flows
Year 1
Years 2 - 3
Years 4 and after - 5
Accounts payable and accrued liabilities
$
89,571
$
89,571
$
89,571
$
-
$
-
Long-term debt
8,422
9,522
1,899
5,082
2,541
Total
$
97,993
$
99,093
$
91,470
$
5,082
$
2,541
Summary of Valuation Techniques and Key Inputs Used in Fair Value Measurement of Level 2 Financial InstrumentsThe following table summarizes the valuation techniques and key inputs used in the fair value measurement of level 2 financial instruments:
Financial asset/financial liability
Valuation techniques and key inputs
Key inputs
AusCann shares
Put option pricing model
Quoted prices in active market
AusCann options
Black-Scholes option pricing model
Quoted prices in active market
TerrAscend warrants
Black-Scholes option pricing model
Quoted prices in active market
Summary of Valuation Techniques and Significant Unobservable Inputs in Fair Value Measurement of Level 3 Financial InstrumentsThe following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of level 3 financial instruments
Financial asset/financial liability
Valuation techniques
Significant unobservable inputs
Relationship of unobservable inputs to fair value
JWC warrants
Black-Scholes option pricing model
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
JWC shares
Market approach
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
HydRx shares
Market approach
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
HydRx warrants
Black-Scholes option pricing model
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
Agripharm warrant
Black-Scholes option pricing model
Share price
Increase or decrease in share price will result in an increase or decrease in fair value
BC Tweed and Vert Mirabel put liability
Discounted cash flow
Discount rate
Increase or decrease in discount rate will result in a decrease or increase in fair value
Future wholesale price and production levels
Increase in future wholesale price and production levels will result in an increase in fair value
BC Tweed call option liability
Market approach
Appraised value of property
Increase or decrease in value will result in a increase or decrease in fair value

Description of Business - Addit

Description of Business - Additional Information (Details)12 Months Ended
Mar. 31, 2018
Disclosure Of Business Description [Abstract]
Country of incorporationCanada

Basis of Presentation - Disclos

Basis of Presentation - Disclosure of Company Subsidiaries and Ownership Interest Held by Non-Controlling Interests (Details)12 Months Ended
Mar. 31, 2018
Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesCanopy Rivers Corporation
Non-controlling interests68.50%
Tweed Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesTweed Inc.
Tweed Farms Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesTweed Farms Inc.
Bedrocan Canada Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesBedrocan Canada Inc.
Spectrum Cannabis Canada Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Cannabis Canada Ltd.
(formerly Mettrum Ltd.)
Tweed Grasslands Cannabis Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesTweed Grasslands Cannabis Inc.
Les Serres Vert Cannabis
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesLes Serres Vert Cannabis
Non-controlling interests33.30%
Spot Therapeutics Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpot Therapeutics Inc.
Vert Cannabis Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesVert Cannabis Inc.
Mettrum Hempworks Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesMettrum Hempworks Inc.
Groupe H.E.M.P.CA
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesGroupe H.E.M.P.CA
Non-controlling interests25.00%
Spectrum Health Corp.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Health Corp.
(formerly Mettrum Health Corp.)
10252832 Canada Inc
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Subsidiaries10252832 Canada Inc
9388036 Canada Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Subsidiaries9388036 Canada Inc.
10663824 Canada Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Subsidiaries10663824 Canada Inc.
80694 Newfoundand and Labrador Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Subsidiaries80694 Newfoundand and Labrador Inc.
2344823 Ontario Inc. d/b/a Bodystream
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Subsidiaries2344823 Ontario Inc. d/b/a Bodystream
Apollo Applied Research Inc. and Apollo CRO Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesApollo Applied Research Inc. and
Apollo CRO Inc.
Spektrum Cannabis GmbH
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpektrum Cannabis GmbH
Canopy LATAM Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesCanopy LATAM Corporation
Spectrum Chile SpA
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Chile SpA
Non-controlling interests15.00%
Grow House JA Limited
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesGrow House JA Limited
Non-controlling interests51.00%
Spectrum Cannabis Denmark Aps
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Cannabis Denmark Aps
Spectrum Polska Sp
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Polska Sp
Spectrum Cannabis Australia PTY Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Cannabis Australia PTY Ltd.
Spectrum Cannabis Italia srl
Disclosure Of Significant Investments In Subsidiaries [Line Items]
SubsidiariesSpectrum Cannabis Italia srl

Significant Accounting Polici67

Significant Accounting Policies - Schedule of Useful Lives of Property, Plant and Equipment (Details)12 Months Ended
Mar. 31, 2018
Computer Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Useful life2-3 years
Office/Lab Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Useful life3-5 years
Furniture and Fixtures
Disclosure Of Property Plant And Equipment [Line Items]
Useful life3-10 years
Warehouse Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Useful life5-15 years
Production Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Useful life3-30 years
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Useful life3-20 years
Building and Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Useful life20-40 years
Greenhouse and Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Useful life20-25 years

Significant Accounting Polici68

Significant Accounting Policies - Schedule of Useful Lives of Finite-Lived Intangible Assets (Details)12 Months Ended
Mar. 31, 2018
Domain Name
Disclosure Of Intangible Assets [Line Items]
Useful life5 years
Health Canada Licenses
Disclosure Of Intangible Assets [Line Items]
Useful lifeUseful life of facility or lease term
Distribution Channel
Disclosure Of Intangible Assets [Line Items]
Useful life5 years
Import License
Disclosure Of Intangible Assets [Line Items]
Useful life4 years
Software
Disclosure Of Intangible Assets [Line Items]
Useful life3 years

Significant Accounting Polici69

Significant Accounting Policies - Additional Information (Details)12 Months Ended
Mar. 31, 2018Segment
Disclosure Of Significant Accounting Policies [Abstract]
Number of reportable segment1

Significant Accounting Polici70

Significant Accounting Policies - Additional Information (Details 1)12 Months Ended
Mar. 31, 2018
BC Tweed
Disclosure Of Joint Ventures [Line Items]
Proportion of ownership interest in joint operation100.00%

Amounts Receivable - Summary of

Amounts Receivable - Summary of Amounts Receivable (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Trade And Other Receivables [Abstract]
Accounts receivable $ 5,863 $ 2,794
Commodity tax receivable15,262 2,769
Interest receivable300 252
Total amounts receivable $ 21,425 $ 5,815

Biological Assets - Disclosure

Biological Assets - Disclosure of Continuity of Biological Assets (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Reconciliation Of Changes In Biological Assets [Abstract]
Balance, beginning of year $ 14,725 $ 5,321
Purchases of seeds271 70
Acquired biological assets1,691
Disposed biological assets due to disposal of consolidated entity (Note 10(c))(1,430)
Unrealized gain on changes in fair value of biological assets100,302 49,090
Increase in biological assets due to capitalized costs17,309 11,983
Transferred to inventory upon harvest(114,829)(53,430)
Balance, end of year $ 16,348 $ 14,725

Biological Assets - Additional

Biological Assets - Additional Information (Details)Mar. 31, 2018Mar. 31, 2017
Disclosure Of Reconciliation Of Changes In Biological Assets [Abstract]
Average completion percentage of biological assets to the next expected harvest date12.00%43.00%

Biological Assets - Summary of

Biological Assets - Summary of Significant Unobservable Inputs and Range of Values (Details)12 Months Ended
Mar. 31, 2018Gram
Estimated Yield per Plant
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets [Line Items]
Unobservable InputsEstimated Yield per Plant – varies by strain and is obtained through historical growing results (trailing 6-months moving average) or grower estimate if historical results are not available.
SensitivityA slight increase in the estimated yield per plant would result in a significant increase in fair value, and vice versa.
Estimated Yield per Plant | Minimum
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets [Line Items]
Range25
Estimated Yield per Plant | Maximum
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets [Line Items]
Range400
Listed Selling Price of Dry Cannabis
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets [Line Items]
Unobservable InputsListed Selling Price of Dry Cannabis – varies by strain and is obtained through listed selling prices or estimated selling prices if historical results are not available.
SensitivityA slight increase in the estimated selling price per strain would result in a significant increase in fair value, and vice versa.
Listed Selling Price of Dry Cannabis | Minimum
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets [Line Items]
Range6
Listed Selling Price of Dry Cannabis | Maximum
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets [Line Items]
Range12

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Classes Of Inventories [Abstract]
Dry Cannabis, Finished goods $ 14,114 $ 2,478
Dry Cannabis, Work-in-process51,309 33,418
Dry Cannabis, Inventory Gross65,423 35,896
Cannabis Oils, Finished goods9,624 2,085
Cannabis Oils, Work-in-process20,574 5,492
Cannabis Oils, Inventory Gross30,198 7,577
Capsules - Finished goods2,705
Seeds - Finished goods63 74
Total Other Cannabis Finished Goods Inventory2,768 74
Total Cannabis and Cannabis Derivatives Inventory98,389 43,547
Product for resale (vaporizers and other)571 1,017
Supplies and consumables2,647 1,417
Total inventory $ 101,607 $ 45,981

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Thousands3 Months Ended12 Months Ended
Mar. 31, 2018Mar. 31, 2018Mar. 31, 2017
Classes Of Inventories [Abstract]
Inventories expensed during the period $ 92,683 $ 39,210
Fair value changes in biological assets included in inventory sold and other inventory charges66,268 $ 34,978
Fair value changes in biological assets included in inventory sold40,509
Other inventory charges included in the fair value changes in biological assets included in inventory sold and other inventory charges25,759
Net realizable value adjustment for anticipated price changes $ 8,431
Inventory write-off $ 7,903

Prepaid Expenses and Other As77

Prepaid Expenses and Other Assets - Schedule of Prepaid Expenses and Other Assets (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Prepaid Expenses And Other Assets [Line Items]
Restricted short-term investments $ 664 $ 550
Other assets2,199 801
Prepaid expenses and other assets19,837 4,285
Prepaid Packaging
Prepaid Expenses And Other Assets [Line Items]
Prepaid expenses8,774
Prepaid Expenses
Prepaid Expenses And Other Assets [Line Items]
Prepaid expenses7,358 $ 2,934
Prepaid Deposits
Prepaid Expenses And Other Assets [Line Items]
Prepaid expenses $ 842

Prepaid Expenses and Other As78

Prepaid Expenses and Other Assets - Additional Information (Details) $ in Thousands12 Months Ended
Mar. 31, 2018CAD ($)
Prepaid Expenses And Other Assets [Abstract]
Other long-term assets $ 8,340
Deposits on property, plant and equipment6,487
Lease payments $ 1,853

Assets Classified as Held for79

Assets Classified as Held for Sale - Additional Information (Details) - CAD ($) $ in ThousandsSep. 13, 2017Mar. 31, 2018
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners [Abstract]
Proceeds on assets classified as held for sale $ 7,000 $ 7,000
Deferred tax liabilities $ 820
Term of agreement3 years

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance $ 96,270 $ 44,984
Ending Balance303,682 96,270
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance102,850 47,697
Additions218,322 33,147
Additions from acquisitions6,086 23,352
Disposal of consolidated entity(7,802)
Transfers/disposals(1,625)(1,346)
Ending Balance317,831 102,850
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance6,580 2,713
Depreciation8,725 4,146
Disposal of consolidated entity(840)
Transfers/disposals(316)(279)
Ending Balance14,149 6,580
Computer Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance4,181 958
Additions1,219 886
Additions from acquisitions313
Disposal of consolidated entity(101)
Transfers/disposals942 2,024
Ending Balance6,241 4,181
Computer Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance889 255
Depreciation1,043 516
Disposal of consolidated entity(31)
Transfers/disposals(1)118
Ending Balance1,900 889
Office/Lab Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance831 935
Additions626 536
Additions from acquisitions408
Disposal of consolidated entity(16)
Transfers/disposals279 (1,048)
Ending Balance1,720 831
Office/Lab Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance82 157
Depreciation404 266
Disposal of consolidated entity(5)
Transfers/disposals(2)(341)
Ending Balance479 82
Furniture and Fixtures | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance875 2,428
Additions348 1,343
Additions from acquisitions109 26
Transfers/disposals49 (2,922)
Ending Balance1,381 875
Furniture and Fixtures | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance82 223
Depreciation137 356
Transfers/disposals(1)(497)
Ending Balance218 82
Production Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance11,132 1,543
Additions4,511 1,668
Additions from acquisitions468 3,789
Disposal of consolidated entity(2,619)
Transfers/disposals15,272 4,132
Ending Balance28,764 11,132
Production Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance1,038 139
Depreciation2,539 279
Disposal of consolidated entity(587)
Transfers/disposals(260)620
Ending Balance2,730 1,038
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance17,155 37,620
Additions338 2,972
Additions from acquisitions229
Transfers/disposals4,989 (23,666)
Ending Balance22,482 17,155
Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance1,930 1,714
Depreciation1,510 2,455
Transfers/disposals12 (2,239)
Ending Balance3,452 1,930
Building and Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance43,449 136
Additions3,799 6,551
Additions from acquisitions12,449
Disposal of consolidated entity(5,066)
Transfers/disposals25,331 24,313
Ending Balance67,513 43,449
Building and Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance2,182 14
Depreciation2,920 156
Disposal of consolidated entity(217)
Transfers/disposals(64)2,012
Ending Balance4,821 2,182
Greenhouse and Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance3,528 2,951
Additions106
Transfers/disposals461 577
Ending Balance4,095 3,528
Greenhouse and Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance358 211
Depreciation155 118
Transfers/disposals29
Ending Balance513 358
Land and Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance2,397 723
Additions5,728 420
Additions from acquisitions345 1,000
Transfers/disposals254
Ending Balance8,470 2,397
Land and Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance19
Depreciation11
Transfers/disposals19
Ending Balance30 19
Warehouse Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Additions138
Transfers/disposals29
Ending Balance167
Warehouse Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation6
Ending Balance6
Assets in Process
Disclosure Of Property Plant And Equipment [Line Items]
Additions201,509 18,771
Assets in Process | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance19,302 403
Additions201,509 18,771
Additions from acquisitions5,164 5,138
Transfers/disposals(48,977)(5,010)
Ending Balance $ 176,998 $ 19,302

Property, Plant and Equipment81

Property, Plant and Equipment - Additional Information (Details) $ in ThousandsFeb. 07, 2018CAD ($)sharesSep. 07, 2017CAD ($)sharesJan. 13, 2017CAD ($)ft²sharesMar. 31, 2018CAD ($)sharesMar. 31, 2017CAD ($)sharesDec. 12, 2016sharesMar. 31, 2016shares
Disclosure Of Property Plant And Equipment [Line Items]
Cash paid $ 6,000
Number of common shares issued | shares111,366 490,641
Gross proceeds from common shares $ 3,239 $ 1,003
Purchase price paid through issuance of common shares2,000
Present value of obligation1,862
Acquisition costs capitalized71
Number of common shares issued | shares117,253 199,320,981 162,187,262 98,818,213
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Additions $ 218,322 $ 33,147
Property, plant and equipment, Property, plant and equipment, cost disposals/adjustments(1,625)(1,346)
Transfers to intangibles632
Niagara-on-the-Lake Greenhouse
Disclosure Of Property Plant And Equipment [Line Items]
Total consideration transferred $ 8,865
Hershey
Disclosure Of Property Plant And Equipment [Line Items]
Additions $ 7,163
Gross proceeds from common shares $ 858
Number of square foot acquired | ft²472,000
Acquisition-related transaction costs $ 179
Number of common shares issued | shares94,397
Rent deposit $ 450
Assets in Process
Disclosure Of Property Plant And Equipment [Line Items]
Additions201,509 18,771
Assets in Process | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Additions201,509 18,771
Property, plant and equipment, Property, plant and equipment, cost disposals/adjustments(48,977)(5,010)
Expansion Or Growing Operations
Disclosure Of Property Plant And Equipment [Line Items]
Additions15,997
Expansion Or Growing Operations | BC Tweed
Disclosure Of Property Plant And Equipment [Line Items]
Additions71,155
Expansion Or Growing Operations | Tweed Inc.
Disclosure Of Property Plant And Equipment [Line Items]
Additions64,813
Expansion Or Growing Operations | Tweed Farms Inc.
Disclosure Of Property Plant And Equipment [Line Items]
Additions43,847
Ongoing Projects
Disclosure Of Property Plant And Equipment [Line Items]
Additions21,694
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Additions338 2,972
Property, plant and equipment, Property, plant and equipment, cost disposals/adjustments $ 4,989 $ (23,666)

Acquistions and Disposals - Sum

Acquistions and Disposals - Summary of Balance Sheet Impact on Acquisition Date (Details) - CAD ($)Feb. 07, 2018Mar. 31, 2018Mar. 31, 2017Sep. 07, 2017Sep. 06, 2017May 01, 2017Jan. 31, 2017Dec. 12, 2016Mar. 31, 2016
Disclosure Of Business Combinations [Line Items]
Goodwill $ 314,923,000 $ 241,371,000 $ 20,866,000
Consideration paid in cash $ 6,000,000
Consideration paid in cash $ (6,000,000)
Acquisition-related costs expensed $ 43,000 3,406,000 7,369,000
Tweed Grasslands
Disclosure Of Business Combinations [Line Items]
Cash and cash equivalents59,000
Amounts receivable16,000
Prepaids and other assets6,000
Property, plant and equipment1,446,000
Goodwill29,736,000
Accounts payable and accrued liablities(336,000)
Net assets30,927,000
Net assets acquired30,927,000
Consideration paid in cash450,000
Consideration paid in shares6,381,000
Other consideration2,382,000
Contingent consideration21,714,000 $ 21,714,000
Total consideration30,927,000 $ 30,927,000
Consideration paid in cash(450,000)
Net cash (outflow) inflow(391,000)
Acquisition-related costs expensed302,000
Tweed JA
Disclosure Of Business Combinations [Line Items]
Cash and cash equivalents125,000
Subscription receivable3,669,000
Property, plant and equipment182,000
Goodwill1,835,000
Accounts payable and accrued liablities(29,000)
Net assets5,782,000
Non-controlling interests(2,013,000)
Net assets acquired3,769,000
Consideration paid in cash100,000
Future cash consideration3,669,000
Total consideration3,769,000 $ 3,769,000
Consideration paid in cash(100,000)
Net cash (outflow) inflow25,000
Acquisition-related costs expensed24,000
Spectrum Cannabis Denmark Aps
Disclosure Of Business Combinations [Line Items]
Inventory173,000
Property, plant and equipment3,990,000
Deferred tax liability(297,000)
Net assets3,866,000
Net assets acquired3,866,000
Consideration paid in cash3,228,000
Total consideration3,228,000
Consideration paid in cash(3,228,000)
Net cash (outflow) inflow(3,228,000)
Acquisition-related costs expensed33,000
Mettrum
Disclosure Of Business Combinations [Line Items]
Cash and cash equivalents12,309,000 $ 12,309,000
Amounts receivable2,140,000
Inventory5,022,000
Prepaids and other assets1,184,000
Property, plant and equipment22,451,000
Goodwill207,081,000
Accounts payable and accrued liablities(5,663,000)
Net assets350,334,000
Net assets acquired350,334,000
Consideration paid in shares337,511,000
Other consideration12,823,000
Total consideration350,334,000 $ 350,334,000
Net cash (outflow) inflow12,309,000
Acquisition-related costs expensed5,190,000
Biological assets1,691,000
Assets classified as held for sale7,000,000
Intangible assets131,009,000
Debt(3,576,000)
Other liabilities(768,000)
Deferred tax liability(29,546,000)
Vert Mirabel
Disclosure Of Business Combinations [Line Items]
Goodwill5,625,000
Net assets5,625,000
Non-controlling interests(2,839,000)
Net assets acquired2,786,000
Other consideration3,750,000
Total consideration3,750,000
Acquisition-related costs expensed54,000
MedCann
Disclosure Of Business Combinations [Line Items]
Amounts receivable5,000
Inventory137,000
Prepaids and other assets102,000
Property, plant and equipment336,000
Goodwill9,209,000
Accounts payable and accrued liablities(107,000)
Net assets10,406,000
Net assets acquired10,406,000
Consideration paid in shares9,720,000
Contingent consideration688,000
Total consideration10,408,000 $ 3,660,000
Acquisition-related costs expensed372,000
Intangible assets784,000
Deferred tax liability(60,000)
Other Acquisitions
Disclosure Of Business Combinations [Line Items]
Cash and cash equivalents7,000 15,000
Amounts receivable14,000
Prepaids and other assets107,000 24,000
Property, plant and equipment468,000 565,000
Goodwill1,562,000 4,024,000
Accounts payable and accrued liablities(143,000)(115,000)
Net assets2,015,000 4,525,000
Non-controlling interests(19,000)
Net assets acquired2,015,000 4,506,000
Consideration paid in cash166,000 1,131,000
Consideration paid in shares1,850,000 2,124,000
Contingent consideration1,251,000
Total consideration2,016,000 4,506,000
Consideration paid in cash(166,000)(1,131,000)
Net cash (outflow) inflow(159,000)(1,116,000)
Acquisition-related costs expensed $ 213,000 163,000
Intangible assets $ 12,000

Acquistions and Disposals - Add

Acquistions and Disposals - Additional Information (Details)Jan. 24, 2018CAD ($)shares$ / sharesDec. 31, 2017CAD ($)Dec. 18, 2017CAD ($)ft²Dec. 05, 2017CAD ($)ft²Dec. 01, 2017Nov. 30, 2017CAD ($)Oct. 10, 2017Sep. 20, 2017Sep. 06, 2017CAD ($)Aug. 28, 2017CAD ($)$ / sharessharesMay 01, 2017CAD ($)$ / sharessharesMar. 31, 2017CAD ($)sharesJan. 31, 2017CAD ($)shares$ / sharesDec. 12, 2016CAD ($)sharesNov. 01, 2016CAD ($)sharesMar. 31, 2018CAD ($)sharesMar. 31, 2018CAD ($)sharesMar. 31, 2017CAD ($)shares$ / sharesFeb. 07, 2018sharesJan. 31, 2018CAD ($)Nov. 23, 2017sharesSep. 07, 2017CAD ($)sharesMar. 30, 2017CAD ($)Mar. 31, 2016CAD ($)shares
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired0.00%0.00%
Name of joint operationBC Tweed Joint Venture Inc.
Purchase price of property $ 176,037,000 $ 29,391,000
Transfer of Vert Mirabel investment to Canopy Rivers964,000
Proceeds from issuance of common shares and warrants $ 470,670,000 $ 130,276,000
Number of common shares issued | shares162,187,262 199,320,981 199,320,981 162,187,262 117,253 98,818,213
Consideration paid in cash $ 6,000,000
common shares issued | shares490,641 111,366
Goodwill $ 241,371,000 $ 314,923,000 $ 314,923,000 $ 241,371,000 $ 20,866,000
Agripharm Corp.
Disclosure Of Business Combinations [Line Items]
Proportion of ownership interest in subsidiary40.00%100.00%
Goodwill $ 2,259,000 2,259,000 2,259,000
Transaction costs included in carrying value of investment $ 311,000
Products agreed to sell by consolidated entity percent100.00%
Percent of products sold by consolidated entity in retail location25.00%
Royalty term20 years
Advance under royalty agreement $ 3,000,000
Percentage of acquisition through Warrant4.00%
Consideration to be paid through warrant exercise $ 5,000,000
Warrant expiration dateNovember 16, 2020
Fair value of the warrant estimated by black-scholes model586,000 $ 586,000
Receivable under the royalty agreement3,000,000 3,000,000
Amount allocated to the royalty receivable2,414,000 2,414,000
Canopy Rivers
Disclosure Of Business Combinations [Line Items]
Share-based compensation expense3,579,000 $ 0
Maximum | Agripharm Corp.
Disclosure Of Business Combinations [Line Items]
Advance under repayable debentures and royalty agreement total20,000,000
Vert Mirabel
Disclosure Of Business Combinations [Line Items]
Profit loss1,411,000
Share-based compensation expense $ 1,131,000
Name of ventureVert Mirabel
Place in businessQuebec
Ownership interest40.70%
Purchase price of property $ 20,000
Percentage of increase property3.00%
License agreement period5 years
Fair value of put option estimated using discounted cash flow approach $ 3,750,000
Put liability $ 4,850,000 4,850,000
Changes in fair value of put liability1,100,000
Cash contributed to exchange of preference share15,000,000
Cumulative preferred dividends $ 750,000
Preferred dividend rate18.00%
Proceeds from issuance of common shares and warrants $ 2,750,000
Fair value grant date discount value2,599,000
Acquisition related costs $ 54,000
Vert Mirabel | Investments Accounted for Using Equity Method
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired100.00%100.00%
Vert Mirabel | Property Plant and Equipment under Operating Leases
Disclosure Of Business Combinations [Line Items]
Area of Greenhouse | ft²700,000
Vert Mirabel | Canopy Rivers
Disclosure Of Business Combinations [Line Items]
Proportion of ownership interest in subsidiary26.00%
Vert Mirabel | Les Serres Vert Cannabis Inc
Disclosure Of Business Combinations [Line Items]
Proportion of ownership interest held by non-controlling interest33.30%
Vert Mirabel | Minimum
Disclosure Of Business Combinations [Line Items]
Purchase price of property $ 23,000
Green Hemp Industries Ltd
Disclosure Of Business Combinations [Line Items]
Name of acquireeGreen Hemp Industries Ltd
Date of acquisitionJan. 24,
2018
Share issue price | $ / shares $ 34.87
Total consideration $ 1,023,000
Share-based compensation expense857,000
Consideration paid in shares857,000
Consideration paid in cash $ 166,000
common shares issued | shares24,577
R Trees
Disclosure Of Business Combinations [Line Items]
Name of acquireeTweed Grasslands Cannabis Inc. (formerly rTrees)
Date of acquisitionMay 1,
2017
Percentage of voting equity interests acquired100.00%
Common shares issued | shares3,494,505
common shares held in escrow | shares2,795,604
Number of shares issued | shares698,901
Share issue price | $ / shares $ 9.13
Equity consideration $ 6,381,000
Gross contingent consideration $ 25,524,000
Contingent consideration fair value21,714,000 $ 21,714,000 21,714,000
Replacement options1,079,000
Warrants issued1,303,000
Effective settlement of receivable450,000
Total consideration $ 30,927,000 30,927,000 30,927,000
Profit loss1,565,000
Consideration paid in shares6,381,000 6,381,000
Consideration paid in cash450,000 450,000
Cash and cash equivalents59,000 59,000
Goodwill29,736,000 $ 29,736,000
Warrant expiration dateApril 30, 2018
Tweed JA
Disclosure Of Business Combinations [Line Items]
Name of acquireeTweed JA
Date of acquisitionSep. 6,
2017
Total consideration $ 3,769,000 3,769,000 $ 3,769,000
Profit loss391,000
Percentage of equity financial interest49.00%
Subscription receivable $ 2,000,000
Consideration paid in cash100,000 100,000
Cash and cash equivalents125,000 125,000
Goodwill1,835,000 1,835,000
Spectrum Cannabis Denmark ApS
Disclosure Of Business Combinations [Line Items]
Total consideration3,228,000 3,228,000
Profit loss $ 1,772,000
Name of joint operationSpectrum Cannabis Denmark ApS
Principal place of businessEurope
Proportion of ownership interest in subsidiary62.00%
Proportion of ownership interest held by non-controlling interest38.00%
Number of shares transferred | shares1,906,214
Vesting period of exchange4 years
Cost to purchase remaining interest $ 6,000,000
Fair value options granted18,805,000 18,805,000
Share-based compensation expense7,206,000
Operating facility acquired | ft²40,000
Cash Paid As Consideration Adjusted Amount $ 3,228,000
Gain on bargain purchase638,000
Consideration paid in cash $ 3,228,000 $ 3,228,000
Spot Therapeutics Inc.
Disclosure Of Business Combinations [Line Items]
Name of acquireeSpot Therapeutics Inc.
Date of acquisitionAug. 28,
2017
Percentage of voting equity interests acquired100.00%
Share issue price | $ / shares $ 8.90
Share-based compensation expense $ 844,000
Number of common shares issued | shares111,669
Consideration paid in shares $ 993,000
Consideration paid in cash $ 907,000
Mettrum
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired100.00%
Share issue price | $ / shares $ 9.85 $ 11.93
Equity consideration $ 337,511,000
Replacement options11,663,000
Total consideration350,334,000 350,334,000 $ 350,334,000
Profit loss4,053,000
Share-based compensation expense $ 480,000
Acquisition related costs5,190,000
Consideration paid in shares $ 337,511,000 $ 337,511,000
common shares issued | shares83,822 34,265,042 83,822
Cash and cash equivalents $ 12,309,000 $ 12,309,000 $ 12,309,000
Settlement of accounts receivable $ 680,000
Options exchanged ratio0.7132%
Changes in fair value of biological assets2,659,000
Changes in Revenue3,033,000
Revenue of acquiree15,428,000
Profit loss of acquiree12,673,000
Acquisition of accounts receivable $ 680,000
Goodwill207,081,000 207,081,000
Mettrum | Common Shares
Disclosure Of Business Combinations [Line Items]
Equity consideration1,000,000 1,000,000
MedCann
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired100.00%
Equity consideration $ 6,746,000
Contingent consideration fair value688,000 688,000
Total consideration10,408,000 $ 3,660,000 10,408,000
Profit loss462,000
Consideration paid in shares9,720,000 9,720,000
Changes in Revenue106,000
Revenue of acquiree35,000
Profit loss of acquiree542,000
Common shares issued | shares674,631
Contingent consideration $ 4,906,000
Goodwill9,209,000 9,209,000
MedCann | Escrow
Disclosure Of Business Combinations [Line Items]
common shares issued | shares1,165,272 122,660 122,660 367,981
Vert Medical Inc Green Medical Inc
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired100.00%
Number of shares issued | shares58,978
Equity consideration $ 498,000
common shares issued | shares294,900
Contingent consideration $ 1,651,000
Contingent consideration fair value1,251,000
Vert Medical Inc Green Medical Inc | Escrow
Disclosure Of Business Combinations [Line Items]
Equity consideration $ 413,000
common shares issued235,922 88,469,000 88,469,000 147,453,000
Hemp
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired75.00%
Equity consideration $ 903,000 $ 595,000 903,000
Total consideration2,344,000
Proportion of ownership interest held by non-controlling interest25.00%
Consideration paid in cash338,000 $ 295,000
Common shares issued | shares129,016
Hemp | Escrow
Disclosure Of Business Combinations [Line Items]
Equity consideration $ 808,000 $ 808,000 $ 808,000
common shares issued | shares129,016
Hemp | Maximum
Disclosure Of Business Combinations [Line Items]
common shares issued | shares258,037

Acquistions and Disposals - S84

Acquistions and Disposals - Summary of Derecognized Assets And Liabilities Related To Deconsolidation Of Subsidiaries (Details) - CAD ($) $ in Thousands1 Months Ended
Nov. 30, 2017Mar. 31, 2018Mar. 31, 2017Mar. 31, 2016
Disclosure Of Business Combinations [Line Items]
Cash and cash equivalents $ (322,560) $ (101,800) $ (15,397)
Amounts receivable21,425 5,815
Inventory101,607 45,981
Biological assets16,348 14,725
Prepaid expenses and other assets19,837 4,285
Property, plant and equipment303,682 96,270 44,984
Intangible assets101,526 162,263 31,861
Goodwill314,923 241,371 $ 20,866
Accounts payable and accrued liabilities(89,571)(15,386)
Deferred tax liability(33,536) $ (35,924)
Agripharm Corp.
Disclosure Of Business Combinations [Line Items]
Cash and cash equivalents $ (17)
Amounts receivable158
Inventory21
Biological assets1,430
Prepaid expenses and other assets451
Property, plant and equipment6,962
Intangible assets26,282
Goodwill2,259 $ 2,259
Accounts payable and accrued liabilities(1,194)
Capital lease obligations(1,073)
Deferred tax liability(5,699)
Net assets disposed29,580
Fair value of retained interest38,400
Gain on disposal of consolidated entity $ 8,820

Intangible Assets And Goodwil85

Intangible Assets And Goodwill - Summary of Continuity of Intangible Assets (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Intangible Assets [Line Items]
Beginning balance $ 162,263 $ 31,861
Ending balance101,526 162,263
Internally Generated Intangibles in Process
Disclosure Of Intangible Assets [Line Items]
Additions326
Ending balance326
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning balance164,648 32,054
Additions2,089 141
Additions from acquisitions3,232 131,805
Disposals/ adjustments(55,651)632
Exchange differences44 16
Ending balance114,362 164,648
Cost | Health Canada Licenses
Disclosure Of Intangible Assets [Line Items]
Beginning balance92,200 4,000
Additions from acquisitions88,200
Disposals/ adjustments(27,600)
Ending balance64,600 92,200
Cost | Distribution Channel
Disclosure Of Intangible Assets [Line Items]
Beginning balance38,900
Additions from acquisitions38,900
Ending balance38,900 38,900
Cost | Product Rights
Disclosure Of Intangible Assets [Line Items]
Beginning balance28,000 28,000
Disposals/ adjustments(28,000)
Ending balance28,000
Cost | Brand
Disclosure Of Intangible Assets [Line Items]
Beginning balance3,410
Additions from acquisitions2,632 3,410
Ending balance6,042 3,410
Cost | Import License
Disclosure Of Intangible Assets [Line Items]
Beginning balance795
Additions from acquisitions779
Exchange differences46 16
Ending balance841 795
Cost | Software
Disclosure Of Intangible Assets [Line Items]
Beginning balance1,197
Additions117 49
Additions from acquisitions516
Disposals/ adjustments143 632
Exchange differences(2)
Ending balance1,455 1,197
Cost | Domain Name
Disclosure Of Intangible Assets [Line Items]
Beginning balance54 54
Ending balance54 54
Cost | Intangibles in Process
Disclosure Of Intangible Assets [Line Items]
Beginning balance92
Additions1,646 92
Additions from acquisitions600
Disposals/ adjustments(194)
Ending balance2,144 92
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning balance2,385 193
Amortization11,761 1,918
Disposals/ adjustments(1,318)274
Exchange differences8
Ending balance12,836 2,385
Accumulated Amortization | Health Canada Licenses
Disclosure Of Intangible Assets [Line Items]
Beginning balance985 166
Amortization2,957 819
Disposals/ adjustments(1,318)
Ending balance2,624 985
Accumulated Amortization | Distribution Channel
Disclosure Of Intangible Assets [Line Items]
Beginning balance1,000
Amortization8,077 1,000
Ending balance9,077 1,000
Accumulated Amortization | Import License
Disclosure Of Intangible Assets [Line Items]
Beginning balance57
Amortization155 57
Exchange differences7
Ending balance219 57
Accumulated Amortization | Software
Disclosure Of Intangible Assets [Line Items]
Beginning balance305
Amortization557 31
Disposals/ adjustments274
Exchange differences1
Ending balance863 305
Accumulated Amortization | Domain Name
Disclosure Of Intangible Assets [Line Items]
Beginning balance38 27
Amortization15 11
Ending balance $ 53 $ 38

Intangible Assets And Goodwil86

Intangible Assets And Goodwill - Additional Information (Details) - CAD ($) $ in ThousandsFeb. 07, 2018Sep. 07, 2017Mar. 31, 2018Mar. 31, 2018Mar. 31, 2017Mar. 31, 2016
Disclosure Of Intangible Assets [Line Items]
Impairment loss $ 28,000
Number of common shares issued117,253 199,320,981 199,320,981 162,187,262 98,818,213
Common shares issued value $ 3,239 $ 1,003
Acquisition-related costs expensed43 $ 3,406 $ 7,369
Property, plant and equipment $ 303,682 303,682 96,270 $ 44,984
Intangible assets $ 101,526 101,526 $ 162,263 $ 31,861
Shares received value1,127
Health Canada Licenses
Disclosure Of Intangible Assets [Line Items]
Net derecognition of intangible assets $ 26,282
Tangible And Intangible Asset Acquisition
Disclosure Of Intangible Assets [Line Items]
Property, plant and equipment50
Intangible assets $ 3,232

Intangible Assets And Goodwil87

Intangible Assets And Goodwill - Summary of Net Change in Goodwill(Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Intangible Assets [Line Items]
Beginning balance $ 241,371 $ 20,866
Exchange differences653 191
Ending balance314,923 241,371
Disposal of consolidated entity(2,259)
Joint Operations
Disclosure Of Intangible Assets [Line Items]
Additions from acquisitions36,400
Subsidiaries
Disclosure Of Intangible Assets [Line Items]
Additions from acquisitions $ 38,758 $ 220,314

Formation of Canopy Rivers - Ad

Formation of Canopy Rivers - Additional Information (Details)Jan. 08, 2018CAD ($)sharesMay 12, 2017CAD ($)sharesMar. 31, 2018CAD ($)shares$ / sharesMar. 31, 2017CAD ($)Sep. 07, 2017sharesDec. 12, 2016shares
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Number of shares provided in exchange for service | shares668
Equity financing issue costs net of tax $ 1,709,000
Net assets acquired recorded as equity attributable to the parent $ 1,158,773,000 $ 639,758,000
common shares issued | shares111,366 490,641
Transaction costs10,008,000 $ 8,066,000
Increase (decrease) in equity $ 1,047,000
Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Advanced convertible debenture for formation of subsidiary $ 20,000,000
Proportion of ownership interest in subsidiary31.50%34.10%
Voting rights, percentage89.10%91.20%
Net assets acquired recorded as equity attributable to the parent $ 1,065,000 $ (35,550,000)
Percentage of option granted to acquire subsidiary8.70%
Description of vesting term of option grantedvest in 3 equal tranches over 3 years
Share-based compensation expense $ 3,090,000
Description of options exercisable termexercisable in increments, with one third being exercisable on each of the first, second and third anniversaries from the date of grant.
Description of expiry date of optionDecember 4, 2022 to March 26, 2023
Share-based compensation expense with non-employees $ 489,000
Investments by Canopy Growth $ 5,141,000
Class B Common Shares | Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Seed capital advanced $ 953,000
Number of shares to be purchased with seed capital advanced | shares19,066,667
Proceeds from issuing shares $ 26,000,000 $ 36,899,000
Options granted, per share | $ / shares $ 0.05
Exercise price, share options granted $ 0.60
common shares issued | shares23,636,365
Transaction costs $ 738,000
Class B Common Shares | Employees And Other Individual | Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Seed capital advanced by employees503,000
Class B Common Shares | Employees | Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Number of option granted | shares3,475,000
Class B Common Shares | Consultants | Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Number of option granted | shares2,440,000
Class A Common Shares | Canopy Rivers Corporation
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Debenture interest converted to shares $ 57,000

Joint Operations - Additional I

Joint Operations - Additional Information (Details) $ in Thousands, ft² in MillionsOct. 10, 2017CAD ($)ft²aMar. 31, 2018CAD ($)sharesMar. 31, 2017CAD ($)
Disclosure Of Joint Operations [Line Items]
Name of joint operationBC Tweed Joint Venture Inc.
Share capital $ 1,076,838 $ 621,541
BC Tweed
Disclosure Of Joint Operations [Line Items]
Ownership interest in joint operation66.67%
Ownership percentage held by partner33.33%
Fair value of put option estimated using discounted cash flow approach36,400
Put liability56,300
Changes in fair value of put liability19,900
Cash commitments to joint venture20,000
Cash advanced to joint venture $ 1,000 $ 79,879
Preferred dividend rate24.00%
Adjustment to Prime Rate for Borrowings3.00%
Percentage of cannabis produced for a fixed price per gram100.00%
Grant date fair value of share-based compensation $ 6,731
Contribution to loss19,907
Acquisition-related transaction costs641
BC Tweed | BC Lease 1
Disclosure Of Joint Operations [Line Items]
Purchase Price for Acquiring Limited Partnership Units $ 28,000
BC Tweed | BC Lease 1 | License Date
Disclosure Of Joint Operations [Line Items]
Percentage of increase in purchase price3.00%
BC Tweed | BC Lease 1 | Fifth Anniversary
Disclosure Of Joint Operations [Line Items]
Percentage of increase in purchase price8.00%
BC Tweed | BC Lease 2
Disclosure Of Joint Operations [Line Items]
Purchase Price for Acquiring Limited Partnership Units $ 45,000
BC Tweed | BC Lease 2 | License Date
Disclosure Of Joint Operations [Line Items]
Percentage of increase in purchase price3.00%
BC Tweed | BC Lease 2 | Fifth Anniversary
Disclosure Of Joint Operations [Line Items]
Percentage of increase in purchase price8.00%
BC Tweed | Two Tranches
Disclosure Of Joint Operations [Line Items]
Number of shares to be issued | shares310,316
BC Tweed | Additional Two Tranches
Disclosure Of Joint Operations [Line Items]
Share capital $ 2,750
BC Tweed | BC Tweed
Disclosure Of Joint Operations [Line Items]
Share-based compensation expense $ 5,001
BC Tweed | Partner | British Columbia
Disclosure Of Joint Operations [Line Items]
Area of land | a55
BC Tweed | Partner | British Columbia | BC Lease 1
Disclosure Of Joint Operations [Line Items]
Area of greenhouse | ft²1.3
BC Tweed | Partner | British Columbia | BC Lease 2
Disclosure Of Joint Operations [Line Items]
Area of greenhouse | ft²1.7

Non-controlling Interests - Sum

Non-controlling Interests - Summary of Financial Information About Company's Subsidiaries That Have Non-controlling Interests (Details) - CAD ($) $ in ThousandsMar. 31, 2018May 12, 2017Mar. 31, 2017Mar. 31, 2016
Disclosure Of Non Controlling Interests [Line Items]
Cash and cash equivalents $ 322,560 $ 101,800 $ 15,397
Investments in associates63,106
Property, plant and equipment303,682 96,270 44,984
Goodwill314,923 241,371 $ 20,866
Accounts payable and accrued liabilities(89,571)(15,386)
Deferred tax liability(33,536)(35,924)
Non-controlling interests(84,465)32
Equity attributable to Canopy Growth(1,158,773) $ (639,758)
Canopy Rivers Corporation
Disclosure Of Non Controlling Interests [Line Items]
Cash and cash equivalents46,299
Amounts receivable519
Prepaid expenses and other assets2
Investments in associates13,225
Other financial assets57,491
Property, plant and equipment2,610
Preferred shares5,455
Accounts payable and accrued liabilities(4,705)
Deferred tax liability(4,502)
Non-controlling interests(80,844)
Equity attributable to Canopy Growth35,550 $ (1,065)
Tweed JA
Disclosure Of Non Controlling Interests [Line Items]
Cash and cash equivalents12
Subscription receivable1,769
Property, plant and equipment1,677
Goodwill1,939
Accounts payable and accrued liabilities(451)
Non-controlling interests(1,686)
Equity attributable to Canopy Growth3,260
Vert Mirabel
Disclosure Of Non Controlling Interests [Line Items]
Cash and cash equivalents508
Amounts receivable650
Prepaid expenses and other assets94
Property, plant and equipment6,818
Goodwill5,625
Accounts payable and accrued liabilities(3,940)
Other current liabilities(88)
Other long-term liabilities(5,455)
Non-controlling interests(2,155)
Equity attributable to Canopy Growth $ 2,057

Non-controlling Interests - S91

Non-controlling Interests - Summary of Net Change in Non-controlling Interests (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Non Controlling Interests [Line Items]
Begining Balance $ (32)
Non-controlling interests16,219 $ (51)
Other comprehensive income4,033
Share-based compensation3,579
Acquisitions60,666 19
Ending Balance84,465 (32)
Canopy Rivers Corporation
Disclosure Of Non Controlling Interests [Line Items]
Non-controlling interests17,490
Other comprehensive income3,998
Share-based compensation3,579
Acquisitions55,777
Ending Balance80,844
Tweed JA
Disclosure Of Non Controlling Interests [Line Items]
Non-controlling interests(366)
Other comprehensive income39
Acquisitions2,013
Ending Balance1,686
Vert Mirabel
Disclosure Of Non Controlling Interests [Line Items]
Non-controlling interests(721)
Acquisitions2,876
Ending Balance2,155
Subsidiaries With Other Material Noncontrolling Interests
Disclosure Of Non Controlling Interests [Line Items]
Begining Balance(32)
Non-controlling interests(184)(51)
Other comprehensive income(4)
Acquisitions19
Ending Balance $ (220) $ (32)

Non-controlling Interests - S92

Non-controlling Interests - Summary of Net Change in Non-controlling Interests (Parenthetical) (Details) $ in ThousandsMar. 31, 2018CAD ($)
Vert Mirabel
Disclosure Of Non Controlling Interests [Line Items]
Noncontrolling interest arising on acquisition $ 2,839
Canopy Rivers Corporation
Disclosure Of Non Controlling Interests [Line Items]
Non-controlling interest arising on the change in ownership interest $ 37

Investments in Associates - Sum

Investments in Associates - Summary of Changes in Investments in Associates Accounted for Using Equity Method (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Significant Investments In Associates [Line Items]
Beginning balance $ 0
Additions64,689
Share of net (loss)/income(1,473) $ (50)
Interest income(110)
Ending balance $ 63,106 0
Agripharm Corp. | Shares
Disclosure Of Significant Investments In Associates [Line Items]
Participating40.00%
Beginning balance $ 0
Additions38,711
Share of net (loss)/income(232)
Interest income0
Ending balance $ 38,479 0
TerrAscend Corp | Shares
Disclosure Of Significant Investments In Associates [Line Items]
Participating24.00%
Beginning balance $ 0
Additions16,978
Share of net (loss)/income(66)
Interest income0
Ending balance $ 16,912 0
Radicle Medical Marijuana Inc | Convertible Debenture
Disclosure Of Significant Investments In Associates [Line Items]
Participating23.80%
Beginning balance $ 0
Additions5,000
Share of net (loss)/income(136)
Interest income(110)
Ending balance $ 4,754 0
Canopy Health Innovations Inc. | Shares
Disclosure Of Significant Investments In Associates [Line Items]
Participating43.00%
Beginning balance $ 0
Additions4,000
Share of net (loss)/income(1,039)
Interest income0
Ending balance $ 2,961 0
Bedrocan Brasil S.A. | Shares
Disclosure Of Significant Investments In Associates [Line Items]
Participating39.80%
Beginning balance $ 0
Additions0
Share of net (loss)/income0
Interest income0
Ending balance $ 0 0
Entourage Phytolab S.A. | Shares
Disclosure Of Significant Investments In Associates [Line Items]
Participating40.00%
Beginning balance $ 0
Additions0
Share of net (loss)/income0
Interest income0
Ending balance $ 0 $ 0

Investments in Associates - S94

Investments in Associates - Summary of Investments in Associates (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Significant Investments In Associates [Line Items]
Current assets $ 481,777 $ 178,786
Current liabilities92,028 17,665
Revenue77,948 39,895
Net loss(54,134) $ (7,572)
Investments Accounted for Using Equity Method
Disclosure Of Significant Investments In Associates [Line Items]
Current assets75,508
Non-current assets110,814
Current liabilities5,631
Non-current liabilities18,070
Net loss(14,040)
Investments Accounted for Using Equity Method | Agripharm Corp.
Disclosure Of Significant Investments In Associates [Line Items]
Current assets4,671
Non-current assets90,716
Current liabilities1,391
Non-current liabilities10,896
Net loss(557)
Investments Accounted for Using Equity Method | TerrAscend Corp
Disclosure Of Significant Investments In Associates [Line Items]
Current assets53,693
Non-current assets15,369
Current liabilities1,692
Net loss(6,805)
Investments Accounted for Using Equity Method | Radicle Medical Marijuana Inc
Disclosure Of Significant Investments In Associates [Line Items]
Current assets2,576
Non-current assets4,382
Current liabilities94
Non-current liabilities7,174
Net loss(506)
Investments Accounted for Using Equity Method | Canopy Health Innovations Inc.
Disclosure Of Significant Investments In Associates [Line Items]
Current assets12,160
Non-current assets123
Current liabilities364
Net loss(3,949)
Investments Accounted for Using Equity Method | Bedrocan Brasil S.A.
Disclosure Of Significant Investments In Associates [Line Items]
Current assets659
Current liabilities34
Net loss(162)
Investments Accounted for Using Equity Method | Entourage Phytolab S.A.
Disclosure Of Significant Investments In Associates [Line Items]
Current assets1,749
Non-current assets224
Current liabilities2,056
Net loss $ (2,061)

Investments in Associates - S95

Investments in Associates - Summary of Investments in Associates (Parenthetical) (Details) - CAD ($)Dec. 08, 2017Nov. 27, 2017Dec. 21, 2016Sep. 30, 2017Mar. 31, 2018Mar. 31, 2017
Disclosure Of Significant Investments In Associates [Line Items]
Percentage of voting equity interests acquired0.00%
Investments in associates $ 63,106,000 $ 0
Radicle Medical Marijuana Inc
Disclosure Of Significant Investments In Associates [Line Items]
Interest rate of debenture5.00%
Royalty term20 years
Amount advanced under convertible debenture $ 5,000,000
Amount advanced under repayable debenture3,000,000
Radicle Medical Marijuana Inc | Convertible Debenture
Disclosure Of Significant Investments In Associates [Line Items]
Investments in associates5,000,000
Radicle Medical Marijuana Inc | Repayable Debenture
Disclosure Of Significant Investments In Associates [Line Items]
Investments in associates5,000,000
TerrAscend Corp
Disclosure Of Significant Investments In Associates [Line Items]
Number of units directly subscribed9,545,456
Purchase value of units $ 1.10
Number of common shares included in unit1
Number of common share to purchase warrant included in unit1
Exercise price of warrants $ 1.10
Purchase price of shares13,460,000
Purchase price of warrants $ 7,540,000
Number of additional common shares directly subscribed1,740,000
Purchase price of additional shares $ 1
Percentage of voting equity interests acquired24.00%
Investment cost capitalized $ 38,000
Percentage sale of current production25.00%
Term of Production to be sold2 years
Renewal Term of Production to Be Sold1 year
TerrAscend Corp | Canopy Rivers Corporation
Disclosure Of Significant Investments In Associates [Line Items]
Number of units indirectly subscribed9,545,456
Number of additional common shares indirectly subscribed1,740,000
Canopy Rivers Corporation
Disclosure Of Significant Investments In Associates [Line Items]
Percentage of debentures converted to common shares23.80%
Canopy Health Innovations Inc.
Disclosure Of Significant Investments In Associates [Line Items]
Percentage of voting equity interests acquired46.15%43.00%0.00%
Investments in associates $ 4,000,000
Proceeds from issuing shares $ 7,000,000 $ 8,842,000
Bedrocan Brasil S.A.
Disclosure Of Significant Investments In Associates [Line Items]
Percentage of voting equity interests acquired39.762%
Entourage Phytolab S.A.
Disclosure Of Significant Investments In Associates [Line Items]
Percentage of voting equity interests acquired39.99%

Other Financial Assets - Summar

Other Financial Assets - Summary of Changes in Other Financial Assets (Details) $ in Thousands12 Months Ended
Mar. 31, 2018CAD ($)
Disclosure Of Financial Assets [Line Items]
Beginning balance $ 24,030
Additions22,439
Fair Value Through Other Comprehensive Income38,673
Fair Value Through Profit or Loss78,172
Interest revenue149
Ending balance $ 163,463
TerrAscend Corp | Warrants
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTPL
Additions $ 7,540
Fair Value Through Profit or Loss67,614
Ending balance $ 75,154
AusCann Group Holdings Ltd. | Shares
Disclosure Of Financial Assets [Line Items]
Accounting methodFVOCI
Beginning balance $ 18,328
Additions1,214
Fair Value Through Other Comprehensive Income19,544
Ending balance $ 39,086
AusCann Group Holdings Ltd. | Options
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTPL
Beginning balance $ 5,702
Fair Value Through Profit or Loss4,785
Ending balance $ 10,487
James E. Wagner Cultivation Ltd. | Warrants
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTPL
Additions $ 112
Fair Value Through Profit or Loss702
Ending balance $ 814
James E. Wagner Cultivation Ltd. | Shares
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTOCI
Additions $ 3,863
Fair Value Through Other Comprehensive Income6,728
Ending balance $ 10,591
James E. Wagner Cultivation Ltd. | Royalty Interest
Disclosure Of Financial Assets [Line Items]
Accounting methodamortized
cost
Additions $ 2,500
Interest revenue162
Ending balance $ 2,662
Agripharm Corp. | Warrants
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTPL
Additions $ 586
Fair Value Through Profit or Loss(139)
Ending balance $ 447
Agripharm Corp. | Royalty Interest
Disclosure Of Financial Assets [Line Items]
Accounting methodamortized
cost
Additions $ 2,414
Interest revenue(88)
Ending balance $ 2,326
Vapium Incorporated | Shares
Disclosure Of Financial Assets [Line Items]
Accounting methodcost
Additions $ 1,210
Ending balance $ 1,210
Radicle Medical Marijuana Inc | Repayable Debenture
Disclosure Of Financial Assets [Line Items]
Accounting methodamortized
cost
Additions $ 3,000
Interest revenue75
Ending balance $ 3,075
HydRx Farms Ltd. | Warrants
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTPL
Fair Value Through Profit or Loss $ 5,210
Ending balance $ 5,210
HydRx Farms Ltd. | Shares
Disclosure Of Financial Assets [Line Items]
Accounting methodFVTOCI
Fair Value Through Other Comprehensive Income $ 12,401
Ending balance $ 12,401

Other Financial Assets - Summ97

Other Financial Assets - Summary of Changes in Other Financial Assets (Parenthetical) (Details)Dec. 31, 2017sharesNov. 27, 2017CAD ($)Sep. 29, 2017CAD ($)Mar. 31, 2018CAD ($)sharesMar. 31, 2018CAD ($)WarrantsharesMar. 31, 2017CAD ($)Mar. 31, 2018AUD ($)shares
Disclosure Of Financial Assets [Line Items]
Exercise price of share options exercisable $ 4.55 $ 4.55
Percentage of voting equity interests acquired0.00%0.00%0.00%
Proceeds from exercise of stock options $ 11,053,000 $ 6,961,000
AusCann Group Holdings Ltd.
Disclosure Of Financial Assets [Line Items]
Number of ordinary shares held | shares29,865,000
Percentage of issued and outstanding ordinary shares11.00%
Number of options held | shares7,677,639
Number of ordinary shares placed in escrow | shares27,465,000
Exercise price of share options exercisable $ 0.20
AusCann Group Holdings Ltd. | Shares
Disclosure Of Financial Assets [Line Items]
Gain on fair value changes on available for sale financial assets15,900,000
Gain on fair value changes on available for sale financial assets, Taxes2,428,000
AusCann Group Holdings Ltd. | Options
Disclosure Of Financial Assets [Line Items]
Gain on fair value changes on available for sale financial assets $ 5,702,000
James E. Wagner Cultivation Ltd. | Canopy Rivers Corporation
Disclosure Of Financial Assets [Line Items]
Number of common shares acquired from affiliate | shares37,000
Number of warrants acquired from affiliate | Warrant5,000
Payments for purchase of ordinary shares and warrants from affiliate $ 3,975,000
Cash advanced to joint venture $ 2,500,000
Interest rate8.00%8.00%8.00%
Royalty receivable term20 years
Percentage of voting equity interests acquired14.70%14.70%14.70%
Carrying value of ordinary shares $ 3,863,000
Carrying value of warrants112,000
Fair value of ordinary shares10,591,000
Fair value of warrants $ 814,000
Vapium Incorporated
Disclosure Of Financial Assets [Line Items]
Percentage of voting equity interests acquired12.24%9.93%
Ownership interest for cash investment $ 960,000
Proceeds from exercise of stock options $ 250,000
HydRx Farms Ltd.
Disclosure Of Financial Assets [Line Items]
Number of ordinary shares held | shares3,100,307 3,100,307 3,100,307
Percentage of voting equity interests acquired8.70%8.70%8.70%
Fair value of warrants $ 5,210,000
Fair value of common shares $ 12,401,000 $ 12,401,000
Number of warrants held | shares1,860,680 1,860,680 1,860,680

Accounts Payable and Accrued 98

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Accounts Payable And Accrued Liabilities [Abstract]
Trade payables $ 46,175 $ 5,661
Accrued liabilities43,396 9,725
Total accounts payable and accrued liabilities $ 89,571 $ 15,386

Accounts Payable and Accrued 99

Accounts Payable and Accrued Liabilities - Additional Information (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Accounts Payable And Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities $ 89,571 $ 15,386
Property, plant and equipment62,034 2,804
Professional fees7,391 1,642
Compensation related liabilities5,747 2,349
Miscellaneous liabilities $ 14,399 $ 8,591

Long-term Debt and Other Lon100

Long-term Debt and Other Long-Term Liabilities - Summary of Detailed Information About Borrowings (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings $ 8,422 $ 10,330
Less: current portion(1,557)(1,691)
Long-term debt6,865 8,639
Annual Interest Rate 4.9% Mortgage Payable Due August 1, 2021
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings2,777 3,210
Annual Interest Rate of 5.3% Mortgage Payable Due December 1, 2019
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings1,089 1,345
Annual Interest Rate of 4.8% Mortgage Payable Due December 1, 2020
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings2,648 2,994
Term Loan 10% Due October 1, 2024
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings1,564 1,724
Interest Rate 5.9%-17.1% Finance Lease
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings $ 344 $ 1,057

Long-term Debt and Other Lon101

Long-term Debt and Other Long-Term Liabilities - Summary of Detailed Information About Borrowings (Parenthetical) (Details)12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Annual Interest Rate 4.9% Mortgage Payable Due August 1, 2021
Disclosure Of Detailed Information About Borrowings [Line Items]
Term of mortgage payable5 years5 years
Term of amortization7 years7 years
Interest rate4.90%4.90%
Borrowings, maturityAugust 1, 2021August 1, 2021
Annual Interest Rate of 5.3% Mortgage Payable Due December 1, 2019
Disclosure Of Detailed Information About Borrowings [Line Items]
Term of mortgage payable5 years5 years
Term of amortization7 years7 years
Interest rate5.30%5.30%
Borrowings, maturityDecember 1, 2019December 1, 2019
Annual Interest Rate of 4.8% Mortgage Payable Due December 1, 2020
Disclosure Of Detailed Information About Borrowings [Line Items]
Term of mortgage payable5 years[1]5 years
Term of amortization7 years7 years
Interest rate4.80%4.80%
Borrowings, maturityDecember 1, 2020December 1, 2020
Term Loan 10% Due October 1, 2024
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate10.00%10.00%
Borrowings, maturityOctober 1, 2024October 1, 2024
Interest Rate 5.9%-17.1% Finance Lease | Minimum
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate5.90%5.90%
Borrowing term2 years2 years
Interest Rate 5.9%-17.1% Finance Lease | Maximum
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate17.10%17.10%
Borrowing term5 years5 years
[1]five-year

Long-term Debt and Other Lon102

Long-term Debt and Other Long-Term Liabilities - Additional Information (Details) - CAD ($)12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Annual Interest Rate 4.9% Mortgage Payable Due August 1, 2021
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, maturityAugust 1, 2021August 1, 2021
Interest rate4.90%4.90%
Annual Interest Rate of 5.3% Mortgage Payable Due December 1, 2019
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, maturityDecember 1, 2019December 1, 2019
Interest rate5.30%5.30%
Annual Interest Rate of 4.8% Mortgage Payable Due December 1, 2020
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, maturityDecember 1, 2020December 1, 2020
Interest rate4.80%4.80%
Revolving Line of Credit | Canada | CIBC Prime Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Description of variable interest basisCIBC prime rate plus 1.2%CIBC prime rate plus 1.2%
Adjustment to Prime Rate for Borrowings1.20%1.20%
Variable interest rate term5 years5 years
Revolving Line of Credit | Canada | Maximum
Disclosure Of Detailed Information About Borrowings [Line Items]
Revolving lines of credit $ 5,500,000 $ 5,500,000
Term Loan 10% Due October 1, 2024
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, maturityOctober 1, 2024October 1, 2024
Interest rate10.00%10.00%
Term of mortgage payable10 years
Rent expenses $ 27,000

Long-term Debt and Other Lon103

Long-term Debt and Other Long-Term Liabilities - Summary of Principal Repayments of Long-term Debt (Details) - Long term Borrowings $ in ThousandsMar. 31, 2018CAD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments $ 8,422
2,019
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments1,547
2,020
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments2,048
2,021
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments2,537
2,022
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments1,588
2,023
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments263
Thereafter
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments $ 439

Long-term Debt and Other Lon104

Long-term Debt and Other Long-Term Liabilities - Summary of Principal Repayments of Long-term Debt (Parenthetical) (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Disclosure Of Detailed Information About Borrowings [Line Items]
Other long-term liabilities $ 61,150 $ 766
BC Tweed
Disclosure Of Detailed Information About Borrowings [Line Items]
Put liability56,300
Vert Mirabel
Disclosure Of Detailed Information About Borrowings [Line Items]
Put liability $ 4,850

Reconciliation of Liabilitie105

Reconciliation of Liabilities Arising From Financing Activities - Schedule of Reconciliation of Liabilities Arising From Financing Activities (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities at beginning of period $ 10,330 $ 4,022
Non-cash changes cash flows(1,531)2,801
Non-cash changes acquisition/ disposal(396)3,507
Non-cash changes new leases19
Liabilities arising from financing activities at end of period8,422 10,330
Long term Borrowings
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities at beginning of period9,273 3,457
Non-cash changes cash flows(1,195)2,813
Non-cash changes acquisition/ disposal3,003
Liabilities arising from financing activities at end of period8,078 9,273
Finance Lease Obligations
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities at beginning of period1,057 565
Non-cash changes cash flows(336)(12)
Non-cash changes acquisition/ disposal(396)504
Non-cash changes new leases19
Liabilities arising from financing activities at end of period $ 344 $ 1,057

Share Capital - Equity Raises -

Share Capital - Equity Raises - Summary of Equity Financing (Details) - CAD ($) $ in ThousandsFeb. 07, 2018Nov. 02, 2017Jul. 21, 2017Mar. 22, 2017Dec. 22, 2016Aug. 24, 2016Apr. 15, 2016Mar. 31, 2018Mar. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Equity raise share issuances, shares5,800,000 3,105,590 2,500,000 5,662,000 9,453,000 5,002,500 27,782,491 22,617,500
Equity raise share issuances $ 192,065 $ 24,922 $ 24,160 $ 56,131 $ 32,096 $ 10,799 $ 390,752 $ 123,186
Greenstar investment
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Equity raise share issuances, shares18,876,901
Equity raise share issuances $ 173,765

Share Capital - Equity Raise107

Share Capital - Equity Raises - Summary of Equity Financing (Parenthetical) (Details) - CAD ($) $ in ThousandsFeb. 07, 2018Nov. 02, 2017Jul. 21, 2017Mar. 22, 2017Dec. 22, 2016Aug. 24, 2016Apr. 15, 2016
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Equity financing issue costs $ 8,615 $ 78 $ 90 $ 3,886 $ 2,407 $ 707
Greenstar investment
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Equity financing issue costs $ 707

Share Capital - Additional Info

Share Capital - Additional Information (Details)Nov. 02, 2017CAD ($)shares$ / sharesOct. 20, 2017sharesOct. 01, 2017sharesJul. 04, 2017sharesApr. 03, 2017sharesJan. 31, 2017CAD ($)sharesMar. 31, 2018CAD ($)sharesMar. 31, 2018CAD ($)shares$ / sharesMar. 31, 2017CAD ($)shares$ / sharesFeb. 07, 2018sharesSep. 07, 2017sharesDec. 12, 2016sharesApr. 07, 2016CAD ($)sharesMar. 31, 2016CAD ($)shares
Disclosure Of Classes Of Share Capital [Line Items]
common shares issued | shares111,366 490,641
Transaction costs $ 10,008,000 $ 8,066,000
Shares issued | shares199,320,981 199,320,981 162,187,262 117,253 98,818,213
Warrants exercised | shares207,297 213,104
Warrants exercise price | $ / shares $ 3.72 $ 0.59
Weighted average exercise price of options outstanding $ 12.95 $ 12.95
Exercise price of share options exercisable $ 4.55 4.55
Share-based compensation expense $ 4,774,000
Number of options provided in exchange for services | shares420,000
Proceeds from exercise of stock options $ 11,053,000 $ 6,961,000
Share-based compensation47,597,000 10,043,000
Share based payments1,151,000 1,307,000
Common shares issue for payment of royalties | shares79,717
Expense3,110,000 1,416,000
Cost of Sale
Disclosure Of Classes Of Share Capital [Line Items]
Expense920,000 0
Canopy Rivers
Disclosure Of Classes Of Share Capital [Line Items]
Share-based compensation expense3,579,000 0
Options
Disclosure Of Classes Of Share Capital [Line Items]
Share-based compensation expense $ 21,278,000 $ 7,650,000
Maximum
Disclosure Of Classes Of Share Capital [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards10.00%
Number of common shares reserved for Awards | shares19,955,721 19,955,721
Omnibus Incentive Plan
Disclosure Of Classes Of Share Capital [Line Items]
Aggregate number of common shares that may be issued | shares400,000
Aggregate number of common shares that may be issued | shares200,000
Purchase Plan
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued | shares0
ESOP
Disclosure Of Classes Of Share Capital [Line Items]
Percentage of options exercisable on each anniversaries from date of grant33.33%
ESOP expiration period6 years
Weighted average exercise price of options outstanding $ 12.95 $ 12.95 $ 3.97 $ 2.05
Options exercised | shares3,912,946 4,010,865
Proceeds from exercise of stock options $ 11,053,000
ESOP | Maximum
Disclosure Of Classes Of Share Capital [Line Items]
Exercise price, share options granted11.71
ESOP | Minimum
Disclosure Of Classes Of Share Capital [Line Items]
Exercise price, share options granted $ 0.43
XIB Consulting Inc | Corporate Development Initiatives
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued | shares72,418
MedCann Access
Disclosure Of Classes Of Share Capital [Line Items]
Shares released from escrow related to the acquisition, shares | shares240,678 1,011,239
Shares released and cancelled from escrow account | shares48,078 1,149,892
Share-based compensation $ 14,000 $ (396,000)
LBC Holdings, Inc
Disclosure Of Classes Of Share Capital [Line Items]
Shares released from escrow related to the acquisition, shares | shares87,836 87,836 87,836 138,032
Shares released from escrow | shares25,097
Mettrum
Disclosure Of Classes Of Share Capital [Line Items]
common shares issued | shares34,265,042 83,822
Total consideration $ 350,334,000 $ 350,334,000
Equity consideration337,511,000
Share-based compensation expense $ 480,000
Mettrum | Common Shares
Disclosure Of Classes Of Share Capital [Line Items]
Equity consideration $ 1,000,000
Mettrum | XIB Consulting Inc | Corporate Development Initiatives | Common Shares
Disclosure Of Classes Of Share Capital [Line Items]
common shares issued | shares83,822
Equity consideration $ 1,000,000
Greenstar investment
Disclosure Of Classes Of Share Capital [Line Items]
common shares issued | shares18,876,901
Total consideration $ 244,990,000
offering price | $ / shares $ 12.9783
Purchase price of shares $ 174,472,000
Purchase price of warrants70,518,000
Warrants expiration descriptionThe warrants, each exercisable at $12.9783 per warrant for a common share expire May 2, 2020 and are exercisable in two equal tranches, with the first exercisable tranche date being August 1, 2018, and the second exercisable tranche date being February 1, 2019, provided at the time of exercising the warrants, the Company still owns the 18,876,901 common shares.
Transaction costs $ 707,000
Warrants | Greenstar investment
Disclosure Of Classes Of Share Capital [Line Items]
common shares issued | shares18,876,901
Transaction costs $ 253,000

Share Capital - Acquisitions -

Share Capital - Acquisitions - Summary of Equity Issuances Related to Acquisitions (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares4,515,879 36,138,911
Acquisition related share issuance's $ 30,248 $ 353,214
Acquisition related share based reserve $ 689 11,675
R Trees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares3,494,505
Acquisition related share issuance's $ 28,026
Acquisition related share based reserve $ 1,079
Spot
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares111,669
Acquisition related share issuance's $ 984
Green Hemp
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares24,577
Acquisition related share issuance's $ 848
MedCann Access
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Acquisition related share based reserve $ (390) $ (468)
Shares released from escrow related to the acquisition, shares240,678 1,011,239
Shares released from escrow related to the acquisition $ 390 $ 2,919
Hemp
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares129,021
Acquisition related share issuance's $ 1,711
Shares released from escrow related to the acquisition, shares129,016
Spectrum Cannabis GmbH
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares released from escrow related to the acquisition, shares367,981
Vert Medical
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares released from escrow related to the acquisition, shares147,453
Mettrum Hempworks Inc.
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares34,265,042
Acquisition related share issuance's $ 336,514
Acquisition related share based reserve $ 12,143
Spektrum Cannabis GmbH
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares674,631
Acquisition related share issuance's $ 10,406
Vert
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares58,978
Acquisition related share issuance's $ 1,664

Share Capital - Acquisitions110

Share Capital - Acquisitions - Summary of Equity Issuances Related to Acquisitions (Details) (Parenthetical) (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs $ 2,448 $ 2,448
R Trees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs69
Spot
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs9
Green Hemp
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs $ 9
Mettrum Hempworks Inc.
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs $ 997

Share Capital - Other - Summary

Share Capital - Other - Summary of Other Equity Issuances (Details) - CAD ($) $ in ThousandsOct. 01, 2017Jul. 04, 2017Apr. 03, 2017Mar. 31, 2018Mar. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquired intangible - net of share issue costs117,253
Total other share issuances, shares715,106 388,669
Issuance of shares for acquisition, Shares4,515,879 36,138,911
Issuance of shares per service agreements, shares156,240
Share capital
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquired intangible - net of share issue costs $ 3,225
Total other share issuances9,795 $ 2,830
Issuance of shares per service agreements1,333
Share-based reserve
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Total other share issuances $ (5,575) $ (639)
LBC Holdings, Inc
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares released from escrow to LBC Holdings, Inc., shares87,836
Shares released from escrow related to the acquisition, shares87,836 87,836 87,836 138,032
LBC Holdings, Inc | Share capital
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares released from escrow to LBC Holdings, Inc. $ 1,297 $ 639
LBC Holdings, Inc | Share-based reserve
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares released from escrow to LBC Holdings, Inc. $ (1,297) $ (639)
BC Tweed Partner
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares issued to BC Tweed Partner for performance conditions, shares155,158
BC Tweed Partner | Share capital
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares issued to BC Tweed Partner for performance conditions $ 1,880
BC Tweed Partner | Share-based reserve
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares issued to BC Tweed Partner for performance conditions $ (1,880)
Apollo/Bodystream
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares issued for Apollo/Bodystream earnout, shares243,493
Apollo/Bodystream | Share capital
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares issued for Apollo/Bodystream earnout $ 2,398
Apollo/Bodystream | Share-based reserve
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Shares issued for Apollo/Bodystream earnout $ (2,398)
Niagara Asset Acquisition
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for Niagara asset acquisition - net of share issue costs111,366
Niagara Asset Acquisition | Share capital
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Acquisition related share issuance's $ 995
Hershey
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Issuance of shares for acquisition, Shares94,397
Hershey | Share capital
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Acquisition related share issuance's $ 858

Share Capital - Other - Summ112

Share Capital - Other - Summary of Other Equity Issuances (Parenthetical) (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs $ 2,448 $ 2,448
Intangible Asset Acquisition
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs14
Niagara Asset Acquisition
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share issue costs $ 8

Share Capital - Summary of Warr

Share Capital - Summary of Warrants (Details)12 Months Ended
Mar. 31, 2018CAD ($)shares
Disclosure Of Warrants [Line Items]
Exercise of warrants | shares(207,297)
Number of whole warrants, Ending Balance | shares18,912,012
Exercise of warrants $ 3.72
Average Exercise Price of Warrants, Ending Balance12.96
Exercise of warrants(1,113,000)
Warrant value, Ending Balance $ 70,454,000
R Trees
Disclosure Of Warrants [Line Items]
rTrees acquisition | shares242,408
rTrees acquisition $ 3.83
rTrees acquisition $ 1,302,000
Warrant expiration dateApril 30, 2018
Greenstar investment
Disclosure Of Warrants [Line Items]
Greenstar equity investment - net of warrant issue cost | shares18,876,901
Greenstar equity investment - net of warrant issue cost $ 12.98
Greenstar equity investment - net of warrant issue cost $ 70,265,000
Warrant expiration dateMay 1, 2020

Share Capital - Summary of W114

Share Capital - Summary of Warrants (Parenthetical) (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Warrants [Line Items]
Share issue costs $ 2,448 $ 2,448
Greenstar investment | Warrants
Disclosure Of Warrants [Line Items]
Share issue costs $ 253

Share Capital - Summary of Chan

Share Capital - Summary of Changes in ESOP Options (Details)12 Months Ended
Mar. 31, 2018CAD ($)sharesMar. 31, 2017CAD ($)shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price at end of year $ 12.95
ESOP
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Options issued at beginning of year | shares10,044,112 8,446,182
Number of option granted | shares12,832,237 4,337,701
Options exercised | shares(3,912,946)(4,010,865)
Options forfeited/cancelled | shares(1,942,001)(1,146,008)
Options issued at end of year | shares17,245,835 10,044,112
Weighted average exercise price at beginning of year $ 3.97 $ 2.05
Weighted average exercise price - Options granted16.506.23
Weighted average exercise price - Options exercised2.821.74
Weighted average exercise price - Options forfeited/cancelled9.322.78
Weighted average exercise price at end of year $ 12.95 $ 3.97
ESOP | Mettrum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Replacement options issued as a result of acquisition | shares2,417,102
Weighted average exercise price - Replacement options issued as a result of acquisition $ 2.35
ESOP | R Trees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Replacement options issued as a result of acquisition | shares224,433
Weighted average exercise price - Replacement options issued as a result of acquisition $ 3.18

Share Capital - Summary of Outs

Share Capital - Summary of Outstanding Stock Options (Details)Mar. 31, 2018CAD ($)sharesYear
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price of share options exercisable $ 4.55
Weighted Average Remaining Contractual Life (3.41 years)
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding | shares3,471,904
Options Outstanding | Year3.41
Options Exercisable | shares1,569,274
Weighted Average Remaining Contractual Life (3.41 years) | Minimum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding $ 0.56
Exercise price of share options exercisable0.56
Weighted Average Remaining Contractual Life (3.41 years) | Maximum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding3.78
Exercise price of share options exercisable $ 3.78
Weighted Average Remaining Contractual Life (5.13 years)
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding | shares5,731,691
Options Outstanding | Year5.13
Options Exercisable | shares577,665
Weighted Average Remaining Contractual Life (5.13 years) | Minimum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding $ 3.79
Exercise price of share options exercisable3.79
Weighted Average Remaining Contractual Life (5.13 years) | Maximum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding8.51
Exercise price of share options exercisable $ 8.51
Weighted Average Remaining Contractual Life (4.91 years)
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding | shares2,712,240
Options Outstanding | Year4.91
Options Exercisable | shares536,254
Weighted Average Remaining Contractual Life (4.91 years) | Minimum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding $ 8.52
Exercise price of share options exercisable8.52
Weighted Average Remaining Contractual Life (4.91 years) | Maximum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding11.76
Exercise price of share options exercisable $ 11.76
Weighted Average Remaining Contractual Life (5.67 years)
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding | shares1,540,000
Options Outstanding | Year5.67
Options Exercisable | shares16,667
Weighted Average Remaining Contractual Life (5.67 years) | Minimum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding $ 11.77
Exercise price of share options exercisable11.77
Weighted Average Remaining Contractual Life (5.67 years) | Maximum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding27.94
Exercise price of share options exercisable $ 27.94
Weighted Average Remaining Contractual Life (5.88 years)
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding | shares3,790,000
Options Outstanding | Year5.88
Weighted Average Remaining Contractual Life (5.88 years) | Minimum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding $ 27.95
Exercise price of share options exercisable27.95
Weighted Average Remaining Contractual Life (5.88 years) | Maximum
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding33.66
Exercise price of share options exercisable $ 33.66
Weighted Average Remaining Contractual Life (4.96 years)
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options Outstanding | shares17,245,835
Options Outstanding | Year4.96
Options Exercisable | shares2,699,860

Share Capital - Summary of Assu

Share Capital - Summary of Assumptions Used Following Black-Scholes Option Pricing Model to Establish Fair Value of Options (Details) - Employees12 Months Ended
Mar. 31, 2018CAD ($)YearMar. 31, 2017CAD ($)Year
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate1.54%
Expected annualized volatility64.00%
Expected forfeiture rate11.00%7.00%
Expected dividend yield
Weighted average fair value at measurement date, share options granted $ 8.88
Minimum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate0.50%
Expected life of options (years) | Year3 1
Expected annualized volatility55.00%
Weighted average fair value at measurement date, share options granted $ 0.20
Maximum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate1.94%
Expected life of options (years) | Year5 6
Expected annualized volatility70.00%
Weighted average fair value at measurement date, share options granted $ 6.09

Share Capital - Summary of Shar

Share Capital - Summary of Share-based Compensation Expense related to Acquisition and Asset Purchase Milestones (Details) $ in Thousands12 Months Ended
Mar. 31, 2018CAD ($)sharesMar. 31, 2017CAD ($)Sep. 07, 2017sharesDec. 12, 2016shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation expense related to acquisition milestones | $ $ 19,475 $ 690
common shares issued111,366 490,641
Apollo/Bodystream
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Released during fiscal 2018243,493
Remaining shares to be issued on completion of milestones*1,941,804
Share-based compensation expense related to acquisition milestones | $ $ 5,095 $ 690
Spectrum Cannabis GmbH
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Remaining shares to be issued on completion of milestones*23,570
Share-based compensation expense related to acquisition milestones | $ $ 349
Spot
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Remaining shares to be issued on completion of milestones*30,658
Share-based compensation expense related to acquisition milestones | $ $ 330
Spectrum Denmark
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Remaining shares to be issued on completion of milestones*1,906,214
Share-based compensation expense related to acquisition milestones | $ $ 7,206
BC Tweed
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Released during fiscal 2018155,158
Remaining shares to be issued on completion of milestones*240,061
Share-based compensation expense related to acquisition milestones | $ $ 5,001
Vert Mirabel
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Remaining shares to be issued on completion of milestones*84,903
Share-based compensation expense related to acquisition milestones | $ $ 1,131
Green Hemp
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Remaining shares to be issued on completion of milestones*24,567
Share-based compensation expense related to acquisition milestones | $ $ 167
Intellectual property acquisition
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Remaining shares to be issued on completion of milestones*33,804
Share-based compensation expense related to acquisition milestones | $ $ 196
Apollo C R O Inc
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
common shares issued1,111,702
Body Stream
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
common shares issued1,073,595

Other Income (Expense) - Summar

Other Income (Expense) - Summary of Other Income (Expense) (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Analysis Of Income And Expense [Abstract]
Fair value changes on financial assets $ 78,172 $ 5,702
Impairment of product rights(28,000)
Fair value increase in BC Tweed Put Liability and Vert Mirabel Put Liability(21,000)
Gain on disposal of consolidated entity8,820
Bargain purchase gain638
Partner expense(4,995)
Gain/loss disposal of property, plant and equipment(1,181)
Increase in fair value of acquisition consideration related liabilities(1,193)
Other expense, net(1,241)(651)
Total other income, net $ 31,213 $ 3,858

Expenses by Nature - Additional

Expenses by Nature - Additional Information (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Expense By Nature [Abstract]
Total operating expenses by nature $ 160,229 $ 53,978

Expenses by Nature - Summary of

Expenses by Nature - Summary of Operating Expenses Distributed by Nature (Details) - CAD ($) $ in ThousandsFeb. 07, 2018Mar. 31, 2018Mar. 31, 2017
Expense By Nature [Abstract]
Employee compensation and benefits $ 49,971 $ 21,726
Raw materials used and consumables13,286 8,105
Other costs of sales12,340 5,603
Net valuation gains related to inventory and biological assets(53,652)(25,555)
Share-based compensation51,177 10,043
Acquisition-related costs $ 43 3,406 7,369
Depreciation and amortization20,486 6,064
Legal and professional fees10,370 2,947
Royalties3,110 1,416
Consultants12,385 3,391
Facility expenses12,669 3,087
Patient assistance7,365 2,913
Marketing and promotion3,835 2,314
Office expenses6,454 1,986
Travel and other employee expenses5,141 1,672
Bank and payment processor fees1,886 897
Total $ 160,229 $ 53,978

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Major Components Of Tax Expense Income [Abstract]
Loss from operations $ (52,541) $ (10,275)
Expected tax rate26.50%26.50%
Expected tax benefit resulting from loss $ 13,923 $ 2,723
Non-deductible expenses(19,310)(2,156)
Increase in unrecognized temporary differences(5,506)2,258
Non-taxable portion of capital gains and losses9,421
Other(121)(122)
Income tax (expense) recovery $ (1,593) $ 2,703

Income Taxes - Summary of Effec

Income Taxes - Summary of Effect of Temporary Differences and Loss Carryforwards (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Beginning balance $ (35,924)
Deferred tax liabilities associated with asset held for sale820
Deferred tax liability, Ending balance(33,536) $ (35,924)
Temporary Differences Between Assets and Liabilities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred taxes, Beginning balance(35,924)(7,413)
Net deferred taxes, Recognized in profit or loss(1,593)2,703
Net deferred taxes, Recognized in equity4,511
Net deferred taxes, Recognized in goodwill(29,606)
Net deferred taxes, Recognized in other comprehensive income(5,124)(2,428)
Net deferred taxes, Disposal of consolidated entity5,699
Net deferred taxes, Business combinations and assets held for sale(1,105)
Net deferred taxes, Liabilities associated with asset held for sale820
Net deferred taxes, Ending balance(33,536)(35,924)
Temporary Differences Between Assets and Liabilities | Other
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax asset, Beginning balance829 224
Deferred tax asset, Recognized in profit or loss(62)
Deferred tax asset, Recognized in equity4,511
Deferred tax asset, Recognized in goodwill667
Deferred tax asset, Ending balance5,340 829
Deferred tax liability, Beginning balance381 (3)
Deferred tax liability, Recognized in profit or loss(922)107
Deferred tax liability, Recognized in goodwill277
Deferred tax liability, Disposal of consolidated entity(284)
Deferred tax liability, Business combinations and assets held for sale12
Deferred tax liability, Ending balance(813)381
Temporary Differences Between Assets and Liabilities | Loss Carryforwards
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax asset, Beginning balance30,494 9,100
Deferred tax asset, Recognized in profit or loss5,677 15,332
Deferred tax asset, Recognized in goodwill6,062
Deferred tax asset, Disposal of consolidated entity(1,014)
Deferred tax asset, Ending balance35,157 30,494
Temporary Differences Between Assets and Liabilities | Deferred Tax Asset
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax asset, Beginning balance31,323 9,324
Deferred tax asset, Recognized in profit or loss5,677 15,270
Deferred tax asset, Recognized in equity4,511
Deferred tax asset, Recognized in goodwill6,729
Deferred tax asset, Disposal of consolidated entity(1,014)
Deferred tax asset, Ending balance40,497 31,323
Temporary Differences Between Assets and Liabilities | Intangibles
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Beginning balance(42,703)(8,436)
Deferred tax liability, Recognized in profit or loss10,310 479
Deferred tax liability, Recognized in goodwill(34,746)
Deferred tax liability, Disposal of consolidated entity6,965
Deferred tax liability, Ending balance(25,428)(42,703)
Temporary Differences Between Assets and Liabilities | Fixed Assets
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Beginning balance(1,126)(1,097)
Deferred tax liability, Recognized in profit or loss3,577 132
Deferred tax liability, Recognized in goodwill(161)
Deferred tax liability, Disposal of consolidated entity(263)
Deferred tax liability, Business combinations and assets held for sale(1,117)
Deferred tax liability, Ending balance1,071 (1,126)
Temporary Differences Between Assets and Liabilities | Other Long-term Liabilities
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Recognized in profit or loss2,783
Deferred tax liability, Ending balance2,783
Temporary Differences Between Assets and Liabilities | Biological Assets
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Beginning balance(20,615)(7,201)
Deferred tax liability, Recognized in profit or loss(9,460)(12,529)
Deferred tax liability, Recognized in goodwill(885)
Deferred tax liability, Disposal of consolidated entity295
Deferred tax liability, Ending balance(29,780)(20,615)
Temporary Differences Between Assets and Liabilities | Investments
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Beginning balance(3,184)
Deferred tax liability, Recognized in profit or loss(13,558)(756)
Deferred tax liability, Recognized in other comprehensive income(5,124)(2,428)
Deferred tax liability, Ending balance(21,866)(3,184)
Temporary Differences Between Assets and Liabilities | Deferred Tax Liability
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Beginning balance(67,247)(16,737)
Deferred tax liability, Recognized in profit or loss(7,270)(12,567)
Deferred tax liability, Recognized in goodwill(36,335)
Deferred tax liability, Recognized in other comprehensive income(5,124)(2,428)
Deferred tax liability, Disposal of consolidated entity6,713
Deferred tax liability, Business combinations and assets held for sale(1,105)
Deferred tax liabilities associated with asset held for sale820
Deferred tax liability, Ending balance $ (74,033)(67,247)
Temporary Differences Between Assets and Liabilities | Asset Held for Sale
Deferred Tax Assets And Liabilities [Line Items]
Deferred tax liability, Recognized in goodwill(820)
Deferred tax liabilities associated with asset held for sale $ 820

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Temporary Differences (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unrecognized temporary differences $ 30,041 $ 12,698
Losses Carried Forward
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unrecognized temporary differences $ 30,041 2,792
Intangibles Assets and Fixed Asset
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unrecognized temporary differences $ 9,906

Income Taxes - Non-Capital Loss

Income Taxes - Non-Capital Losses Available to Reduce Future Years Taxable Income (Details) $ in Thousands12 Months Ended
Mar. 31, 2018CAD ($)
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Non-capital losses $ 171,397
2,030
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,030
Non-capital losses $ 40
2,031
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,031
Non-capital losses $ 123
2,032
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,032
Non-capital losses $ 376
2,033
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,033
Non-capital losses $ 3,195
2,034
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,034
Non-capital losses $ 7,258
2,035
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,035
Non-capital losses $ 18,196
2,036
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,036
Non-capital losses $ 29,806
2,037
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,037
Non-capital losses $ 29,202
2,038
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration dates2,038
Non-capital losses $ 79,301
Foreign- Indefinite
Non Capital Losses Available To Reduce Future Taxable Income [Line Items]
Expiration datesForeign - indefinite
Non-capital losses $ 3,900

Related Parties - Additional In

Related Parties - Additional Information (Details) - CAD ($) $ in Thousands12 Months Ended17 Months Ended
Mar. 31, 2018Mar. 31, 2017Mar. 31, 2018
Disclosure Of Related Party Transactions [Line Items]
Percentage of shares owned by key management personnel5.00%
Loan balance $ 8,422 $ 10,330 $ 8,422
Term Loan 10% Due October 1, 2024
Disclosure Of Related Party Transactions [Line Items]
Loan balance1,564 1,724 1,564
Key management personnel of entity or parent [member]
Disclosure Of Related Party Transactions [Line Items]
Employee severance cost $ 300
Hershey
Disclosure Of Related Party Transactions [Line Items]
Lease including base rent and operating costs2,118
Bedrocan Facilities One
Disclosure Of Related Party Transactions [Line Items]
Lease expiration dateOct. 15,
2018
Optional lease renewal period5 years
Bedrocan
Disclosure Of Related Party Transactions [Line Items]
Lease including base rent and operating costs $ 2,686 785
Consulting services159
Lease liabilities $ 137 137
Bedrocan Facility Two
Disclosure Of Related Party Transactions [Line Items]
Lease expiration dateAug. 31,
2024
Mettrum Hempworks Inc.
Disclosure Of Related Party Transactions [Line Items]
Lease including base rent and operating costs $ 131 8
Lease expiration dateMar. 31,
2020
Lease liabilities $ 24 8 24
Lease term5 years
Chief Executive Officers
Disclosure Of Related Party Transactions [Line Items]
Quarterly consulting services fee $ 55
Cash compensation bonus300
Consulting expenses including travel531 400
Accrued interest owed included in accounts payable and accrued liabilities stockholders375 255 375
Directors
Disclosure Of Related Party Transactions [Line Items]
Interest expense169 179
Directors' fees $ 708 $ 223
Hemp
Disclosure Of Related Party Transactions [Line Items]
Lease including base rent and operating costs $ 84
Lease expiration dateNov. 1,
2036
Lease renewal term10 years

Related Parties - Summary of Ke

Related Parties - Summary of Key Management Personnel Compensation (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Transactions Between Related Parties [Abstract]
Short-term employee benefits $ 3,746 $ 1,420
Share-based compensation5,786 1,535
Total $ 9,532 $ 2,955

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease and Royalty Payments (Details) $ in ThousandsMar. 31, 2018CAD ($)
Disclosure Of Commitments And Contingencies [Abstract]
2,019 $ 21,767
2,020 21,712
2,021 21,017
2,022 21,076
2,023 19,366
Thereafter85,200
Total $ 190,138

Commitments and Contingencie129

Commitments and Contingencies - Additional Information (Details) - CAD ($)Mar. 31, 2018Mar. 31, 2015
Disclosure Of Commitments And Contingencies [Abstract]
Ongoing litigation claim amount $ 330,000
Litigation settlement amount to other party $ 0

Supplementary Cash Flow Info130

Supplementary Cash Flow Information - Summary of Changes in Non-Cash Working Capital (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Cash Flow Statement [Abstract]
Amounts receivable $ (15,738) $ (2,184)
Prepaid expenses and other assets(15,770)(1,493)
Biological assets and inventory(24,493)(12,270)
Accounts payable and accrued liabilities27,130 (200)
Deferred revenue312 55
Other liabilities40 (256)
Total $ (28,519) $ (16,348)

Supplementary Cash Flow Info131

Supplementary Cash Flow Information - Additional Information (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Cash Flow Statement [Abstract]
Accounts payable and accrued liabilities $ 49,679 $ 3,860
Property, plant and equipment and assets in process purchases49,627 3,770
Share issue costs52 90
Accounts payable and accrued liabilities, recognized3,860 946
Property, plant and equipment and assets in process purchases, recognized3,770 877
Share issue costs, recognized $ 90 $ 69

Supplementary Cash Flow Info132

Supplementary Cash Flow Information - Summary of Cash and Cash Equivalents (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017Mar. 31, 2016
Disclosure Of Cash Flow Statement [Abstract]
Cash $ 322,560 $ 16,700
Short-term guaranteed investment certificates85,100
Total cash and cash equivalents $ 322,560 $ 101,800 $ 15,397

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) - CAD ($) $ in Thousands12 Months Ended
Mar. 31, 2018Mar. 31, 2017
Disclosure Of Financial Instruments [Line Items]
Percentage of change in financial assets2.00%1.00%
Percentage of change in financial liabilities3.00%1.00%
Restricted short-term investments $ 664 $ 550
Allowance for doubtful accounts78
Maximum exposure to credit risk344,659 $ 108,165
Gross cash proceeds from equity financing $ 54,876
Government Agencies
Disclosure Of Financial Instruments [Line Items]
Portion of receivable19.00%55.00%
Credit Card Processor And Bill Payment
Disclosure Of Financial Instruments [Line Items]
Portion of receivable42.00%30.00%
Interest Rate Risk
Disclosure Of Financial Instruments [Line Items]
Restricted short-term investments $ 65,395
Liqudity Risk
Disclosure Of Financial Instruments [Line Items]
Gross cash proceeds from equity financing $ 470,670

Financial Instruments - Summary

Financial Instruments - Summary of Aging of Receivables (Details) - CAD ($) $ in ThousandsMar. 31, 2018Mar. 31, 2017
Disclosure Of Aging Of Receivables [Line Items]
Receivables $ 5,941 $ 3,046
0-60 Days
Disclosure Of Aging Of Receivables [Line Items]
Receivables5,683 2,137
61-120 Days
Disclosure Of Aging Of Receivables [Line Items]
Receivables $ 258 $ 909

Financial Instruments - Summ135

Financial Instruments - Summary Contractual Maturities of Undiscounted Cash Flows (Details) $ in ThousandsMar. 31, 2018CAD ($)
Carrying Amount
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Accounts payable and accrued liabilities $ 89,571
Long-term debt8,422
Total97,993
Contractual Cash Flow
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Accounts payable and accrued liabilities89,571
Long-term debt9,522
Total99,093
Year 1
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Accounts payable and accrued liabilities89,571
Long-term debt1,899
Total91,470
Years 2 - 3
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Long-term debt5,082
Total5,082
Years 4 and After - 5
Disclosure Of Maturity Analysis For Nonderivative Financial Liabilities [Line Items]
Long-term debt2,541
Total $ 2,541

Financial Instruments - Summ136

Financial Instruments - Summary of Valuation Techniques and Key Inputs Used in Fair Value Measurement of Level 2 Financial Instruments (Details) - Level 212 Months Ended
Mar. 31, 2018
AusCann Shares
Disclosure Of Financial Instruments [Line Items]
Valuation techniques and key inputsPut option pricing model
Key inputsQuoted prices in active market
AusCann Options
Disclosure Of Financial Instruments [Line Items]
Valuation techniques and key inputsBlack-Scholes option pricing model
Key inputsQuoted prices in active market
TerrAscend Warrants
Disclosure Of Financial Instruments [Line Items]
Valuation techniques and key inputsBlack-Scholes option pricing model
Key inputsQuoted prices in active market

Financial Instruments - Summ137

Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in Fair Value Measurement of Level 3 Financial Instruments (Details) - Level 312 Months Ended
Mar. 31, 2018
JWC Warrants
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesBlack-Scholes option pricing model
Significant unobservable inputsShare price
Relationship of unobservable inputs to fair valueIncrease or decrease in share price will result in an increase or decrease in fair value
JWC Shares
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesMarket approach
Significant unobservable inputsShare price
Relationship of unobservable inputs to fair valueIncrease or decrease in share price will result in an increase or decrease in fair value
HydRx Shares
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesMarket approach
Significant unobservable inputsShare price
Relationship of unobservable inputs to fair valueIncrease or decrease in share price will result in an increase or decrease in fair value
HydRx Warrants
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesBlack-Scholes option pricing model
Significant unobservable inputsShare price
Relationship of unobservable inputs to fair valueIncrease or decrease in share price will result in an increase or decrease in fair value
Agripharm Warrant
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesBlack-Scholes option pricing model
Significant unobservable inputsShare price
Relationship of unobservable inputs to fair valueIncrease or decrease in share price will result in an increase or decrease in fair value
BC Tweed Call Option Liability
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesMarket approach
Significant unobservable inputsAppraised value of property
Relationship of unobservable inputs to fair valueIncrease or decrease in value will result in a increase or decrease in fair value
BC Tweed and Vert Mirabel Put Liability
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesDiscounted cash flow
Significant unobservable inputsDiscount rate
Relationship of unobservable inputs to fair valueIncrease or decrease in discount rate will result in a decrease or increase in fair value
BC Tweed and Vert Mirabel Put Liability
Disclosure Of Financial Instruments [Line Items]
Valuation techniquesDiscounted cash flow
Significant unobservable inputsFuture wholesale price and production levels
Relationship of unobservable inputs to fair valueIncrease in future wholesale price and production levels will result in an increase in fair value

Segmented Information - Additio

Segmented Information - Additional Information (Details) $ in Thousands12 Months Ended
Mar. 31, 2018CAD ($)SegmentMar. 31, 2017CAD ($)
Disclosure Of Operating Segments [Line Items]
Number of operating segments | Segment1
Revenue $ 77,948 $ 39,895
Other Country
Disclosure Of Operating Segments [Line Items]
Property plant and equipment and intangible assets6,242
Revenue $ 3,746 $ 35

Capital Management - Additional

Capital Management - Additional Information (Details) - CAD ($)Mar. 31, 2018Mar. 31, 2017
Disclosure Of Financial Risk Management [Abstract]
Dividends payable to shareholders $ 0
Total managed capital $ 1,251,660,000 $ 650,056,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ / shares in Units, ft² in MillionsMay 15, 2018CAD ($)sharesMay 09, 2018CAD ($)sharesApr. 23, 2018CAD ($)$ / sharessharesApr. 17, 2018CAD ($)$ / sharesApr. 15, 2018CAD ($)sharesJun. 30, 2018CAD ($)$ / sharessharesMar. 31, 2018$ / sharessharesMar. 31, 2017$ / sharessharesMay 17, 2018CAD ($)sharesMay 07, 2018ft²Feb. 07, 2018sharesSep. 07, 2017sharesDec. 12, 2016sharesMar. 31, 2016shares
Disclosure Of Property Plant And Equipment [Line Items]
Warrants exercise price | $ / shares $ 3.72 $ 0.59
Number of common shares issued199,320,981 162,187,262 117,253 98,818,213
common shares issued111,366 490,641
Redemption price percentage if the note redeemde before the due date130.00%
Redemption description of convertible senior notesCanopy Growth may not redeem the notes prior to July 20, 2021, except in the event of certain changes in Canadian tax law. Canopy Growth may redeem for cash all or any portion of the notes, at its option, on or after July 20, 2021 if the last reported sale price of Canopy Growth’s common shares for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on the trading day immediately preceding the date on which Canopy Growth provides notice of redemption has been at least 130% of the conversion price then in effect on each such trading day. Redemptions of notes in either case shall be at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Daddy Cann Lesotho PTY Ltd
Disclosure Of Property Plant And Equipment [Line Items]
Total consideration | $ $ 28,800,000
common shares issued999,643
Initial Share Issue | Daddy Cann Lesotho PTY Ltd
Disclosure Of Property Plant And Equipment [Line Items]
common shares issued666,362
Additional Shares Issued | Daddy Cann Lesotho PTY Ltd
Disclosure Of Property Plant And Equipment [Line Items]
Number of common shares issued333,281
Subsequent Events
Disclosure Of Property Plant And Equipment [Line Items]
Area of greenhouse | ft²1.2
Subsequent Events | Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Number of common shares issued332,009
Common share, value | $ $ 10,000,000
Loan to landlord | $ $ 10,000,000
Subsequent Events | LiveWell
Disclosure Of Property Plant And Equipment [Line Items]
Shares issued by the strategic agreement5,487,642
Equity interest ownership percentage10.00%
Number of shares placed in Escrow5,487,642
Subsequent Events | Good Leaf, Inc
Disclosure Of Property Plant And Equipment [Line Items]
Equity interest ownership percentage8.80%
Warrants exercise price | $ / shares $ 0.01
Warrants expiration description7 years
Investment | $ $ 5,478,000
Subsequent Events | Good Leaf, Inc | Preference Shares
Disclosure Of Property Plant And Equipment [Line Items]
Exchange of shares674,709
Subsequent Events | Good Leaf, Inc | Common Shares
Disclosure Of Property Plant And Equipment [Line Items]
Warrants to acquire shares of common stock139,432
Subsequent Events | Canopy Health Innovations Inc.
Disclosure Of Property Plant And Equipment [Line Items]
Number of common shares issued3,037,771
Exchange ratio per share0.3790
Total consideration | $ $ 101,261,000
Subsequent Events | Canopy Health Innovations Inc. | Common Shares
Disclosure Of Property Plant And Equipment [Line Items]
Value of the shares issued for the transaction | $91,573,000
Subsequent Events | Canopy Health Innovations Inc. | Stock options
Disclosure Of Property Plant And Equipment [Line Items]
In-the-money value of CHI options | $ $ 9,688,000
Convertible Debt Financing
Disclosure Of Property Plant And Equipment [Line Items]
Convertible senior notes issued | $ $ 600,000,000
Convertible senior notes issued subject to over - allotment | $ $ 100,000,000
Interest rate4.25%
Convertible senior notes issued, convertion rate per $1 principal amount of notes20.7577
Convertible senior notes issued, initial convertion rate | $ / shares $ 48.18
Convertible senior notes, maturity dateJul. 15,
2023
Canopy Rivers | Subsequent Events | LiveWell
Disclosure Of Property Plant And Equipment [Line Items]
Shares issued by the strategic agreement5,487,642
Debt financing maximum borrowing capacity | $ $ 20,000,000
Canopy Rivers | Strategic Investment and Collaboration Agreement | Civilized Worldwide Inc
Disclosure Of Property Plant And Equipment [Line Items]
Investment in debenture, convertible into common shares | $ $ 5,000,000
Warrants exercise price | $ / shares $ 3,500
Warrants expiration description24 month